V1,V2,n
ACE inhibitors,ARBs,2
ACE inhibitors,RCT,1
ACE inhibitors,acute coronary syndrome,1
ACE inhibitors,andor nitroglycerin,1
ACE inhibitors,antialdosterone,1
ACE inhibitors,antiplatelet therapy,1
ACE inhibitors,blockers,1
ACE inhibitors,bnp,1
ACE inhibitors,diuretic therapy,1
ACE inhibitors,egfr,1
ACE inhibitors,hypertension,1
ACE inhibitors,insulin (measurment),1
ACE inhibitors,insulin treatment,1
ACE inhibitors,monocyte chemoattractant protin1 m,1
ACE inhibitors,nitrates,1
ACE inhibitors,pioglitazone treatment,1
ACE inhibitors,statins,1
ACE inhibitors,urinary acr,1
ACEI/ARB,antidiabetic medication,1
ACEI/ARB,insulin treatment,2
ACEI/ARB,lipidlowering therapy,1
ACEI/ARB,uoer,1
ARBs,acute coronary syndrome,1
ARBs,age,1
ARBs,andor nitroglycerin,1
ARBs,antialdosterone,1
ARBs,antidepressants,1
ARBs,antihypertensive use,2
ARBs,antiplatelet therapy,1
ARBs,beta-blocker,2
ARBs,blockers,2
ARBs,bnp,1
ARBs,calcium channel blockers,2
ARBs,diuretic therapy,1
ARBs,fibrates,1
ARBs,hyperlipidemia,1
ARBs,hypertension,1
ARBs,insulin treatment,1
ARBs,monocyte chemoattractant protin1 m,1
ARBs,neuropathy,1
ARBs,nitrates,1
ARBs,peripheral artery disease,1
ARBs,race/ethnicity,1
ARBs,secretagogues,1
ARBs,socioeconomic variables,1
ARBs,statins,1
ApoAI,apoAI/apoB ratio,1
ApoAI,apoB,1
ApoAI,c-reactive protein,1
ApoAI,coronary artery disease,1
ApoAI,fibrinogen,2
ApoAI,homair,1
ApoAI,homocysteine,1
ApoAI,idf metabolic syndrome,1
ApoAI,insulin (measurment),1
ApoAI,peripheral arterial occlusive disease,1
ApoAI,stroke,1
CCr,albumin excretion rate,1
CCr,cholesterol,2
CCr,coronary heart disease,1
CCr,diastolic blood pressure,1
CCr,hba1c,1
CCr,smoking,1
CCr,systolic blood pressure,1
Elixhauser comorbidies,blood pressure,1
Elixhauser comorbidies,bmi,1
Elixhauser comorbidies,cholesterol,1
Elixhauser comorbidies,creatinine,1
Elixhauser comorbidies,microalbuminuria,1
Elixhauser comorbidies,provider quality controls,1
Elixhauser comorbidies,sociodemographics,1
Elixhauser comorbidies,sulfonylurea,1
Elixhauser comorbidies,year fixed effects,1
Elixhauser comorbidies,young severity index,1
Lp(a),apo(a) phenotypes,1
Lp(a),cholesterol,3
Lp(a),hba1c,1
Lp(a),multivessel coronary disease,1
Lp(a),stent,1
Lp(a),triglycerides,1
RCT,ACE inhibitors,1
RCT,acr,1
RCT,age,4
RCT,albumin to creatinine ratio,2
RCT,alcohol use,2
RCT,alternative healthy eating index ahei diet quality score quintiles,1
RCT,angina,1
RCT,antihypertensive use,1
RCT,atrial fibrillation,2
RCT,blood glucose,2
RCT,bmi,5
RCT,bnp,1
RCT,c-reactive protein,2
RCT,cardiovascular disease,5
RCT,cholesterol,13
RCT,coronary artery disease,1
RCT,creatinine,1
RCT,diabetes duration,6
RCT,diabetic neuropathy,1
RCT,diastolic blood pressure,1
RCT,egfr,6
RCT,ejection fraction,1
RCT,fasting status at blood draw,1
RCT,gender,4
RCT,hba1c,7
RCT,heart failure,1
RCT,heart rate,2
RCT,hormone therapy,1
RCT,hyperlipidemia,1
RCT,hypertension,5
RCT,left ventricular ejection fraction,1
RCT,macroalbuminuria,1
RCT,macrovascular complications,1
RCT,menopausal status pre post uncertain missing,1
RCT,microvascular disease,1
RCT,myocardial infarction,2
RCT,nterminal probrain natriuretic peptide,1
RCT,pacemaker implantation,1
RCT,physical activity,1
RCT,prior event,1
RCT,pro btype natriuretic peptide quartiles,1
RCT,race/ethnicity,1
RCT,retinopathy,1
RCT,smoking,8
RCT,statins,2
RCT,systolic blood pressure,7
RCT,triglycerides,3
RCT,troponin,2
RCT,urinary acr,1
RCT,white blood cell count,2
acr,blood glucose,1
acr,cholesterol,1
acr,egfr,2
acr,hba1c,1
acr,triglycerides,1
acute coronary syndrome,ACE inhibitors,1
acute coronary syndrome,beta-blocker,1
acute coronary syndrome,blood glucose,1
acute coronary syndrome,bnp,1
acute coronary syndrome,c-reactive protein,1
acute coronary syndrome,complex lesions,1
acute coronary syndrome,diuretic therapy,2
acute coronary syndrome,egfr,1
acute coronary syndrome,insulin (measurment),1
acute coronary syndrome,insulin treatment,2
acute coronary syndrome,left ventricular ejection fraction,1
acute coronary syndrome,metformin,1
acute coronary syndrome,monocyte chemoattractant protin1 m,1
acute coronary syndrome,multivessel coronary disease,1
acute coronary syndrome,myocardial infarction,1
acute coronary syndrome,peripheral arterial occlusive disease,1
acute coronary syndrome,pioglitazone treatment,1
acute coronary syndrome,prior coronary artery bypass,1
acute coronary syndrome,statins,1
acute coronary syndrome,stroke,1
acute coronary syndrome,sulfonylurea,1
acute kidney injury,albumin,1
acute kidney injury,egfr,1
acute kidney injury,myocardial infarction,1
adherence to medication,dcsi,1
adherence to medication,hyperlipidemia,1
adiponectin,cholesterol,1
adiponectin,creatinine,1
adiponectin,egfr,1
adiponectin,hemoglobin,1
adiponectin,interleukin 6,1
adiponectin,parathyroid harmone (PTH),1
adiponectin,phosphate,1
adjusted for baseline morbidity,baseline medications,1
adjusted for baseline morbidity,baseline related risk factor level,1
adjusted for baseline morbidity,comorbidity,1
adjusted for baseline morbidity,diabetes duration,1
age,ACE inhibitors,6
age,ACEI/ARB,5
age,ARBs,4
age,ApoAI,2
age,CCr,1
age,RCT,16
age,Serum 25-hydroxyvitamin D,1
age,acr,2
age,acute coronary syndrome,3
age,adherence to medication,1
age,adiponectin,1
age,albumin,31
age,albumin excretion rate,8
age,albumin to creatinine ratio,12
age,alcohol use,24
age,alphaglucosidase inhibitor,1
age,alternative healthy eating index ahei diet quality score quintiles,1
age,andor nitroglycerin,1
age,angina,5
age,ankle-brachial index (ABI),4
age,antiaggregating agents,1
age,antialdosterone,1
age,anticoagulants,1
age,antidepressants,1
age,antidiabetic medication,3
age,antihyperlipidemic drugs,2
age,antihypertensive use,28
age,antiplatelet therapy,13
age,apelin36 levels,1
age,apoAI/apoB ratio,2
age,apoB,2
age,arteriovenous fistula,1
age,aspirin therapy,17
age,atrial fibrillation,10
age,autonomic dysfunction,2
age,bapwv,1
age,baseline claudication,1
age,beta-blocker,4
age,biomarkers (general),1
age,blockers,2
age,blood glucose,27
age,blood pressure,22
age,bmi,146
age,bnp,13
age,c-reactive protein,21
age,calcium channel blockers,2
age,cancer,1
age,cardiac autonomic neuropathy (CAN),2
age,cardiovascular disease,50
age,cardiovascular risk factors,6
age,carotid artery imt,1
age,carotid intima media thickness,1
age,carotid plaque,1
age,cerebrovascular disease,6
age,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
age,charlson index,2
age,choleseterol,1
age,cholesterol,275
age,chronic kidney disease,8
age,chronic obstructive pulmonary disease,1
age,chronic renal failure,1
age,ci,1
age,cimt,3
age,clinic,1
age,clinic gamma frailty,1
age,clopidigrel,1
age,clopidogrel,1
age,clustering by clinic,1
age,combined alox12 genotypes,1
age,complete revascularization,1
age,complex lesions,1
age,coronary artery calcium score,4
age,coronary artery disease,18
age,coronary heart disease,12
age,creatinine,51
age,dcb use,1
age,dcsi,1
age,depression,1
age,diabetes,13
age,diabetes duration,134
age,diabetes treatment,23
age,diabetic neuropathy,2
age,dialysis,5
age,diastolic blood pressure,38
age,dipeptidyl peptidase 4 inhibitor at discharge,1
age,dipyridamole stress test,1
age,disease duration,1
age,distal polyneuropathy,1
age,diuretic therapy,3
age,dpucmgp,1
age,duration,2
age,ecg abnormalities,22
age,echolucent plaque,1
age,egfr,64
age,ejection fraction,2
age,ejection fraction 40,1
age,endothelial dysfunction,1
age,fasting cpeptide,1
age,fasting plasma glucose,5
age,fasting status at blood draw,1
age,fasting status yes or no,1
age,fibrates,2
age,fibrinogen,9
age,final timi flow,1
age,folate,1
age,fpi,1
age,frailty effect for cohort,1
age,gamma frailty,1
age,gender,212
age,gliclazide,1
age,glycated hemoglobin,3
age,glycemic control,9
age,hab1c,1
age,haemoglobin,1
age,hba1c,152
age,heart failure,17
age,heart rate,11
age,heart valve calcium,1
age,height,3
age,hemoglobin,2
age,high density lipoprotein level,1
age,highdensity lipoprotein,3
age,history of copd,1
age,history of coronary disease,3
age,homair,5
age,homocysteine,2
age,homocysteine at baseline,1
age,hormone therapy,1
age,hyperlipidemia,23
age,hypertension,91
age,hypoglycaemic treatment,1
age,idf metabolic syndrome,1
age,indigenous australian,1
age,inflammatory markers,1
age,insulin (measurment),6
age,insulin treatment,27
age,intensive treatment,1
age,interleukin 6,2
age,intervention arm no interaction model,1
age,ischemia,2
age,ischemic heart disease,5
age,kidney function,2
age,left atrial diameter,1
age,left bundle branch block,1
age,left ventricular ejection fraction,11
age,left ventricular hypertrophy,2
age,"leisure time physical activity",1
age,lipid profile,4
age,lipidlowering therapy,18
age,living alone,1
age,lm treatment,1
age,log101  acr,1
age,logaer,1
age,lowdensity lipoprotein,2
age,macroalbuminuria,4
age,macrovascular complications,13
age,marital status,2
age,mca stenosis,1
age,medication differences,1
age,medications,1
age,menopausal status pre post uncertain missing,1
age,metformin,5
age,microalbuminuria,15
age,microvascular disease,11
age,mild plaque calcifi cation,1
age,monocyte chemoattractant protin1 m,1
age,multivessel coronary disease,2
age,myocardial infarction,25
age,nephropathy,5
age,neuropathy,4
age,nitrates,1
age,nterminal probrain natriuretic peptide,2
age,nzdep quintile,1
age,other complications,1
age,other conventional risk factors,1
age,other lifestyle risk factors,1
age,pIMT,1
age,pacemaker implantation,1
age,parathyroid harmone (PTH),2
age,percent low density plaque,1
age,percutaneous coronary intervention,4
age,peripheral arterial occlusive disease,2
age,peripheral artery disease,13
age,peripheral neuropathy,1
age,peripheral vascular disease,3
age,peripherovascular morbidity,1
age,phosphate,6
age,physical activity,16
age,physical inactivity,5
age,pioglitazone treatment,1
age,plaque thickness,1
age,plaque volume,1
age,postpci thrombolysis in mitimiflow,1
age,previous pcicabg,1
age,prior coronary artery bypass,3
age,prior event,1
age,pro btype natriuretic peptide quartiles,1
age,proteinuria,6
age,psychiatric medications,1
age,pulse pressure,3
age,race/ethnicity,26
age,ratio between total,1
age,referring physician,1
age,renal function,1
age,renal impairment,1
age,renal insufficiency,1
age,renin-angiotensin system inhibitors,3
age,retinopathy,15
age,rosiglitazone during followup,1
age,secretagogues,1
age,sensory neuropathy,1
age,sensory neuropathy presentabsent,1
age,significant proximal lad disease,1
age,skinfold thickness,1
age,sleep duration,1
age,smoking,181
age,sociodemographics,14
age,socioeconomic variables,11
age,sodium concentration,1
age,statins,35
age,stent,1
age,stroke,13
age,study treatment,1
age,sulfonylurea,4
age,syntax score,1
age,systolic blood pressure,119
age,the presence of total occlusion,1
age,the ukpds risk score,1
age,the use of drugs yesno,1
age,therapy for hypercoagulation,1
age,thiazolidinediones,1
age,tnfalpha,1
age,"to tal",1
age,top three multidimensional scaling axes,1
age,tot chol,1
age,total energy kcalday,1
age,treatment,1
age,triacylglycerol,4
age,triglycerides,68
age,troponin,3
age,tryglycerides,1
age,type of treatment,1
age,ultrafiltration volume,2
age,uoer,2
age,uric acid,5
age,urinary acr,5
age,urinary albumin excretion rate,10
age,urinary protein log,1
age,use of blockers,1
age,use of sulfonamides,1
age,vitamin b12,1
age,waist measurements,17
age,wasting,1
age,weight,1
age,white blood cell count,4
age,year of followup start,1
age,years of enrolment,1
albumin,Lp(a),1
albumin,RCT,1
albumin,age,2
albumin,apo(a) phenotypes,1
albumin,arteriovenous fistula,1
albumin,aspirin therapy,1
albumin,autonomic dysfunction,1
albumin,blood pressure,1
albumin,bmi,1
albumin,bnp,2
albumin,c-reactive protein,3
albumin,cardiovascular disease,2
albumin,carotid intima media thickness,1
albumin,cholesterol,11
albumin,chronic kidney disease,1
albumin,cimt,2
albumin,combined alox12 genotypes,1
albumin,coronary artery disease,2
albumin,creatinine,2
albumin,diabetes duration,2
albumin,diabetes treatment,3
albumin,dialysis,1
albumin,ecg abnormalities,2
albumin,egfr,2
albumin,endothelial dysfunction,1
albumin,gender,1
albumin,hba1c,7
albumin,heart failure,2
albumin,homair,1
albumin,hyperlipidemia,1
albumin,hypertension,2
albumin,insulin (measurment),1
albumin,insulin treatment,1
albumin,interleukin 6,1
albumin,ischemic heart disease,1
albumin,macrovascular complications,1
albumin,metformin,1
albumin,microvascular disease,1
albumin,multivessel coronary disease,1
albumin,myocardial infarction,4
albumin,parathyroid harmone (PTH),1
albumin,phosphate,3
albumin,race/ethnicity,1
albumin,retinopathy,1
albumin,smoking,4
albumin,sociodemographics,1
albumin,socioeconomic variables,1
albumin,stent,1
albumin,sulfonylurea,1
albumin,systolic blood pressure,2
albumin,therapy for hypercoagulation,1
albumin,tnfalpha,1
albumin,triglycerides,3
albumin,uric acid,1
albumin excretion rate,ankle-brachial index (ABI),1
albumin excretion rate,bmi,1
albumin excretion rate,bnp,1
albumin excretion rate,c-reactive protein,1
albumin excretion rate,cardiovascular disease,1
albumin excretion rate,cholesterol,2
albumin excretion rate,coronary heart disease,1
albumin excretion rate,diabetes treatment,1
albumin excretion rate,diastolic blood pressure,1
albumin excretion rate,ecg abnormalities,1
albumin excretion rate,fibrinogen,1
albumin excretion rate,glycemic control,1
albumin excretion rate,hba1c,1
albumin excretion rate,heart rate,1
albumin excretion rate,microalbuminuria,1
albumin excretion rate,nterminal probrain natriuretic peptide,1
albumin excretion rate,peripheral artery disease,1
albumin excretion rate,physical activity,1
albumin excretion rate,retinopathy,1
albumin excretion rate,sensory neuropathy presentabsent,1
albumin excretion rate,smoking,1
albumin excretion rate,stroke,1
albumin excretion rate,systolic blood pressure,1
albumin excretion rate,the use of drugs yesno,1
albumin excretion rate,white blood cell count,1
albumin to creatinine ratio,ACE inhibitors,1
albumin to creatinine ratio,acute coronary syndrome,1
albumin to creatinine ratio,albumin,1
albumin to creatinine ratio,alcohol use,2
albumin to creatinine ratio,antihypertensive use,1
albumin to creatinine ratio,average of 3 daily 2hour bg levels after meals,1
albumin to creatinine ratio,beta-blocker,1
albumin to creatinine ratio,blood glucose,1
albumin to creatinine ratio,blood pressure,1
albumin to creatinine ratio,bmi,3
albumin to creatinine ratio,c-reactive protein,1
albumin to creatinine ratio,cardiovascular disease,1
albumin to creatinine ratio,cholesterol,7
albumin to creatinine ratio,chronic kidney disease,2
albumin to creatinine ratio,coronary artery disease,1
albumin to creatinine ratio,creatinine,1
albumin to creatinine ratio,diabetes duration,2
albumin to creatinine ratio,diabetes treatment,4
albumin to creatinine ratio,diastolic blood pressure,1
albumin to creatinine ratio,diuretic therapy,1
albumin to creatinine ratio,egfr,1
albumin to creatinine ratio,glycemic control,3
albumin to creatinine ratio,hba1c,5
albumin to creatinine ratio,heart failure,1
albumin to creatinine ratio,heart rate,1
albumin to creatinine ratio,high density lipoprotein level,1
albumin to creatinine ratio,hypertension,2
albumin to creatinine ratio,insulin (measurment),1
albumin to creatinine ratio,lipidlowering therapy,1
albumin to creatinine ratio,macrovascular complications,1
albumin to creatinine ratio,marital status,1
albumin to creatinine ratio,metformin,1
albumin to creatinine ratio,microalbuminuria,1
albumin to creatinine ratio,microvascular disease,1
albumin to creatinine ratio,myocardial infarction,2
albumin to creatinine ratio,nterminal probrain natriuretic peptide,1
albumin to creatinine ratio,peripheral arterial occlusive disease,1
albumin to creatinine ratio,pioglitazone treatment,1
albumin to creatinine ratio,prior coronary artery bypass,1
albumin to creatinine ratio,smoking,3
albumin to creatinine ratio,sociodemographics,1
albumin to creatinine ratio,statins,2
albumin to creatinine ratio,stroke,1
albumin to creatinine ratio,sulfonylurea,1
albumin to creatinine ratio,systolic blood pressure,3
albumin to creatinine ratio,triglycerides,2
albumin to creatinine ratio,troponin,1
albumin to creatinine ratio,waist measurements,1
alcohol use,ACEI/ARB,1
alcohol use,ApoAI,1
alcohol use,albumin,1
alcohol use,albumin to creatinine ratio,1
alcohol use,alphaglucosidase inhibitor,1
alcohol use,angina,1
alcohol use,antidiabetic medication,1
alcohol use,antihypertensive use,3
alcohol use,antiplatelet therapy,3
alcohol use,apoAI/apoB ratio,1
alcohol use,apoB,1
alcohol use,aspirin therapy,3
alcohol use,beta-blocker,1
alcohol use,blood glucose,2
alcohol use,blood pressure,2
alcohol use,bmi,8
alcohol use,c-reactive protein,2
alcohol use,calcium channel blockers,1
alcohol use,cardiovascular disease,2
alcohol use,cholesterol,19
alcohol use,chronic kidney disease,2
alcohol use,chronic obstructive pulmonary disease,1
alcohol use,clopidigrel,1
alcohol use,complete revascularization,1
alcohol use,coronary artery disease,1
alcohol use,coronary heart disease,2
alcohol use,creatinine,5
alcohol use,dcb use,1
alcohol use,diabetes duration,3
alcohol use,diabetes treatment,5
alcohol use,diastolic blood pressure,2
alcohol use,dipeptidyl peptidase 4 inhibitor at discharge,1
alcohol use,ecg abnormalities,3
alcohol use,egfr,2
alcohol use,fasting plasma glucose,1
alcohol use,fasting status yes or no,1
alcohol use,fibrinogen,2
alcohol use,glycemic control,1
alcohol use,hba1c,10
alcohol use,heart rate,3
alcohol use,homair,1
alcohol use,homocysteine,1
alcohol use,hyperlipidemia,4
alcohol use,hypertension,8
alcohol use,idf metabolic syndrome,1
alcohol use,insulin (measurment),2
alcohol use,insulin treatment,3
alcohol use,left ventricular ejection fraction,2
alcohol use,lipidlowering therapy,1
alcohol use,lm treatment,1
alcohol use,myocardial infarction,2
alcohol use,other lifestyle risk factors,1
alcohol use,percutaneous coronary intervention,2
alcohol use,peripheral artery disease,1
alcohol use,peripheral vascular disease,1
alcohol use,physical activity,9
alcohol use,psychiatric medications,1
alcohol use,retinopathy,2
alcohol use,smoking,2
alcohol use,socioeconomic variables,1
alcohol use,statins,4
alcohol use,stroke,2
alcohol use,sulfonylurea,1
alcohol use,syntax score,1
alcohol use,systolic blood pressure,2
alcohol use,total energy kcalday,1
alcohol use,triacylglycerol,1
alcohol use,triglycerides,5
alcohol use,use of blockers,1
alcohol use,waist measurements,3
alphaglucosidase inhibitor,dipeptidyl peptidase 4 inhibitor at discharge,1
alphaglucosidase inhibitor,insulin (measurment),1
alphaglucosidase inhibitor,sulfonylurea,1
alternative healthy eating index ahei diet quality score quintiles,alcohol use,1
alternative healthy eating index ahei diet quality score quintiles,bmi,1
alternative healthy eating index ahei diet quality score quintiles,cholesterol,1
alternative healthy eating index ahei diet quality score quintiles,hypertension,1
alternative healthy eating index ahei diet quality score quintiles,physical activity,1
andor nitroglycerin,acute coronary syndrome,1
andor nitroglycerin,bnp,1
andor nitroglycerin,diuretic therapy,1
andor nitroglycerin,insulin treatment,1
andor nitroglycerin,monocyte chemoattractant protin1 m,1
angina,ACEI/ARB,1
angina,antidiabetic medication,1
angina,atrial fibrillation,1
angina,beta-blocker,1
angina,cerebrovascular disease,1
angina,cholesterol,2
angina,clopidigrel,1
angina,creatinine,1
angina,dipyridamole stress test,1
angina,ecg abnormalities,2
angina,insulin treatment,1
angina,ischemia,1
angina,left ventricular ejection fraction,2
angina,myocardial infarction,2
angina,pacemaker implantation,1
angina,peripheral artery disease,1
angina,statins,1
ankle-brachial index (ABI),age,1
ankle-brachial index (ABI),bmi,1
ankle-brachial index (ABI),cholesterol,2
ankle-brachial index (ABI),coronary artery disease,1
ankle-brachial index (ABI),diabetes duration,1
ankle-brachial index (ABI),diastolic blood pressure,1
ankle-brachial index (ABI),ecg abnormalities,6
ankle-brachial index (ABI),egfr,1
ankle-brachial index (ABI),fasting plasma glucose,1
ankle-brachial index (ABI),hba1c,2
ankle-brachial index (ABI),heart rate,1
ankle-brachial index (ABI),significant proximal lad disease,1
ankle-brachial index (ABI),statins,1
ankle-brachial index (ABI),systolic blood pressure,1
ankle-brachial index (ABI),the presence of total occlusion,1
antialdosterone,acute coronary syndrome,1
antialdosterone,andor nitroglycerin,1
antialdosterone,blockers,1
antialdosterone,bnp,1
antialdosterone,diuretic therapy,1
antialdosterone,insulin treatment,1
antialdosterone,monocyte chemoattractant protin1 m,1
antialdosterone,nitrates,1
anticoagulants,ACE inhibitors,1
anticoagulants,ARBs,1
anticoagulants,acute coronary syndrome,1
anticoagulants,andor nitroglycerin,1
anticoagulants,antialdosterone,1
anticoagulants,blockers,1
anticoagulants,bnp,1
anticoagulants,diuretic therapy,1
anticoagulants,insulin treatment,1
anticoagulants,monocyte chemoattractant protin1 m,1
anticoagulants,nitrates,1
anticoagulants,statins,1
antidiabetic medication,antihypertensive use,2
antidiabetic medication,antiplatelet therapy,1
antidiabetic medication,insulin treatment,1
antidiabetic medication,statins,1
antihyperlipidemic drugs,cholesterol,3
antihyperlipidemic drugs,egfr,1
antihyperlipidemic drugs,triglycerides,1
antihyperlipidemic drugs,waist measurements,1
antihypertensive use,ACE inhibitors,1
antihypertensive use,ApoAI,1
antihypertensive use,RCT,1
antihypertensive use,age,1
antihypertensive use,albumin,1
antihypertensive use,alcohol use,2
antihypertensive use,antidepressants,1
antihypertensive use,antihyperlipidemic drugs,1
antihypertensive use,antiplatelet therapy,2
antihypertensive use,apoAI/apoB ratio,1
antihypertensive use,apoB,1
antihypertensive use,aspirin therapy,2
antihypertensive use,atrial fibrillation,1
antihypertensive use,blood glucose,3
antihypertensive use,bmi,2
antihypertensive use,c-reactive protein,1
antihypertensive use,calcium channel blockers,1
antihypertensive use,cardiovascular disease,2
antihypertensive use,cholesterol,8
antihypertensive use,coronary heart disease,1
antihypertensive use,creatinine,2
antihypertensive use,diabetes duration,1
antihypertensive use,diabetes treatment,1
antihypertensive use,egfr,2
antihypertensive use,fibrates,1
antihypertensive use,fibrinogen,1
antihypertensive use,hba1c,2
antihypertensive use,heart failure,2
antihypertensive use,heart rate,2
antihypertensive use,homair,1
antihypertensive use,homocysteine,1
antihypertensive use,idf metabolic syndrome,1
antihypertensive use,insulin (measurment),2
antihypertensive use,lipidlowering therapy,9
antihypertensive use,microalbuminuria,1
antihypertensive use,peripheral artery disease,1
antihypertensive use,physical activity,1
antihypertensive use,psychiatric medications,1
antihypertensive use,race/ethnicity,1
antihypertensive use,renal impairment,1
antihypertensive use,retinopathy,1
antihypertensive use,sleep duration,1
antihypertensive use,smoking,3
antihypertensive use,sociodemographics,1
antihypertensive use,socioeconomic variables,1
antihypertensive use,statins,2
antihypertensive use,systolic blood pressure,2
antihypertensive use,triglycerides,4
antihypertensive use,use of blockers,1
antihypertensive use,waist measurements,3
antiplatelet therapy,ACE inhibitors,1
antiplatelet therapy,ARBs,3
antiplatelet therapy,RCT,1
antiplatelet therapy,acute coronary syndrome,1
antiplatelet therapy,age,1
antiplatelet therapy,alphaglucosidase inhibitor,2
antiplatelet therapy,andor nitroglycerin,1
antiplatelet therapy,antialdosterone,1
antiplatelet therapy,anticoagulants,1
antiplatelet therapy,antihypertensive use,3
antiplatelet therapy,beta-blocker,2
antiplatelet therapy,blockers,1
antiplatelet therapy,blood glucose,1
antiplatelet therapy,bmi,2
antiplatelet therapy,bnp,1
antiplatelet therapy,calcium channel blockers,2
antiplatelet therapy,cholesterol,3
antiplatelet therapy,diastolic blood pressure,1
antiplatelet therapy,dipeptidyl peptidase 4 inhibitor at discharge,2
antiplatelet therapy,diuretic therapy,1
antiplatelet therapy,egfr,1
antiplatelet therapy,glycemic control,2
antiplatelet therapy,hba1c,3
antiplatelet therapy,heart failure,1
antiplatelet therapy,hyperlipidemia,1
antiplatelet therapy,hypertension,1
antiplatelet therapy,insulin (measurment),2
antiplatelet therapy,insulin treatment,1
antiplatelet therapy,lipidlowering therapy,1
antiplatelet therapy,monocyte chemoattractant protin1 m,1
antiplatelet therapy,neuropathy,1
antiplatelet therapy,nitrates,1
antiplatelet therapy,peripheral artery disease,1
antiplatelet therapy,psychiatric medications,1
antiplatelet therapy,race/ethnicity,1
antiplatelet therapy,secretagogues,1
antiplatelet therapy,smoking,1
antiplatelet therapy,socioeconomic variables,1
antiplatelet therapy,statins,7
antiplatelet therapy,study treatment,1
antiplatelet therapy,sulfonylurea,2
antiplatelet therapy,systolic blood pressure,1
antiplatelet therapy,triglycerides,1
antiplatelet therapy,uric acid,1
antiplatelet therapy,urinary acr,1
apelin36 levels,adiponectin,1
apelin36 levels,cholesterol,1
apelin36 levels,creatinine,1
apelin36 levels,egfr,1
apelin36 levels,hemoglobin,1
apelin36 levels,homair,1
apelin36 levels,interleukin 6,1
apelin36 levels,parathyroid harmone (PTH),1
apelin36 levels,phosphate,1
apoAI/apoB ratio,albumin excretion rate,1
apoAI/apoB ratio,c-reactive protein,2
apoAI/apoB ratio,cardiovascular disease,1
apoAI/apoB ratio,diabetes treatment,1
apoAI/apoB ratio,egfr,1
apoAI/apoB ratio,fibrinogen,1
apoAI/apoB ratio,homair,1
apoAI/apoB ratio,homocysteine,1
apoAI/apoB ratio,idf metabolic syndrome,1
apoAI/apoB ratio,insulin (measurment),1
apoB,apoAI/apoB ratio,1
apoB,c-reactive protein,1
apoB,fibrinogen,1
apoB,homair,1
apoB,homocysteine,1
apoB,idf metabolic syndrome,1
apoB,insulin (measurment),1
apoB,microalbuminuria,1
aspirin therapy,ACE inhibitors,1
aspirin therapy,ARBs,1
aspirin therapy,RCT,1
aspirin therapy,acute coronary syndrome,1
aspirin therapy,age,1
aspirin therapy,andor nitroglycerin,1
aspirin therapy,antialdosterone,1
aspirin therapy,anticoagulants,1
aspirin therapy,antiplatelet therapy,1
aspirin therapy,blockers,1
aspirin therapy,blood glucose,1
aspirin therapy,bnp,1
aspirin therapy,cholesterol,4
aspirin therapy,clopidogrel,1
aspirin therapy,creatinine,2
aspirin therapy,diastolic blood pressure,1
aspirin therapy,diuretic therapy,1
aspirin therapy,fasting plasma glucose,1
aspirin therapy,fibrinogen,1
aspirin therapy,framingham risk score,1
aspirin therapy,gender,1
aspirin therapy,glycemic control,1
aspirin therapy,hba1c,2
aspirin therapy,hypertension,2
aspirin therapy,insulin treatment,1
aspirin therapy,monocyte chemoattractant protin1 m,1
aspirin therapy,nitrates,1
aspirin therapy,smoking,1
aspirin therapy,statins,2
aspirin therapy,systolic blood pressure,3
atrial fibrillation,ACE inhibitors,1
atrial fibrillation,ARBs,1
atrial fibrillation,RCT,1
atrial fibrillation,acute coronary syndrome,1
atrial fibrillation,age,1
atrial fibrillation,albumin,1
atrial fibrillation,andor nitroglycerin,1
atrial fibrillation,angina,1
atrial fibrillation,antialdosterone,1
atrial fibrillation,anticoagulants,1
atrial fibrillation,antiplatelet therapy,1
atrial fibrillation,aspirin therapy,2
atrial fibrillation,blockers,1
atrial fibrillation,bmi,2
atrial fibrillation,bnp,2
atrial fibrillation,c-reactive protein,1
atrial fibrillation,cerebrovascular disease,1
atrial fibrillation,cholesterol,5
atrial fibrillation,chronic kidney disease,1
atrial fibrillation,clopidogrel,1
atrial fibrillation,creatinine,3
atrial fibrillation,diuretic therapy,1
atrial fibrillation,egfr,2
atrial fibrillation,gender,1
atrial fibrillation,hba1c,2
atrial fibrillation,heart failure,2
atrial fibrillation,heart rate,1
atrial fibrillation,insulin treatment,1
atrial fibrillation,left ventricular ejection fraction,1
atrial fibrillation,macroalbuminuria,1
atrial fibrillation,mild plaque calcifi cation,1
atrial fibrillation,monocyte chemoattractant protin1 m,1
atrial fibrillation,nitrates,1
atrial fibrillation,pacemaker implantation,2
atrial fibrillation,percent low density plaque,1
atrial fibrillation,percutaneous coronary intervention,1
atrial fibrillation,peripheral artery disease,1
atrial fibrillation,plaque volume,1
atrial fibrillation,renal impairment,1
atrial fibrillation,smoking,1
atrial fibrillation,sociodemographics,1
atrial fibrillation,sodium concentration,1
atrial fibrillation,statins,1
atrial fibrillation,systolic blood pressure,2
atrial fibrillation,uric acid,1
autonomic dysfunction,ankle-brachial index (ABI),1
autonomic dysfunction,distal polyneuropathy,1
autonomic nervous function,smoking,1
average of 3 daily 2hour bg levels after meals,diastolic blood pressure,1
average of 3 daily 2hour bg levels after meals,glycemic control,2
average of 3 daily 2hour bg levels after meals,hba1c,1
average of 3 daily 2hour bg levels after meals,heart rate,1
average of 3 daily 2hour bg levels after meals,systolic blood pressure,1
bapwv,carotid artery imt,1
baseline claudication,albumin excretion rate,1
baseline claudication,ankle-brachial index (ABI),1
baseline claudication,blood pressure,1
baseline claudication,bmi,2
baseline claudication,cholesterol,2
baseline claudication,clinic,1
baseline claudication,ecg abnormalities,1
baseline claudication,fibrinogen,1
baseline claudication,hba1c,1
baseline claudication,heart rate,1
baseline claudication,microalbuminuria,1
baseline claudication,physical activity,1
baseline medications,diabetes duration,1
baseline related risk factor level,baseline medications,1
baseline related risk factor level,diabetes duration,1
beta-blocker,ACE inhibitors,1
beta-blocker,ACEI/ARB,1
beta-blocker,age,1
beta-blocker,antidiabetic medication,1
beta-blocker,calcium channel blockers,3
beta-blocker,hyperlipidemia,1
beta-blocker,insulin treatment,1
beta-blocker,neuropathy,1
beta-blocker,peripheral artery disease,1
beta-blocker,pioglitazone treatment,1
beta-blocker,secretagogues,1
beta-blocker,statins,1
blockers,acute coronary syndrome,1
blockers,andor nitroglycerin,1
blockers,antidepressants,1
blockers,antihypertensive use,1
blockers,bnp,1
blockers,diuretic therapy,1
blockers,fibrates,1
blockers,insulin treatment,1
blockers,monocyte chemoattractant protin1 m,1
blockers,nitrates,1
blockers,statins,1
blood glucose,ApoAI,1
blood glucose,age,1
blood glucose,albumin,7
blood glucose,alcohol use,1
blood glucose,antihypertensive use,3
blood glucose,apoAI/apoB ratio,1
blood glucose,apoB,1
blood glucose,atrial fibrillation,1
blood glucose,blood pressure,1
blood glucose,bmi,6
blood glucose,c-reactive protein,4
blood glucose,calcium channel blockers,1
blood glucose,cardiovascular disease,3
blood glucose,cardiovascular risk factors,1
blood glucose,cerebrovascular disease,1
blood glucose,choleseterol,1
blood glucose,cholesterol,19
blood glucose,complex lesions,1
blood glucose,coronary artery disease,2
blood glucose,creatinine,8
blood glucose,diabetes,1
blood glucose,diabetes duration,3
blood glucose,diabetes treatment,4
blood glucose,diastolic blood pressure,2
blood glucose,diuretic therapy,1
blood glucose,family history of diabetes,1
blood glucose,fibrinogen,1
blood glucose,final timi flow,1
blood glucose,gender,2
blood glucose,hba1c,6
blood glucose,heart failure,1
blood glucose,heart rate,2
blood glucose,homair,1
blood glucose,homocysteine,1
blood glucose,hypertension,2
blood glucose,idf metabolic syndrome,1
blood glucose,insulin (measurment),1
blood glucose,insulin treatment,2
blood glucose,left ventricular ejection fraction,2
blood glucose,lipidlowering therapy,1
blood glucose,lowdensity lipoprotein,1
blood glucose,macrovascular complications,1
blood glucose,mean blood pressure,1
blood glucose,metformin,1
blood glucose,microalbuminuria,1
blood glucose,multivessel coronary disease,2
blood glucose,myocardial spect,1
blood glucose,nephropathy,1
blood glucose,nterminal probrain natriuretic peptide,1
blood glucose,other complications,1
blood glucose,percutaneous coronary intervention,1
blood glucose,peripheral artery disease,1
blood glucose,peripheral neuropathy,1
blood glucose,peripheral vascular disease,1
blood glucose,proteinuria,1
blood glucose,pulse pressure,1
blood glucose,qt interval,1
blood glucose,renal impairment,1
blood glucose,smoking,4
blood glucose,sociodemographics,1
blood glucose,stent,1
blood glucose,systolic blood pressure,4
blood glucose,triglycerides,10
blood glucose,troponin,1
blood glucose,use of blockers,1
blood glucose,waist measurements,1
blood pressure,ACE inhibitors,1
blood pressure,ACEI/ARB,1
blood pressure,acute coronary syndrome,1
blood pressure,albumin,2
blood pressure,albumin excretion rate,1
blood pressure,ankle-brachial index (ABI),1
blood pressure,antihypertensive use,2
blood pressure,antiplatelet therapy,2
blood pressure,beta-blocker,1
blood pressure,blood glucose,1
blood pressure,bmi,7
blood pressure,bnp,1
blood pressure,cardiovascular disease,1
blood pressure,cholesterol,14
blood pressure,coronary artery disease,1
blood pressure,coronary heart disease,2
blood pressure,creatinine,4
blood pressure,diabetes,1
blood pressure,diabetes treatment,1
blood pressure,diuretic therapy,1
blood pressure,ecg abnormalities,1
blood pressure,egfr,3
blood pressure,fibrinogen,1
blood pressure,hba1c,6
blood pressure,heart failure,2
blood pressure,heart rate,2
blood pressure,hyperlipidemia,1
blood pressure,hypertension,2
blood pressure,insulin (measurment),1
blood pressure,insulin treatment,1
blood pressure,lipid profile,3
blood pressure,lipidlowering therapy,2
blood pressure,metformin,1
blood pressure,microalbuminuria,3
blood pressure,microvascular disease,1
blood pressure,myocardial infarction,1
blood pressure,nephropathy,2
blood pressure,peripheral arterial occlusive disease,1
blood pressure,peripheral artery disease,2
blood pressure,physical activity,1
blood pressure,pioglitazone treatment,1
blood pressure,prior coronary artery bypass,1
blood pressure,provider quality controls,1
blood pressure,retinopathy,1
blood pressure,smoking,2
blood pressure,sociodemographics,1
blood pressure,statins,1
blood pressure,stroke,1
blood pressure,study treatment,1
blood pressure,sulfonylurea,2
blood pressure,therapy for hypercoagulation,1
blood pressure,triglycerides,5
blood pressure,uric acid,1
blood pressure,urinary albumin excretion rate,2
blood pressure,year fixed effects,1
blood transfusion,bmi,1
blood transfusion,diabetes,1
blood transfusion,egfr,1
blood transfusion,gastrointestinal bleeding in past 5 years,1
blood transfusion,heart rate,1
blood transfusion,hyperuricemia-gout,1
blood transfusion,lung disease,1
blood transfusion,peripheral artery disease,1
blood transfusion,systolic blood pressure,1
blood transfusion,white blood cell count,1
bmi,ACE inhibitors,4
bmi,ACEI/ARB,3
bmi,ARBs,5
bmi,ApoAI,1
bmi,CCr,1
bmi,Lp(a),1
bmi,RCT,5
bmi,acr,2
bmi,acute coronary syndrome,3
bmi,age,4
bmi,albumin,17
bmi,albumin excretion rate,5
bmi,albumin to creatinine ratio,4
bmi,alcohol use,11
bmi,alphaglucosidase inhibitor,1
bmi,andor nitroglycerin,1
bmi,angina,3
bmi,ankle-brachial index (ABI),3
bmi,antialdosterone,1
bmi,anticoagulants,1
bmi,antidepressants,1
bmi,antidiabetic medication,3
bmi,antihyperlipidemic drugs,2
bmi,antihypertensive use,18
bmi,antiplatelet therapy,10
bmi,apo(a) phenotypes,1
bmi,apoAI/apoB ratio,1
bmi,apoB,1
bmi,arteriovenous fistula,1
bmi,aspirin therapy,13
bmi,atrial fibrillation,5
bmi,autonomic dysfunction,2
bmi,average of 3 daily 2hour bg levels after meals,1
bmi,bapwv,1
bmi,beta-blocker,4
bmi,blockers,2
bmi,blood glucose,14
bmi,blood pressure,8
bmi,bnp,5
bmi,c-reactive protein,10
bmi,calcium channel blockers,3
bmi,cancer,1
bmi,cardiac autonomic neuropathy (CAN),1
bmi,cardiovascular disease,17
bmi,carotid artery imt,1
bmi,cerebrovascular disease,3
bmi,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
bmi,cholesterol,162
bmi,chronic kidney disease,5
bmi,chronic obstructive pulmonary disease,1
bmi,chronic renal failure,1
bmi,cimt,3
bmi,clinic,1
bmi,clopidigrel,1
bmi,clopidogrel,1
bmi,combined alox12 genotypes,1
bmi,complete revascularization,1
bmi,complex lesions,1
bmi,coronary artery calcium score,2
bmi,coronary artery disease,7
bmi,coronary heart disease,7
bmi,creatinine,32
bmi,dcb use,1
bmi,depression,1
bmi,diabetes,4
bmi,diabetes duration,30
bmi,diabetes treatment,17
bmi,diabetic neuropathy,1
bmi,dialysis,4
bmi,diastolic blood pressure,26
bmi,dipeptidyl peptidase 4 inhibitor at discharge,1
bmi,dipyridamole stress test,1
bmi,distal polyneuropathy,1
bmi,diuretic therapy,3
bmi,dpucmgp,1
bmi,ecg abnormalities,15
bmi,egfr,27
bmi,ejection fraction,1
bmi,ejection fraction 40,1
bmi,endothelial dysfunction,1
bmi,fasting plasma glucose,2
bmi,fasting status yes or no,1
bmi,fibrates,1
bmi,fibrinogen,7
bmi,gastrointestinal bleeding in past 5 years,1
bmi,gender,2
bmi,glycated hemoglobin,1
bmi,glycemic control,6
bmi,hba1c,80
bmi,heart failure,8
bmi,heart rate,7
bmi,height,2
bmi,highdensity lipoprotein,3
bmi,history of coronary disease,1
bmi,homair,3
bmi,homocysteine,2
bmi,homocysteine at baseline,1
bmi,hyperlipidemia,11
bmi,hypertension,42
bmi,hyperuricemia-gout,1
bmi,idf metabolic syndrome,1
bmi,incretins,1
bmi,indigenous australian,1
bmi,inflammatory markers,1
bmi,insulin (measurment),3
bmi,insulin treatment,16
bmi,ischemia,1
bmi,ischemic heart disease,2
bmi,left ventricular ejection fraction,6
bmi,left ventricular hypertrophy,2
bmi,"leisure time physical activity",1
bmi,lipid profile,3
bmi,lipidlowering therapy,10
bmi,lm treatment,1
bmi,lowdensity lipoprotein,1
bmi,lung disease,1
bmi,macroalbuminuria,3
bmi,macroangiopathy,1
bmi,macrovascular complications,9
bmi,medication use,1
bmi,metformin,5
bmi,microalbuminuria,7
bmi,microvascular disease,9
bmi,monocyte chemoattractant protin1 m,1
bmi,multivessel coronary disease,2
bmi,myocardial infarction,11
bmi,myocardial spect,1
bmi,nephropathy,2
bmi,neuropathy,3
bmi,nitrates,1
bmi,nterminal probrain natriuretic peptide,1
bmi,other lifestyle risk factors,1
bmi,pacemaker implantation,1
bmi,pc screen time,1
bmi,percutaneous coronary intervention,3
bmi,peripheral arterial occlusive disease,1
bmi,peripheral artery disease,8
bmi,peripheral neuropathy,1
bmi,peripheral vascular disease,3
bmi,phosphate,2
bmi,physical activity,9
bmi,physical inactivity,4
bmi,pioglitazone treatment,1
bmi,previous pcicabg,1
bmi,prior coronary artery bypass,3
bmi,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
bmi,proteinuria,2
bmi,provider quality controls,1
bmi,psychiatric medications,1
bmi,pulse pressure,2
bmi,race/ethnicity,3
bmi,ratio between total,1
bmi,reactive hyperemia index,1
bmi,renal impairment,1
bmi,renal insufficiency,1
bmi,renin-angiotensin system inhibitors,2
bmi,retinopathy,7
bmi,secretagogues,1
bmi,sensory neuropathy presentabsent,1
bmi,significant proximal lad disease,1
bmi,sleep duration,2
bmi,smoking,60
bmi,sociodemographics,7
bmi,socioeconomic variables,6
bmi,sodium concentration,2
bmi,statins,21
bmi,stent,2
bmi,stroke,9
bmi,study treatment,1
bmi,sulfonylurea,5
bmi,syntax score,1
bmi,systolic blood pressure,53
bmi,the presence of total occlusion,1
bmi,the use of drugs yesno,1
bmi,therapy for hypercoagulation,1
bmi,thiazolidinediones,1
bmi,tot chol,1
bmi,treatment,1
bmi,triacylglycerol,3
bmi,triglycerides,50
bmi,troponin,1
bmi,tryglycerides,1
bmi,tv viewing,1
bmi,ultrafiltration volume,2
bmi,uric acid,1
bmi,urinary acr,3
bmi,urinary albumin excretion rate,3
bmi,urinary protein log,1
bmi,use of blockers,1
bmi,use of sulfonamides,1
bmi,waist measurements,9
bmi,wasting,1
bmi,white blood cell count,2
bmi,year fixed effects,1
bnp,age,1
bnp,angina,2
bnp,atrial fibrillation,1
bnp,cholesterol,1
bnp,creatinine,1
bnp,glycated hemoglobin,1
bnp,haemoglobin,1
bnp,heart rate,2
bnp,lack of coronary revascularization,1
bnp,monocyte chemoattractant protin1 m,1
bnp,myocardial infarction,1
bnp,pacemaker implantation,1
bnp,peripheral artery disease,1
bnp,prior coronary artery bypass,1
bnp,systolic blood pressure,1
c-reactive protein,ACE inhibitors,1
c-reactive protein,ARBs,1
c-reactive protein,RCT,1
c-reactive protein,acute coronary syndrome,1
c-reactive protein,albumin,2
c-reactive protein,andor nitroglycerin,1
c-reactive protein,antialdosterone,1
c-reactive protein,anticoagulants,1
c-reactive protein,antiplatelet therapy,1
c-reactive protein,aspirin therapy,2
c-reactive protein,blockers,1
c-reactive protein,blood glucose,2
c-reactive protein,bmi,2
c-reactive protein,bnp,4
c-reactive protein,cardiovascular disease,2
c-reactive protein,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
c-reactive protein,cholesterol,3
c-reactive protein,chronic obstructive pulmonary disease,1
c-reactive protein,cimt,1
c-reactive protein,clopidogrel,1
c-reactive protein,complex lesions,1
c-reactive protein,coronary artery disease,1
c-reactive protein,creatinine,3
c-reactive protein,diabetes duration,2
c-reactive protein,diabetes treatment,2
c-reactive protein,diastolic blood pressure,1
c-reactive protein,diuretic therapy,2
c-reactive protein,fasting plasma glucose,1
c-reactive protein,fibrinogen,1
c-reactive protein,hba1c,4
c-reactive protein,homocysteine,1
c-reactive protein,hyperlipidemia,1
c-reactive protein,hypertension,1
c-reactive protein,insulin treatment,2
c-reactive protein,left ventricular ejection fraction,2
c-reactive protein,logaer,1
c-reactive protein,medication differences,1
c-reactive protein,monocyte chemoattractant protin1 m,1
c-reactive protein,multivessel coronary disease,1
c-reactive protein,nitrates,1
c-reactive protein,nterminal probrain natriuretic peptide,1
c-reactive protein,peripheral artery disease,1
c-reactive protein,smoking,2
c-reactive protein,statins,2
c-reactive protein,systolic blood pressure,3
c-reactive protein,triglycerides,1
c-reactive protein,troponin,1
c-reactive protein,uric acid,1
calcium channel blockers,age,1
calcium channel blockers,beta-blocker,1
calcium channel blockers,hyperlipidemia,1
calcium channel blockers,neuropathy,1
calcium channel blockers,peripheral artery disease,1
calcium channel blockers,secretagogues,1
calcium channel blockers,systolic blood pressure,1
cardiovascular autonomic neuropathy,diastolic blood pressure,1
cardiovascular autonomic neuropathy,ecg abnormalities,1
cardiovascular autonomic neuropathy,hypertension,1
cardiovascular autonomic neuropathy,insulin treatment,1
cardiovascular autonomic neuropathy,smoking,1
cardiovascular disease,ACE inhibitors,1
cardiovascular disease,ACEI/ARB,1
cardiovascular disease,ARBs,1
cardiovascular disease,RCT,3
cardiovascular disease,Serum 25-hydroxyvitamin D,1
cardiovascular disease,acr,1
cardiovascular disease,age,2
cardiovascular disease,albumin,4
cardiovascular disease,albumin excretion rate,1
cardiovascular disease,alcohol use,1
cardiovascular disease,ankle-brachial index (ABI),1
cardiovascular disease,antidepressants,1
cardiovascular disease,antidiabetic medication,1
cardiovascular disease,antihypertensive use,6
cardiovascular disease,antiplatelet therapy,2
cardiovascular disease,atrial fibrillation,2
cardiovascular disease,blockers,1
cardiovascular disease,blood glucose,3
cardiovascular disease,blood pressure,4
cardiovascular disease,bmi,9
cardiovascular disease,bnp,1
cardiovascular disease,c-reactive protein,1
cardiovascular disease,cancer,1
cardiovascular disease,cholesterol,24
cardiovascular disease,chronic kidney disease,3
cardiovascular disease,cimt,2
cardiovascular disease,combined alox12 genotypes,1
cardiovascular disease,creatinine,4
cardiovascular disease,depression,1
cardiovascular disease,diabetes,3
cardiovascular disease,diabetes duration,7
cardiovascular disease,diabetes treatment,4
cardiovascular disease,diabetic neuropathy,1
cardiovascular disease,diastolic blood pressure,1
cardiovascular disease,dpucmgp,1
cardiovascular disease,ecg abnormalities,2
cardiovascular disease,egfr,6
cardiovascular disease,expected costs,1
cardiovascular disease,fasting plasma glucose,2
cardiovascular disease,fibrates,1
cardiovascular disease,fibrinogen,2
cardiovascular disease,fpi,1
cardiovascular disease,gender,2
cardiovascular disease,glycemic control,2
cardiovascular disease,hba1c,13
cardiovascular disease,heart failure,3
cardiovascular disease,homair,1
cardiovascular disease,homocysteine at baseline,1
cardiovascular disease,hyperlipidemia,1
cardiovascular disease,hypertension,4
cardiovascular disease,insulin treatment,3
cardiovascular disease,left ventricular ejection fraction,1
cardiovascular disease,lipid profile,1
cardiovascular disease,lipidlowering therapy,3
cardiovascular disease,lowdensity lipoprotein,1
cardiovascular disease,macroalbuminuria,1
cardiovascular disease,metformin,1
cardiovascular disease,microalbuminuria,2
cardiovascular disease,microvascular disease,2
cardiovascular disease,nephropathy,3
cardiovascular disease,neuropathy,3
cardiovascular disease,other conventional risk factors,1
cardiovascular disease,pIMT,1
cardiovascular disease,peripheral artery disease,1
cardiovascular disease,peripherovascular morbidity,1
cardiovascular disease,physical activity,1
cardiovascular disease,pulse pressure,1
cardiovascular disease,race/ethnicity,1
cardiovascular disease,ratio between total,1
cardiovascular disease,renal impairment,1
cardiovascular disease,renin-angiotensin system inhibitors,1
cardiovascular disease,retinopathy,4
cardiovascular disease,smoking,15
cardiovascular disease,sociodemographics,3
cardiovascular disease,statins,4
cardiovascular disease,sulfonylurea,1
cardiovascular disease,systolic blood pressure,7
cardiovascular disease,thiazolidinediones,1
cardiovascular disease,treatment intensity,1
cardiovascular disease,triacylglycerol,1
cardiovascular disease,triglycerides,8
cardiovascular disease,type of treatment,1
cardiovascular disease,uric acid,1
cardiovascular disease,urinary acr,1
cardiovascular disease,urinary albumin excretion rate,1
cardiovascular disease,white blood cell count,1
cardiovascular risk factors,albumin,1
cardiovascular risk factors,antihypertensive use,1
cardiovascular risk factors,aspirin therapy,1
cardiovascular risk factors,c-reactive protein,1
cardiovascular risk factors,coronary anatomy,1
cardiovascular risk factors,diabetes,1
cardiovascular risk factors,ecg abnormalities,1
cardiovascular risk factors,lipidlowering therapy,1
cardiovascular risk factors,medication differences,1
cardiovascular risk factors,medications,1
cardiovascular risk factors,metformin,1
cardiovascular risk factors,serum magnesium,1
cerebrovascular disease,ACE inhibitors,1
cerebrovascular disease,ARBs,1
cerebrovascular disease,acute coronary syndrome,1
cerebrovascular disease,age,2
cerebrovascular disease,albumin,2
cerebrovascular disease,andor nitroglycerin,1
cerebrovascular disease,antialdosterone,1
cerebrovascular disease,anticoagulants,1
cerebrovascular disease,antidiabetic medication,1
cerebrovascular disease,antihypertensive use,1
cerebrovascular disease,antiplatelet therapy,1
cerebrovascular disease,aspirin therapy,2
cerebrovascular disease,atrial fibrillation,2
cerebrovascular disease,blockers,1
cerebrovascular disease,bmi,3
cerebrovascular disease,bnp,1
cerebrovascular disease,c-reactive protein,1
cerebrovascular disease,cholesterol,2
cerebrovascular disease,chronic kidney disease,1
cerebrovascular disease,clopidogrel,1
cerebrovascular disease,diabetes duration,1
cerebrovascular disease,diuretic therapy,1
cerebrovascular disease,egfr,1
cerebrovascular disease,ejection fraction 40,1
cerebrovascular disease,gender,1
cerebrovascular disease,hba1c,3
cerebrovascular disease,heart failure,1
cerebrovascular disease,highdensity lipoprotein,1
cerebrovascular disease,hypertension,1
cerebrovascular disease,insulin treatment,1
cerebrovascular disease,lipidlowering therapy,1
cerebrovascular disease,lowdensity lipoprotein,1
cerebrovascular disease,macroalbuminuria,1
cerebrovascular disease,metformin,1
cerebrovascular disease,monocyte chemoattractant protin1 m,1
cerebrovascular disease,myocardial infarction,1
cerebrovascular disease,nitrates,1
cerebrovascular disease,peripheral artery disease,1
cerebrovascular disease,peripheral neuropathy,1
cerebrovascular disease,peripheral vascular disease,1
cerebrovascular disease,sociodemographics,1
cerebrovascular disease,sodium concentration,1
cerebrovascular disease,statins,1
cerebrovascular disease,triacylglycerol,1
charlson index,c-reactive protein,1
charlson index,cardiovascular disease,1
charlson index,diastolic blood pressure,1
charlson index,egfr,1
charlson index,hba1c,1
charlson index,proteinuria,1
charlson index,systolic blood pressure,1
charlson index,total baseline expenditures,1
choleseterol,albumin,1
cholesterol,ACE inhibitors,9
cholesterol,ACEI/ARB,6
cholesterol,ARBs,5
cholesterol,ApoAI,5
cholesterol,RCT,10
cholesterol,acute coronary syndrome,5
cholesterol,age,5
cholesterol,albumin,29
cholesterol,albumin excretion rate,10
cholesterol,albumin to creatinine ratio,4
cholesterol,alcohol use,8
cholesterol,alphaglucosidase inhibitor,2
cholesterol,andor nitroglycerin,2
cholesterol,angina,1
cholesterol,ankle-brachial index (ABI),7
cholesterol,antiaggregating agents,2
cholesterol,antialdosterone,2
cholesterol,anticoagulants,2
cholesterol,antidepressants,1
cholesterol,antidiabetic medication,2
cholesterol,antihyperlipidemic drugs,2
cholesterol,antihypertensive use,28
cholesterol,antiplatelet therapy,12
cholesterol,apo(a) phenotypes,3
cholesterol,apoAI/apoB ratio,5
cholesterol,apoB,5
cholesterol,arteriovenous fistula,1
cholesterol,aspirin therapy,22
cholesterol,atrial fibrillation,6
cholesterol,autonomic dysfunction,6
cholesterol,bapwv,2
cholesterol,beta-blocker,4
cholesterol,blockers,3
cholesterol,blood glucose,14
cholesterol,blood pressure,7
cholesterol,bmi,38
cholesterol,bnp,14
cholesterol,c-reactive protein,25
cholesterol,calcium channel blockers,1
cholesterol,cancer,1
cholesterol,cardiovascular disease,24
cholesterol,carotid artery imt,2
cholesterol,cerebrovascular disease,5
cholesterol,change of esrage endogenous secretory receptor of advanced glycated endproducts,3
cholesterol,charlson index,2
cholesterol,choleseterol,1
cholesterol,chronic kidney disease,5
cholesterol,cimt,7
cholesterol,clopidigrel,2
cholesterol,clopidogrel,2
cholesterol,combined alox12 genotypes,3
cholesterol,complete revascularization,2
cholesterol,complex lesions,1
cholesterol,coronary artery calcium score,4
cholesterol,coronary artery disease,7
cholesterol,coronary heart disease,10
cholesterol,creatinine,35
cholesterol,dcb use,2
cholesterol,depression,1
cholesterol,diabetes,3
cholesterol,diabetes duration,27
cholesterol,diabetes treatment,21
cholesterol,diabetic neuropathy,2
cholesterol,dialysis,2
cholesterol,diastolic blood pressure,20
cholesterol,dipeptidyl peptidase 4 inhibitor at discharge,2
cholesterol,distal polyneuropathy,3
cholesterol,diuretic therapy,5
cholesterol,dpucmgp,2
cholesterol,ecg abnormalities,12
cholesterol,echolucent plaque,2
cholesterol,egfr,39
cholesterol,ejection fraction 40,2
cholesterol,endothelial dysfunction,3
cholesterol,fasting cpeptide,1
cholesterol,fasting plasma glucose,4
cholesterol,fibrates,1
cholesterol,fibrinogen,13
cholesterol,gender,6
cholesterol,glycated hemoglobin,2
cholesterol,glycemic control,7
cholesterol,hba1c,87
cholesterol,heart attack,1
cholesterol,heart failure,5
cholesterol,heart rate,4
cholesterol,height,3
cholesterol,hemoglobin,2
cholesterol,high density lipoprotein level,1
cholesterol,highdensity lipoprotein,2
cholesterol,history of coronary disease,1
cholesterol,homair,5
cholesterol,homocysteine,5
cholesterol,homocysteine at baseline,2
cholesterol,hyperlipidemia,3
cholesterol,hypertension,38
cholesterol,idf metabolic syndrome,5
cholesterol,inflammatory markers,1
cholesterol,insulin (measurment),11
cholesterol,insulin treatment,24
cholesterol,ischemic heart disease,4
cholesterol,left ventricular ejection fraction,6
cholesterol,left ventricular hypertrophy,1
cholesterol,"leisure time physical activity",1
cholesterol,lipidlowering therapy,20
cholesterol,lm treatment,2
cholesterol,log101  acr,2
cholesterol,logaer,1
cholesterol,lowdensity lipoprotein,1
cholesterol,macroalbuminuria,1
cholesterol,macrovascular complications,4
cholesterol,medication use,1
cholesterol,metformin,7
cholesterol,microalbuminuria,5
cholesterol,microvascular disease,5
cholesterol,mild plaque calcifi cation,2
cholesterol,monocyte chemoattractant protin1 m,2
cholesterol,multivessel coronary disease,4
cholesterol,myocardial infarction,8
cholesterol,nephropathy,3
cholesterol,neuropathy,1
cholesterol,nitrates,2
cholesterol,nterminal probrain natriuretic peptide,3
cholesterol,pacemaker implantation,1
cholesterol,pc screen time,1
cholesterol,percent low density plaque,2
cholesterol,peripheral arterial occlusive disease,2
cholesterol,peripheral artery disease,7
cholesterol,peripheral neuropathy,2
cholesterol,peripheral vascular disease,4
cholesterol,phosphate,1
cholesterol,physical activity,7
cholesterol,pioglitazone treatment,2
cholesterol,plaque thickness,2
cholesterol,plaque volume,2
cholesterol,prior coronary artery bypass,3
cholesterol,proteinuria,5
cholesterol,provider quality controls,1
cholesterol,pulse pressure,4
cholesterol,race/ethnicity,6
cholesterol,reactive hyperemia index,1
cholesterol,referring physician,1
cholesterol,renal impairment,1
cholesterol,renal insufficiency,1
cholesterol,renin-angiotensin system inhibitors,5
cholesterol,retinopathy,16
cholesterol,sensory neuropathy,2
cholesterol,sensory neuropathy presentabsent,2
cholesterol,significant proximal lad disease,1
cholesterol,sleep duration,2
cholesterol,smoking,73
cholesterol,sociodemographics,6
cholesterol,socioeconomic variables,4
cholesterol,statins,33
cholesterol,stent,3
cholesterol,stroke,11
cholesterol,sulfonylurea,6
cholesterol,syntax score,2
cholesterol,systolic blood pressure,45
cholesterol,the presence of total occlusion,1
cholesterol,the use of drugs yesno,2
cholesterol,therapy for hypercoagulation,3
cholesterol,thiazolidinediones,1
cholesterol,tot chol,1
cholesterol,triacylglycerol,6
cholesterol,triglycerides,92
cholesterol,troponin,2
cholesterol,tryglycerides,2
cholesterol,tv viewing,1
cholesterol,ultrafiltration volume,1
cholesterol,uric acid,6
cholesterol,urinary,1
cholesterol,urinary acr,4
cholesterol,urinary albumin excretion rate,7
cholesterol,urinary protein log,2
cholesterol,use of blockers,1
cholesterol,waist measurements,10
cholesterol,wasting,1
cholesterol,white blood cell count,1
cholesterol,year fixed effects,1
chronic kidney disease,ACE inhibitors,1
chronic kidney disease,ARBs,2
chronic kidney disease,RCT,1
chronic kidney disease,acute coronary syndrome,1
chronic kidney disease,andor nitroglycerin,1
chronic kidney disease,antialdosterone,1
chronic kidney disease,anticoagulants,1
chronic kidney disease,antidepressants,1
chronic kidney disease,antidiabetic medication,1
chronic kidney disease,antihypertensive use,3
chronic kidney disease,antiplatelet therapy,2
chronic kidney disease,aspirin therapy,1
chronic kidney disease,atrial fibrillation,1
chronic kidney disease,blockers,2
chronic kidney disease,bmi,2
chronic kidney disease,bnp,1
chronic kidney disease,c-reactive protein,1
chronic kidney disease,cardiovascular disease,3
chronic kidney disease,charlson index,1
chronic kidney disease,clopidogrel,1
chronic kidney disease,diabetes duration,1
chronic kidney disease,diabetes treatment,1
chronic kidney disease,diuretic therapy,1
chronic kidney disease,fibrates,1
chronic kidney disease,insulin treatment,3
chronic kidney disease,lipidlowering therapy,1
chronic kidney disease,metformin,1
chronic kidney disease,monocyte chemoattractant protin1 m,1
chronic kidney disease,nitrates,1
chronic kidney disease,proteinuria,1
chronic kidney disease,retinopathy,1
chronic kidney disease,socioeconomic variables,1
chronic kidney disease,statins,3
chronic kidney disease,sulfonylurea,1
chronic kidney disease,thiazolidinediones,1
chronic kidney disease,total baseline expenditures,1
chronic obstructive pulmonary disease,diabetes duration,1
chronic obstructive pulmonary disease,diabetes treatment,1
chronic obstructive pulmonary disease,fasting plasma glucose,1
chronic obstructive pulmonary disease,hba1c,1
chronic renal failure,cholesterol,1
chronic renal failure,diabetes treatment,1
chronic renal failure,statins,1
ci,albumin,1
ci,cholesterol,1
ci,macrovascular complications,1
ci,smoking,1
ci,systolic blood pressure,1
cimt,combined alox12 genotypes,1
cimt,dpucmgp,1
cimt,renin-angiotensin system inhibitors,1
cimt,statins,1
clinic,albumin excretion rate,1
clinic,ankle-brachial index (ABI),1
clinic,blood pressure,1
clinic,bmi,1
clinic,cholesterol,2
clinic,ecg abnormalities,1
clinic,fibrinogen,1
clinic,hba1c,1
clinic,heart rate,1
clinic,microalbuminuria,1
clinic,physical activity,1
clinical risk scores,Computed Tomography Angiography (CTA) variables,1
clinical risk scores,coronary artery calcium score,1
clinical variables,biomarkers,1
clinical variables,cardiovascular risk factors,1
clinical variables,diabetes,1
clinical variables,drug use,1
clinical variables,ecg abnormalities,1
clinical variables,echocardiographic variables,1
clinical variables,imaging risk predictors,1
clinical variables,metformin,1
clinical variables,other complications,1
clinical variables,serum magnesium,1
clinical variables,sociodemographics,1
clinical variables,stress variables,1
clopidigrel,ACEI/ARB,1
clopidigrel,antidiabetic medication,1
clopidigrel,beta-blocker,1
clopidigrel,insulin treatment,1
clopidigrel,statins,1
clopidogrel,ACE inhibitors,1
clopidogrel,ARBs,1
clopidogrel,acute coronary syndrome,1
clopidogrel,andor nitroglycerin,1
clopidogrel,antialdosterone,1
clopidogrel,anticoagulants,1
clopidogrel,antiplatelet therapy,1
clopidogrel,blockers,1
clopidogrel,bnp,1
clopidogrel,diuretic therapy,1
clopidogrel,insulin treatment,1
clopidogrel,monocyte chemoattractant protin1 m,1
clopidogrel,mpv mean platelet volume,1
clopidogrel,nitrates,1
clopidogrel,statins,1
clopidogrel,syntax score,1
clopidogrel,uric acid,1
clustering,age,1
clustering,bmi,1
clustering,diabetes duration,1
clustering,gender,1
clustering,history of coronary disease,1
clustering,smoking,1
comorbidity,baseline medications,1
comorbidity,baseline related risk factor level,1
comorbidity,diabetes duration,1
complete revascularization,alphaglucosidase inhibitor,1
complete revascularization,antiplatelet therapy,2
complete revascularization,dipeptidyl peptidase 4 inhibitor at discharge,1
complete revascularization,glycemic control,1
complete revascularization,insulin (measurment),1
complete revascularization,statins,2
complete revascularization,sulfonylurea,1
complex lesions,diuretic therapy,1
complex lesions,insulin treatment,1
complex lesions,left ventricular ejection fraction,1
coronary artery calcium score,Computed Tomography Angiography (CTA) variables,1
coronary artery calcium score,age,1
coronary artery calcium score,albumin,1
coronary artery calcium score,bnp,2
coronary artery calcium score,carotid intima media thickness,1
coronary artery calcium score,cholesterol,1
coronary artery calcium score,creatinine,1
coronary artery calcium score,inflammatory markers,1
coronary artery calcium score,reactive hyperemia index,1
coronary artery calcium score,tnfalpha,1
coronary artery calcium score,triglycerides,1
coronary artery calcium score,uric acid,1
coronary artery disease,ACE inhibitors,1
coronary artery disease,ACEI/ARB,1
coronary artery disease,Lp(a),1
coronary artery disease,acute coronary syndrome,1
coronary artery disease,age,1
coronary artery disease,albumin,4
coronary artery disease,angina,2
coronary artery disease,ankle-brachial index (ABI),2
coronary artery disease,antidiabetic medication,1
coronary artery disease,apo(a) phenotypes,1
coronary artery disease,arteriovenous fistula,1
coronary artery disease,autonomic dysfunction,2
coronary artery disease,autonomic nervous function,1
coronary artery disease,beta-blocker,2
coronary artery disease,blood glucose,1
coronary artery disease,bmi,5
coronary artery disease,bnp,2
coronary artery disease,c-reactive protein,2
coronary artery disease,cardiovascular disease,2
coronary artery disease,cholesterol,21
coronary artery disease,clopidigrel,1
coronary artery disease,creatinine,2
coronary artery disease,diabetes duration,2
coronary artery disease,diabetes treatment,1
coronary artery disease,dialysis,3
coronary artery disease,dipyridamole stress test,1
coronary artery disease,distal polyneuropathy,1
coronary artery disease,diuretic therapy,1
coronary artery disease,dyslipidaemia,1
coronary artery disease,ecg abnormalities,2
coronary artery disease,egfr,2
coronary artery disease,endothelial dysfunction,1
coronary artery disease,fasting plasma glucose,1
coronary artery disease,gender,1
coronary artery disease,glycemic control,1
coronary artery disease,hba1c,12
coronary artery disease,heart failure,4
coronary artery disease,hemodynamic measures,1
coronary artery disease,hyperlipidemia,2
coronary artery disease,hypertension,3
coronary artery disease,insulin (measurment),1
coronary artery disease,insulin treatment,1
coronary artery disease,ischemia,1
coronary artery disease,left ventricular ejection fraction,2
coronary artery disease,macroalbuminuria,1
coronary artery disease,metformin,1
coronary artery disease,microalbuminuria,4
coronary artery disease,minimum lumen diameter,1
coronary artery disease,multivessel coronary disease,1
coronary artery disease,myocardial infarction,2
coronary artery disease,percutaneous coronary intervention,1
coronary artery disease,peripheral arterial occlusive disease,2
coronary artery disease,peripheral artery disease,2
coronary artery disease,peripheral vascular disease,1
coronary artery disease,phosphate,2
coronary artery disease,pioglitazone treatment,1
coronary artery disease,prior coronary artery bypass,1
coronary artery disease,race/ethnicity,1
coronary artery disease,renal insufficiency,1
coronary artery disease,smoking,9
coronary artery disease,statins,4
coronary artery disease,stent,2
coronary artery disease,stroke,6
coronary artery disease,sulfonylurea,1
coronary artery disease,systolic blood pressure,2
coronary artery disease,triglycerides,6
coronary artery disease,ultrafiltration volume,2
coronary artery disease,vessel size,1
coronary heart disease,ACEI/ARB,1
coronary heart disease,aspirin therapy,1
coronary heart disease,cardiovascular disease,2
coronary heart disease,cholesterol,3
coronary heart disease,creatinine,1
coronary heart disease,diabetes treatment,1
coronary heart disease,fibrinogen,1
coronary heart disease,hba1c,4
coronary heart disease,hypertension,1
coronary heart disease,insulin treatment,1
coronary heart disease,medication use,1
coronary heart disease,neuropathy,1
coronary heart disease,peripheral artery disease,1
coronary heart disease,retinopathy,1
coronary heart disease,smoking,2
coronary heart disease,systolic blood pressure,1
coronary heart disease,uoer,2
coronary heart disease,urinary acr,1
creatinine,ACE inhibitors,1
creatinine,ACEI/ARB,2
creatinine,ARBs,1
creatinine,ApoAI,2
creatinine,CCr,1
creatinine,RCT,2
creatinine,acute coronary syndrome,1
creatinine,age,2
creatinine,albumin,6
creatinine,albumin excretion rate,3
creatinine,angina,1
creatinine,ankle-brachial index (ABI),1
creatinine,antidiabetic medication,1
creatinine,antihyperlipidemic drugs,1
creatinine,antihypertensive use,3
creatinine,antiplatelet therapy,1
creatinine,apoAI/apoB ratio,2
creatinine,apoB,2
creatinine,aspirin therapy,2
creatinine,atrial fibrillation,1
creatinine,beta-blocker,4
creatinine,blood glucose,3
creatinine,blood pressure,1
creatinine,bmi,3
creatinine,bnp,2
creatinine,c-reactive protein,4
creatinine,calcium channel blockers,2
creatinine,cardiovascular disease,1
creatinine,cardiovascular risk factors,1
creatinine,carotid intima media thickness,1
creatinine,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
creatinine,choleseterol,1
creatinine,cholesterol,27
creatinine,chronic obstructive pulmonary disease,1
creatinine,clopidigrel,1
creatinine,coronary artery calcium score,2
creatinine,coronary artery disease,2
creatinine,coronary heart disease,2
creatinine,diabetes,1
creatinine,diabetes duration,5
creatinine,diabetes treatment,6
creatinine,diastolic blood pressure,1
creatinine,diuretic therapy,1
creatinine,ecg abnormalities,3
creatinine,egfr,1
creatinine,fasting plasma glucose,1
creatinine,fibrinogen,2
creatinine,folate,1
creatinine,glycemic control,1
creatinine,hba1c,10
creatinine,hemoglobin,1
creatinine,homair,2
creatinine,homocysteine,3
creatinine,homocysteine at baseline,1
creatinine,hyperlipidemia,3
creatinine,hypertension,3
creatinine,idf metabolic syndrome,2
creatinine,incretins,1
creatinine,inflammatory markers,1
creatinine,insulin (measurment),3
creatinine,insulin treatment,3
creatinine,left ventricular ejection fraction,1
creatinine,lipidlowering therapy,1
creatinine,macroalbuminuria,1
creatinine,macroangiopathy,1
creatinine,metformin,2
creatinine,microalbuminuria,2
creatinine,microvascular disease,1
creatinine,myocardial infarction,1
creatinine,neuropathy,1
creatinine,nterminal probrain natriuretic peptide,1
creatinine,pacemaker implantation,1
creatinine,peripheral arterial occlusive disease,1
creatinine,peripheral artery disease,2
creatinine,pioglitazone treatment,1
creatinine,prior coronary artery bypass,1
creatinine,provider quality controls,1
creatinine,pulse pressure,1
creatinine,race/ethnicity,1
creatinine,secretagogues,1
creatinine,significant proximal lad disease,1
creatinine,smoking,4
creatinine,sociodemographics,1
creatinine,socioeconomic variables,1
creatinine,statins,2
creatinine,stroke,1
creatinine,sulfonylurea,2
creatinine,systolic blood pressure,7
creatinine,the presence of total occlusion,1
creatinine,therapy for hypercoagulation,1
creatinine,tnfalpha,1
creatinine,triglycerides,10
creatinine,uoer,1
creatinine,uric acid,2
creatinine,urinary albumin excretion rate,5
creatinine,vitamin b12,1
creatinine,year fixed effects,1
current multifactorial care,myocardial infarction,1
current multifactorial care,peripheral artery disease,1
dcb use,alphaglucosidase inhibitor,1
dcb use,antiplatelet therapy,2
dcb use,complete revascularization,1
dcb use,dipeptidyl peptidase 4 inhibitor at discharge,1
dcb use,glycemic control,1
dcb use,insulin (measurment),1
dcb use,statins,2
dcb use,sulfonylurea,1
dcsi,hyperlipidemia,1
depression,ARBs,1
depression,antidepressants,1
depression,antihypertensive use,1
depression,blockers,1
depression,chronic kidney disease,1
depression,fibrates,1
depression,insulin treatment,1
depression,metformin,1
depression,statins,1
depression,sulfonylurea,1
depression,thiazolidinediones,1
diabetes,RCT,1
diabetes,Serum 25-hydroxyvitamin D,1
diabetes,antiplatelet therapy,1
diabetes,blood pressure,1
diabetes,bmi,4
diabetes,c-reactive protein,1
diabetes,cancer,1
diabetes,cardiovascular disease,3
diabetes,cardiovascular risk factors,1
diabetes,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
diabetes,cholesterol,7
diabetes,chronic kidney disease,1
diabetes,coronary anatomy,1
diabetes,coronary artery disease,1
diabetes,creatinine,2
diabetes,diabetes duration,3
diabetes,disease duration,1
diabetes,duration,1
diabetes,ecg abnormalities,1
diabetes,egfr,3
diabetes,fpi,1
diabetes,glycemic control,1
diabetes,hba1c,4
diabetes,heart failure,1
diabetes,hemodynamic measures,1
diabetes,hyperlipidemia,1
diabetes,hypertension,2
diabetes,insulin treatment,1
diabetes,lipid profile,1
diabetes,medical diabetic treatment,1
diabetes,metformin,1
diabetes,minimum lumen diameter,1
diabetes,other complications,1
diabetes,serum magnesium,1
diabetes,smoking,4
diabetes,sociodemographics,1
diabetes,statins,1
diabetes,stent,1
diabetes,systolic blood pressure,4
diabetes,triglycerides,2
diabetes,urinary protein log,1
diabetes,vessel size,1
diabetes duration,ACE inhibitors,4
diabetes duration,ACEI/ARB,2
diabetes duration,ARBs,3
diabetes duration,ApoAI,1
diabetes duration,CCr,1
diabetes duration,RCT,6
diabetes duration,acr,2
diabetes duration,acute coronary syndrome,1
diabetes duration,age,4
diabetes duration,albumin,16
diabetes duration,albumin excretion rate,6
diabetes duration,albumin to creatinine ratio,5
diabetes duration,alcohol use,8
diabetes duration,alphaglucosidase inhibitor,1
diabetes duration,ankle-brachial index (ABI),3
diabetes duration,antidepressants,1
diabetes duration,antidiabetic medication,1
diabetes duration,antihyperlipidemic drugs,1
diabetes duration,antihypertensive use,16
diabetes duration,antiplatelet therapy,9
diabetes duration,apoAI/apoB ratio,2
diabetes duration,apoB,1
diabetes duration,aspirin therapy,11
diabetes duration,atrial fibrillation,3
diabetes duration,autonomic dysfunction,2
diabetes duration,baseline claudication,1
diabetes duration,beta-blocker,1
diabetes duration,biomarkers (general),1
diabetes duration,blockers,1
diabetes duration,blood glucose,8
diabetes duration,blood pressure,13
diabetes duration,bmi,53
diabetes duration,bnp,2
diabetes duration,c-reactive protein,5
diabetes duration,calcium channel blockers,1
diabetes duration,cancer,1
diabetes duration,cardiac autonomic neuropathy (CAN),2
diabetes duration,cardiovascular disease,22
diabetes duration,carotid plaque,1
diabetes duration,cerebrovascular disease,2
diabetes duration,cholesterol,126
diabetes duration,chronic kidney disease,2
diabetes duration,cimt,1
diabetes duration,clinic,1
diabetes duration,combined alox12 genotypes,1
diabetes duration,complete revascularization,1
diabetes duration,coronary artery calcium score,1
diabetes duration,coronary artery disease,5
diabetes duration,coronary heart disease,4
diabetes duration,creatinine,18
diabetes duration,dcb use,1
diabetes duration,depression,1
diabetes duration,diabetes,4
diabetes duration,diabetes treatment,8
diabetes duration,diabetic neuropathy,1
diabetes duration,diastolic blood pressure,17
diabetes duration,dipeptidyl peptidase 4 inhibitor at discharge,1
diabetes duration,distal polyneuropathy,1
diabetes duration,diuretic therapy,1
diabetes duration,ecg abnormalities,10
diabetes duration,egfr,36
diabetes duration,endothelial dysfunction,1
diabetes duration,expected costs,1
diabetes duration,fasting cpeptide,2
diabetes duration,fasting plasma glucose,4
diabetes duration,fibrates,2
diabetes duration,fibrinogen,4
diabetes duration,gender,8
diabetes duration,gliclazide,1
diabetes duration,glycemic control,6
diabetes duration,hba1c,85
diabetes duration,heart failure,7
diabetes duration,heart rate,5
diabetes duration,heart valve calcium,1
diabetes duration,height,3
diabetes duration,highdensity lipoprotein,2
diabetes duration,history of copd,1
diabetes duration,history of coronary disease,3
diabetes duration,homair,3
diabetes duration,homocysteine,2
diabetes duration,homocysteine at baseline,1
diabetes duration,hyperlipidemia,6
diabetes duration,hypertension,34
diabetes duration,hypoglycaemic treatment,1
diabetes duration,idf metabolic syndrome,1
diabetes duration,indigenous australian,1
diabetes duration,insulin (measurment),4
diabetes duration,insulin treatment,11
diabetes duration,ischemic heart disease,1
diabetes duration,left atrial diameter,1
diabetes duration,left ventricular ejection fraction,2
diabetes duration,lipid profile,1
diabetes duration,lipidlowering therapy,11
diabetes duration,lm treatment,1
diabetes duration,log101  acr,1
diabetes duration,logaer,1
diabetes duration,lowdensity lipoprotein,1
diabetes duration,macroalbuminuria,2
diabetes duration,macrovascular complications,9
diabetes duration,marital status,1
diabetes duration,mca stenosis,1
diabetes duration,metformin,3
diabetes duration,microalbuminuria,7
diabetes duration,microvascular disease,11
diabetes duration,mild plaque calcifi cation,1
diabetes duration,myocardial infarction,9
diabetes duration,nephropathy,2
diabetes duration,neuropathy,3
diabetes duration,nterminal probrain natriuretic peptide,1
diabetes duration,pIMT,1
diabetes duration,pc screen time,1
diabetes duration,percent low density plaque,1
diabetes duration,percutaneous coronary intervention,1
diabetes duration,peripheral arterial occlusive disease,1
diabetes duration,peripheral artery disease,6
diabetes duration,peripheral neuropathy,1
diabetes duration,peripheral vascular disease,2
diabetes duration,physical activity,7
diabetes duration,physical inactivity,4
diabetes duration,pioglitazone treatment,1
diabetes duration,plaque volume,1
diabetes duration,prior coronary artery bypass,1
diabetes duration,pro btype natriuretic peptide quartiles,1
diabetes duration,proteinuria,3
diabetes duration,pulse pressure,2
diabetes duration,race/ethnicity,4
diabetes duration,ratio between total,1
diabetes duration,renal impairment,1
diabetes duration,renin-angiotensin system inhibitors,2
diabetes duration,retinopathy,12
diabetes duration,rosiglitazone during followup,1
diabetes duration,sensory neuropathy,1
diabetes duration,sensory neuropathy presentabsent,1
diabetes duration,significant proximal lad disease,1
diabetes duration,sleep duration,1
diabetes duration,smoking,73
diabetes duration,sociodemographics,5
diabetes duration,socioeconomic variables,7
diabetes duration,statins,22
diabetes duration,stroke,6
diabetes duration,study treatment,1
diabetes duration,sulfonylurea,4
diabetes duration,syntax score,1
diabetes duration,systolic blood pressure,54
diabetes duration,the presence of total occlusion,1
diabetes duration,the ukpds risk score,1
diabetes duration,the use of drugs yesno,1
diabetes duration,therapy for hypercoagulation,1
diabetes duration,thiazolidinediones,1
diabetes duration,"to tal",1
diabetes duration,total energy kcalday,1
diabetes duration,treatment intensity,1
diabetes duration,triacylglycerol,4
diabetes duration,triglycerides,38
diabetes duration,troponin,2
diabetes duration,tv viewing,1
diabetes duration,type of treatment,1
diabetes duration,uric acid,2
diabetes duration,urinary acr,6
diabetes duration,urinary albumin excretion rate,4
diabetes duration,use of blockers,1
diabetes duration,use of sulfonamides,1
diabetes duration,waist measurements,6
diabetes duration,weight,2
diabetes duration,white blood cell count,1
diabetes duration,years of enrolment,1
diabetes treatment,ACEI/ARB,2
diabetes treatment,adherence to medication,1
diabetes treatment,albumin,5
diabetes treatment,angina,1
diabetes treatment,antidiabetic medication,1
diabetes treatment,antihyperlipidemic drugs,1
diabetes treatment,antihypertensive use,5
diabetes treatment,aspirin therapy,2
diabetes treatment,beta-blocker,1
diabetes treatment,blood glucose,3
diabetes treatment,bmi,2
diabetes treatment,c-reactive protein,3
diabetes treatment,cholesterol,12
diabetes treatment,chronic kidney disease,3
diabetes treatment,cimt,2
diabetes treatment,clopidigrel,1
diabetes treatment,coronary artery disease,4
diabetes treatment,creatinine,4
diabetes treatment,dcsi,1
diabetes treatment,diastolic blood pressure,1
diabetes treatment,dpucmgp,1
diabetes treatment,ecg abnormalities,3
diabetes treatment,egfr,1
diabetes treatment,fasting plasma glucose,1
diabetes treatment,hba1c,6
diabetes treatment,heart failure,1
diabetes treatment,hyperlipidemia,6
diabetes treatment,hypertension,4
diabetes treatment,insulin treatment,1
diabetes treatment,left ventricular ejection fraction,1
diabetes treatment,lipidlowering therapy,3
diabetes treatment,macrovascular complications,1
diabetes treatment,microalbuminuria,1
diabetes treatment,microvascular disease,1
diabetes treatment,myocardial infarction,2
diabetes treatment,percutaneous coronary intervention,1
diabetes treatment,peripheral artery disease,1
diabetes treatment,prior coronary artery bypass,1
diabetes treatment,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
diabetes treatment,renin-angiotensin system inhibitors,1
diabetes treatment,smoking,2
diabetes treatment,statins,4
diabetes treatment,stent,1
diabetes treatment,stroke,2
diabetes treatment,systolic blood pressure,3
diabetes treatment,therapy for hypercoagulation,1
diabetes treatment,triglycerides,3
diabetic neuropathy,creatinine,1
diabetic neuropathy,hba1c,1
diabetic neuropathy,insulin treatment,1
diabetic neuropathy,macroalbuminuria,1
diabetic neuropathy,microalbuminuria,1
dialysis,albumin,2
dialysis,arteriovenous fistula,2
dialysis,bnp,2
dialysis,c-reactive protein,2
dialysis,cholesterol,4
dialysis,coronary artery disease,1
dialysis,diabetes duration,1
dialysis,hba1c,4
dialysis,heart failure,1
dialysis,peripheral vascular disease,1
dialysis,phosphate,2
dialysis,stroke,1
dialysis,triglycerides,2
dialysis,ultrafiltration volume,2
diastolic blood pressure,ACEI/ARB,1
diastolic blood pressure,ARBs,1
diastolic blood pressure,ApoAI,1
diastolic blood pressure,RCT,1
diastolic blood pressure,albumin,3
diastolic blood pressure,albumin excretion rate,3
diastolic blood pressure,albumin to creatinine ratio,1
diastolic blood pressure,alcohol use,3
diastolic blood pressure,alphaglucosidase inhibitor,1
diastolic blood pressure,angina,1
diastolic blood pressure,ankle-brachial index (ABI),1
diastolic blood pressure,antidiabetic medication,1
diastolic blood pressure,antihypertensive use,7
diastolic blood pressure,antiplatelet therapy,5
diastolic blood pressure,apoAI/apoB ratio,1
diastolic blood pressure,apoB,1
diastolic blood pressure,aspirin therapy,1
diastolic blood pressure,beta-blocker,1
diastolic blood pressure,blood glucose,2
diastolic blood pressure,blood pressure,4
diastolic blood pressure,bmi,6
diastolic blood pressure,bnp,2
diastolic blood pressure,c-reactive protein,5
diastolic blood pressure,cardiovascular disease,7
diastolic blood pressure,cholesterol,48
diastolic blood pressure,chronic kidney disease,1
diastolic blood pressure,cimt,1
diastolic blood pressure,clopidigrel,1
diastolic blood pressure,complete revascularization,1
diastolic blood pressure,coronary artery disease,4
diastolic blood pressure,coronary heart disease,4
diastolic blood pressure,creatinine,9
diastolic blood pressure,dcb use,1
diastolic blood pressure,diabetes,2
diastolic blood pressure,diabetes duration,6
diastolic blood pressure,diabetes treatment,6
diastolic blood pressure,dialysis,2
diastolic blood pressure,dipeptidyl peptidase 4 inhibitor at discharge,1
diastolic blood pressure,ecg abnormalities,7
diastolic blood pressure,egfr,10
diastolic blood pressure,fibrinogen,3
diastolic blood pressure,glycemic control,2
diastolic blood pressure,hba1c,20
diastolic blood pressure,heart failure,4
diastolic blood pressure,heart rate,1
diastolic blood pressure,height,1
diastolic blood pressure,homair,1
diastolic blood pressure,homocysteine,1
diastolic blood pressure,hyperlipidemia,5
diastolic blood pressure,hypertension,3
diastolic blood pressure,idf metabolic syndrome,1
diastolic blood pressure,insulin (measurment),2
diastolic blood pressure,insulin treatment,2
diastolic blood pressure,left ventricular ejection fraction,2
diastolic blood pressure,lipid profile,1
diastolic blood pressure,lipidlowering therapy,6
diastolic blood pressure,lm treatment,1
diastolic blood pressure,medication use,1
diastolic blood pressure,microalbuminuria,1
diastolic blood pressure,myocardial infarction,2
diastolic blood pressure,nephropathy,1
diastolic blood pressure,percutaneous coronary intervention,2
diastolic blood pressure,peripheral artery disease,4
diastolic blood pressure,peripheral vascular disease,2
diastolic blood pressure,peripherovascular morbidity,1
diastolic blood pressure,phosphate,1
diastolic blood pressure,physical activity,1
diastolic blood pressure,proteinuria,1
diastolic blood pressure,pulse pressure,1
diastolic blood pressure,race/ethnicity,2
diastolic blood pressure,ratio between total,1
diastolic blood pressure,retinopathy,2
diastolic blood pressure,sensory neuropathy presentabsent,1
diastolic blood pressure,significant proximal lad disease,1
diastolic blood pressure,smoking,10
diastolic blood pressure,socioeconomic variables,3
diastolic blood pressure,statins,3
diastolic blood pressure,stroke,6
diastolic blood pressure,sulfonylurea,1
diastolic blood pressure,syntax score,1
diastolic blood pressure,the presence of total occlusion,1
diastolic blood pressure,the use of drugs yesno,1
diastolic blood pressure,triglycerides,15
diastolic blood pressure,ultrafiltration volume,1
diastolic blood pressure,uric acid,1
diastolic blood pressure,waist measurements,2
diastolic blood pressure,white blood cell count,1
dipeptidyl peptidase 4 inhibitor at discharge,insulin (measurment),1
dipyridamole stress test,ischemia,1
dipyridamole stress test,left ventricular ejection fraction,1
disease duration,bmi,1
disease duration,cardiovascular disease,1
disease duration,cholesterol,2
disease duration,creatinine,1
disease duration,diabetes duration,1
disease duration,hba1c,1
disease duration,smoking,1
disease duration,systolic blood pressure,1
disease duration,triglycerides,1
distal polyneuropathy,ankle-brachial index (ABI),1
diuretic therapy,ACE inhibitors,1
diuretic therapy,acute coronary syndrome,1
diuretic therapy,beta-blocker,1
diuretic therapy,bnp,1
diuretic therapy,insulin treatment,1
diuretic therapy,monocyte chemoattractant protin1 m,1
diuretic therapy,pioglitazone treatment,1
diuretic therapy,statins,1
dpucmgp,renin-angiotensin system inhibitors,1
dpucmgp,statins,1
drug use,biomarkers,1
duration,RCT,1
duration,blood glucose,1
duration,cardiovascular disease,2
duration,cardiovascular risk factors,1
duration,chronic kidney disease,1
duration,other complications,1
dyslipidaemia,autonomic nervous function,1
dyslipidaemia,smoking,1
ecg abnormalities,ACEI/ARB,2
ecg abnormalities,age,2
ecg abnormalities,alphaglucosidase inhibitor,1
ecg abnormalities,antidiabetic medication,2
ecg abnormalities,antiplatelet therapy,2
ecg abnormalities,atrial fibrillation,2
ecg abnormalities,beta-blocker,2
ecg abnormalities,blood glucose,2
ecg abnormalities,bnp,1
ecg abnormalities,c-reactive protein,1
ecg abnormalities,cardiovascular disease,1
ecg abnormalities,cerebrovascular disease,1
ecg abnormalities,cholesterol,11
ecg abnormalities,cimt,1
ecg abnormalities,clopidigrel,2
ecg abnormalities,complete revascularization,1
ecg abnormalities,coronary anatomy,1
ecg abnormalities,coronary artery calcium score,1
ecg abnormalities,coronary heart disease,1
ecg abnormalities,creatinine,3
ecg abnormalities,dcb use,1
ecg abnormalities,diabetes,1
ecg abnormalities,diastolic blood pressure,3
ecg abnormalities,dipeptidyl peptidase 4 inhibitor at discharge,1
ecg abnormalities,dpucmgp,1
ecg abnormalities,echocardiographic variables,1
ecg abnormalities,egfr,5
ecg abnormalities,fasting plasma glucose,1
ecg abnormalities,gender,1
ecg abnormalities,glycated hemoglobin,1
ecg abnormalities,glycemic control,1
ecg abnormalities,hba1c,3
ecg abnormalities,heart failure,1
ecg abnormalities,heart rate,1
ecg abnormalities,hypertension,4
ecg abnormalities,insulin (measurment),2
ecg abnormalities,insulin treatment,3
ecg abnormalities,interleukin 6,1
ecg abnormalities,left bundle branch block,1
ecg abnormalities,left ventricular ejection fraction,4
ecg abnormalities,lm treatment,1
ecg abnormalities,macroalbuminuria,1
ecg abnormalities,neuropathy,1
ecg abnormalities,percutaneous coronary intervention,1
ecg abnormalities,peripheral artery disease,2
ecg abnormalities,peripherovascular morbidity,1
ecg abnormalities,proteinuria,2
ecg abnormalities,renin-angiotensin system inhibitors,1
ecg abnormalities,significant proximal lad disease,3
ecg abnormalities,sodium concentration,2
ecg abnormalities,statins,5
ecg abnormalities,sulfonylurea,1
ecg abnormalities,syntax score,1
ecg abnormalities,systolic blood pressure,4
ecg abnormalities,the presence of total occlusion,3
ecg abnormalities,triglycerides,1
ecg abnormalities,uric acid,1
echolucent plaque,antiaggregating agents,1
egfr,ACE inhibitors,2
egfr,ACEI/ARB,1
egfr,ARBs,2
egfr,RCT,3
egfr,age,2
egfr,albumin,8
egfr,albumin excretion rate,3
egfr,albumin to creatinine ratio,2
egfr,alcohol use,1
egfr,alphaglucosidase inhibitor,1
egfr,antihypertensive use,3
egfr,antiplatelet therapy,8
egfr,aspirin therapy,3
egfr,beta-blocker,2
egfr,biomarkers (general),1
egfr,blood glucose,4
egfr,blood pressure,1
egfr,bmi,5
egfr,bnp,3
egfr,c-reactive protein,7
egfr,calcium channel blockers,2
egfr,cardiovascular disease,4
egfr,cardiovascular risk factors,1
egfr,cerebrovascular disease,1
egfr,cholesterol,27
egfr,chronic kidney disease,1
egfr,cimt,3
egfr,combined alox12 genotypes,1
egfr,complete revascularization,1
egfr,complex lesions,1
egfr,coronary heart disease,1
egfr,creatinine,4
egfr,dcb use,1
egfr,diabetes,1
egfr,diabetes duration,6
egfr,diabetes treatment,4
egfr,diastolic blood pressure,3
egfr,dipeptidyl peptidase 4 inhibitor at discharge,1
egfr,diuretic therapy,1
egfr,dpucmgp,1
egfr,ecg abnormalities,1
egfr,gender,1
egfr,glycemic control,1
egfr,hba1c,22
egfr,heart failure,1
egfr,height,1
egfr,hemoglobin,1
egfr,history of coronary disease,1
egfr,hyperlipidemia,2
egfr,hypertension,5
egfr,incretins,1
egfr,inflammatory markers,1
egfr,insulin (measurment),3
egfr,insulin treatment,7
egfr,interleukin 6,1
egfr,ischemic heart disease,1
egfr,left ventricular ejection fraction,3
egfr,lipidlowering therapy,3
egfr,lm treatment,1
egfr,lung disease,1
egfr,macroalbuminuria,1
egfr,macroangiopathy,1
egfr,macrovascular complications,1
egfr,metformin,1
egfr,microalbuminuria,2
egfr,multivessel coronary disease,1
egfr,myocardial infarction,3
egfr,neuropathy,1
egfr,nterminal probrain natriuretic peptide,1
egfr,parathyroid harmone (PTH),1
egfr,peripheral artery disease,3
egfr,peripherovascular morbidity,1
egfr,phosphate,2
egfr,prior coronary artery bypass,1
egfr,pro btype natriuretic peptide quartiles,1
egfr,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
egfr,proteinuria,2
egfr,renin-angiotensin system inhibitors,2
egfr,retinopathy,4
egfr,secretagogues,1
egfr,sensory neuropathy,1
egfr,sensory neuropathy presentabsent,1
egfr,smoking,11
egfr,sociodemographics,2
egfr,statins,6
egfr,stent,1
egfr,stroke,3
egfr,study treatment,1
egfr,sulfonylurea,2
egfr,syntax score,1
egfr,systolic blood pressure,9
egfr,the use of drugs yesno,1
egfr,treatment,1
egfr,triglycerides,6
egfr,troponin,2
egfr,urinary acr,3
egfr,urinary protein log,1
egfr,use of sulfonamides,1
egfr,waist measurements,1
ejection fraction,angina,1
ejection fraction,atrial fibrillation,2
ejection fraction,blood glucose,1
ejection fraction,bmi,2
ejection fraction,bnp,1
ejection fraction,cholesterol,2
ejection fraction,creatinine,2
ejection fraction,hba1c,1
ejection fraction,heart rate,1
ejection fraction,pacemaker implantation,1
ejection fraction,systolic blood pressure,1
ejection fraction 40,ACE inhibitors,1
ejection fraction 40,ARBs,1
ejection fraction 40,acute coronary syndrome,1
ejection fraction 40,andor nitroglycerin,1
ejection fraction 40,antialdosterone,1
ejection fraction 40,anticoagulants,1
ejection fraction 40,antiplatelet therapy,1
ejection fraction 40,aspirin therapy,1
ejection fraction 40,atrial fibrillation,1
ejection fraction 40,blockers,1
ejection fraction 40,bnp,1
ejection fraction 40,c-reactive protein,1
ejection fraction 40,chronic kidney disease,1
ejection fraction 40,clopidogrel,1
ejection fraction 40,diuretic therapy,1
ejection fraction 40,insulin treatment,1
ejection fraction 40,monocyte chemoattractant protin1 m,1
ejection fraction 40,nitrates,1
ejection fraction 40,statins,1
endothelial dysfunction,autonomic dysfunction,1
expected costs,bmi,1
expected costs,hba1c,1
expected costs,physical activity,1
expected costs,smoking,1
family history of diabetes,bmi,1
family history of diabetes,cardiovascular disease,1
family history of diabetes,cholesterol,1
family history of diabetes,lowdensity lipoprotein,1
family history of diabetes,smoking,1
family history of diabetes,systolic blood pressure,1
family history of diabetes,triglycerides,1
fasting plasma glucose,cholesterol,2
fasting plasma glucose,diastolic blood pressure,1
fasting plasma glucose,glycemic control,1
fasting plasma glucose,hba1c,2
fasting plasma glucose,neuropathy,1
fasting plasma glucose,peripheral artery disease,1
fasting plasma glucose,systolic blood pressure,1
fasting plasma glucose,triglycerides,1
fasting status at blood draw,alcohol use,1
fasting status at blood draw,alternative healthy eating index ahei diet quality score quintiles,1
fasting status at blood draw,bmi,1
fasting status at blood draw,cholesterol,1
fasting status at blood draw,hormone therapy,1
fasting status at blood draw,hypertension,1
fasting status at blood draw,menopausal status pre post uncertain missing,1
fasting status at blood draw,myocardial infarction,1
fasting status at blood draw,physical activity,1
fasting status at blood draw,smoking,1
fasting status at blood draw,white blood cell count,1
fasting status yes or no,aspirin therapy,1
fasting status yes or no,hba1c,1
fasting status yes or no,hypertension,1
fibrates,antidepressants,1
fibrates,gliclazide,1
fibrates,rosiglitazone during followup,1
fibrates,years of enrolment,1
fibrinogen,albumin excretion rate,1
fibrinogen,albumin to creatinine ratio,1
fibrinogen,ankle-brachial index (ABI),1
fibrinogen,bmi,1
fibrinogen,c-reactive protein,1
fibrinogen,cholesterol,1
fibrinogen,coronary artery disease,1
fibrinogen,creatinine,2
fibrinogen,ecg abnormalities,1
fibrinogen,hba1c,1
fibrinogen,heart rate,1
fibrinogen,homocysteine,1
fibrinogen,homocysteine at baseline,1
fibrinogen,insulin treatment,1
fibrinogen,microalbuminuria,1
fibrinogen,peripheral arterial occlusive disease,1
fibrinogen,physical activity,1
fibrinogen,stroke,1
fibrinogen,white blood cell count,1
final timi flow,left ventricular ejection fraction,1
final timi flow,stent,1
folate,cholesterol,1
folate,diabetes duration,1
folate,hba1c,1
folate,hypertension,1
folate,smoking,1
fpi,Serum 25-hydroxyvitamin D,1
fpi,glycemic control,1
fpi,lipid profile,1
fpi,systolic blood pressure,1
frailty effect for cohort,cardiovascular disease,1
frailty effect for cohort,kidney function,1
frailty effect for cohort,lowdensity lipoprotein,1
frailty effect for cohort,microalbuminuria,1
frailty effect for cohort,smoking,1
frailty effect for cohort,systolic blood pressure,1
gamma frailty,antihypertensive use,1
gamma frailty,aspirin therapy,1
gamma frailty,cardiovascular risk factors,1
gamma frailty,lipidlowering therapy,1
gastrointestinal bleeding in past 5 years,diabetes,1
gastrointestinal bleeding in past 5 years,egfr,1
gastrointestinal bleeding in past 5 years,lung disease,1
gastrointestinal bleeding in past 5 years,systolic blood pressure,1
ge,bmi,1
ge,diabetes treatment,1
ge,egfr,1
ge,gender,1
ge,hyperlipidemia,1
ge,hypertension,1
ge,myocardial infarction,1
ge,prior coronary artery bypass,1
ge,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
ge,stent,1
gender,ACE inhibitors,4
gender,ACEI/ARB,4
gender,ARBs,4
gender,ApoAI,1
gender,CCr,1
gender,Lp(a),1
gender,RCT,12
gender,Serum 25-hydroxyvitamin D,1
gender,acr,2
gender,acute coronary syndrome,3
gender,adherence to medication,1
gender,adiponectin,1
gender,age,44
gender,albumin,31
gender,albumin excretion rate,7
gender,albumin to creatinine ratio,10
gender,alcohol use,16
gender,alphaglucosidase inhibitor,1
gender,andor nitroglycerin,1
gender,angina,4
gender,ankle-brachial index (ABI),4
gender,antiaggregating agents,1
gender,antialdosterone,1
gender,anticoagulants,1
gender,antidepressants,1
gender,antidiabetic medication,3
gender,antihyperlipidemic drugs,2
gender,antihypertensive use,23
gender,antiplatelet therapy,13
gender,apelin36 levels,1
gender,apo(a) phenotypes,1
gender,apoAI/apoB ratio,2
gender,apoB,2
gender,arteriovenous fistula,1
gender,aspirin therapy,14
gender,atrial fibrillation,7
gender,autonomic dysfunction,1
gender,bapwv,1
gender,baseline claudication,1
gender,beta-blocker,3
gender,biomarkers (general),1
gender,blockers,2
gender,blood glucose,22
gender,blood pressure,18
gender,blood transfusion,1
gender,bmi,132
gender,bnp,12
gender,c-reactive protein,21
gender,calcium channel blockers,1
gender,cancer,1
gender,cardiac autonomic neuropathy (CAN),1
gender,cardiovascular disease,47
gender,cardiovascular risk factors,6
gender,carotid artery imt,1
gender,carotid plaque,1
gender,cerebrovascular disease,6
gender,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
gender,charlson index,2
gender,choleseterol,1
gender,cholesterol,253
gender,chronic kidney disease,8
gender,chronic obstructive pulmonary disease,1
gender,chronic renal failure,1
gender,ci,1
gender,cimt,3
gender,clinic,1
gender,clinic gamma frailty,1
gender,clopidigrel,1
gender,clopidogrel,1
gender,combined alox12 genotypes,1
gender,complete revascularization,1
gender,complex lesions,1
gender,coronary artery calcium score,4
gender,coronary artery disease,14
gender,coronary heart disease,10
gender,creatinine,44
gender,dcb use,1
gender,dcsi,1
gender,depression,1
gender,diabetes,13
gender,diabetes duration,115
gender,diabetes treatment,21
gender,diabetic neuropathy,2
gender,dialysis,4
gender,diastolic blood pressure,36
gender,dipeptidyl peptidase 4 inhibitor at discharge,1
gender,dipyridamole stress test,1
gender,disease duration,1
gender,distal polyneuropathy,1
gender,diuretic therapy,3
gender,dpucmgp,1
gender,duration,2
gender,ecg abnormalities,20
gender,echolucent plaque,1
gender,egfr,59
gender,ejection fraction,2
gender,ejection fraction 40,1
gender,fasting cpeptide,1
gender,fasting plasma glucose,5
gender,fibrates,1
gender,fibrinogen,5
gender,final timi flow,1
gender,folate,1
gender,fpi,1
gender,frailty effect for cohort,1
gender,gamma frailty,1
gender,gastrointestinal bleeding in past 5 years,1
gender,glycated hemoglobin,2
gender,glycemic control,9
gender,hab1c,1
gender,hba1c,144
gender,heart failure,15
gender,heart rate,10
gender,height,2
gender,hemoglobin,2
gender,high density lipoprotein level,1
gender,highdensity lipoprotein,3
gender,history of copd,1
gender,history of coronary disease,3
gender,homair,5
gender,homocysteine,2
gender,homocysteine at baseline,1
gender,hyperlipidemia,22
gender,hypertension,85
gender,hyperuricemia-gout,1
gender,hypoglycaemic treatment,1
gender,idf metabolic syndrome,1
gender,indigenous australian,1
gender,inflammatory markers,1
gender,insulin (measurment),4
gender,insulin treatment,27
gender,interleukin 6,2
gender,intervention arm no interaction model,1
gender,ischemia,2
gender,ischemic heart disease,4
gender,kidney function,2
gender,left ventricular ejection fraction,10
gender,left ventricular hypertrophy,2
gender,lipid profile,3
gender,lipidlowering therapy,15
gender,living alone,1
gender,lm treatment,1
gender,logaer,1
gender,lowdensity lipoprotein,2
gender,lung disease,1
gender,macroalbuminuria,3
gender,macrovascular complications,12
gender,marital status,2
gender,mca stenosis,1
gender,medication differences,1
gender,medication use,1
gender,medications,1
gender,metformin,5
gender,microalbuminuria,12
gender,microvascular disease,11
gender,mild plaque calcifi cation,1
gender,monocyte chemoattractant protin1 m,1
gender,multivessel coronary disease,3
gender,myocardial infarction,20
gender,nephropathy,5
gender,neuropathy,3
gender,nitrates,1
gender,nterminal probrain natriuretic peptide,2
gender,nzdep quintile,1
gender,other complications,1
gender,other conventional risk factors,1
gender,pIMT,1
gender,pacemaker implantation,1
gender,parathyroid harmone (PTH),2
gender,percent low density plaque,1
gender,percutaneous coronary intervention,3
gender,peripheral arterial occlusive disease,1
gender,peripheral artery disease,11
gender,peripheral neuropathy,1
gender,peripheral vascular disease,4
gender,peripherovascular morbidity,1
gender,phosphate,5
gender,physical activity,10
gender,physical inactivity,4
gender,pioglitazone treatment,1
gender,plaque thickness,1
gender,plaque volume,1
gender,previous diseases,1
gender,previous pcicabg,1
gender,prior coronary artery bypass,3
gender,pro btype natriuretic peptide quartiles,1
gender,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
gender,proteinuria,5
gender,psychiatric medications,1
gender,pulse pressure,2
gender,race/ethnicity,21
gender,referring physician,1
gender,renal impairment,1
gender,renal insufficiency,1
gender,renin-angiotensin system inhibitors,4
gender,retinopathy,14
gender,sensory neuropathy presentabsent,1
gender,significant proximal lad disease,1
gender,sleep duration,1
gender,smoking,164
gender,sociodemographics,13
gender,socioeconomic variables,11
gender,sodium concentration,1
gender,statins,32
gender,stent,3
gender,stroke,10
gender,study treatment,1
gender,sulfonylurea,4
gender,syntax score,1
gender,systolic blood pressure,114
gender,the presence of total occlusion,1
gender,the ukpds risk score,1
gender,the use of drugs yesno,1
gender,therapy for hypercoagulation,1
gender,thiazolidinediones,1
gender,top three multidimensional scaling axes,1
gender,tot chol,1
gender,total baseline expenditures,1
gender,treatment,1
gender,triacylglycerol,4
gender,triglycerides,56
gender,troponin,3
gender,ultrafiltration volume,2
gender,uric acid,4
gender,urinary,2
gender,urinary acr,5
gender,urinary albumin excretion rate,10
gender,urinary protein log,1
gender,use of blockers,1
gender,use of sulfonamides,1
gender,vitamin b12,1
gender,waist measurements,13
gender,wasting,1
gender,weight,1
gender,white blood cell count,3
gender,year of followup start,1
gliclazide,rosiglitazone during followup,1
gliclazide,years of enrolment,1
glycated hemoglobin,cardiovascular disease,1
glycated hemoglobin,diabetes duration,1
glycated hemoglobin,diastolic blood pressure,1
glycated hemoglobin,egfr,1
glycated hemoglobin,haemoglobin,1
glycated hemoglobin,hypertension,1
glycated hemoglobin,insulin treatment,1
glycated hemoglobin,metformin,1
glycated hemoglobin,microvascular disease,1
glycated hemoglobin,myocardial infarction,1
glycated hemoglobin,peripherovascular morbidity,1
glycated hemoglobin,prior coronary artery bypass,1
glycated hemoglobin,statins,1
glycemic control,Serum 25-hydroxyvitamin D,1
glycemic control,albumin,1
glycemic control,alcohol use,1
glycemic control,alphaglucosidase inhibitor,1
glycemic control,antihypertensive use,2
glycemic control,bmi,2
glycemic control,cardiovascular disease,2
glycemic control,cholesterol,2
glycemic control,diastolic blood pressure,2
glycemic control,dipeptidyl peptidase 4 inhibitor at discharge,1
glycemic control,hba1c,1
glycemic control,heart rate,2
glycemic control,hyperlipidemia,1
glycemic control,hypertension,1
glycemic control,insulin (measurment),1
glycemic control,insulin treatment,1
glycemic control,lipidlowering therapy,1
glycemic control,microvascular disease,1
glycemic control,physical activity,1
glycemic control,retinopathy,1
glycemic control,smoking,2
glycemic control,sociodemographics,1
glycemic control,statins,1
glycemic control,sulfonylurea,1
glycemic control,systolic blood pressure,3
hab1c,albumin,1
hab1c,blood glucose,1
hab1c,choleseterol,1
hab1c,cholesterol,1
hab1c,creatinine,1
haemoglobin,myocardial infarction,1
haemoglobin,prior coronary artery bypass,1
hba1c,ACE inhibitors,4
hba1c,ACEI/ARB,1
hba1c,ARBs,3
hba1c,ApoAI,1
hba1c,Elixhauser comorbidies,1
hba1c,RCT,6
hba1c,acr,1
hba1c,acute coronary syndrome,1
hba1c,age,6
hba1c,albumin,21
hba1c,albumin excretion rate,5
hba1c,albumin to creatinine ratio,4
hba1c,alcohol use,2
hba1c,alphaglucosidase inhibitor,1
hba1c,angina,1
hba1c,ankle-brachial index (ABI),3
hba1c,antiaggregating agents,1
hba1c,antidiabetic medication,1
hba1c,antihyperlipidemic drugs,2
hba1c,antihypertensive use,11
hba1c,antiplatelet therapy,7
hba1c,apo(a) phenotypes,1
hba1c,apoAI/apoB ratio,2
hba1c,apoB,2
hba1c,arteriovenous fistula,2
hba1c,aspirin therapy,9
hba1c,atrial fibrillation,3
hba1c,autonomic dysfunction,2
hba1c,bapwv,1
hba1c,beta-blocker,3
hba1c,blood glucose,6
hba1c,blood pressure,7
hba1c,bmi,25
hba1c,bnp,8
hba1c,c-reactive protein,12
hba1c,calcium channel blockers,2
hba1c,cancer,1
hba1c,cardiac autonomic neuropathy (CAN),2
hba1c,cardiovascular disease,13
hba1c,cardiovascular risk factors,2
hba1c,carotid artery imt,1
hba1c,cerebrovascular disease,3
hba1c,cholesterol,115
hba1c,chronic kidney disease,2
hba1c,cimt,3
hba1c,combined alox12 genotypes,1
hba1c,complete revascularization,1
hba1c,coronary artery calcium score,2
hba1c,coronary artery disease,2
hba1c,coronary heart disease,4
hba1c,creatinine,23
hba1c,dcb use,1
hba1c,diabetes,2
hba1c,diabetes duration,15
hba1c,diabetes treatment,10
hba1c,diabetic neuropathy,1
hba1c,dialysis,2
hba1c,diastolic blood pressure,15
hba1c,dipeptidyl peptidase 4 inhibitor at discharge,1
hba1c,distal polyneuropathy,1
hba1c,diuretic therapy,1
hba1c,dpucmgp,1
hba1c,ecg abnormalities,8
hba1c,echolucent plaque,1
hba1c,egfr,31
hba1c,endothelial dysfunction,1
hba1c,family history of diabetes,1
hba1c,fasting cpeptide,1
hba1c,fasting plasma glucose,2
hba1c,fibrates,1
hba1c,fibrinogen,5
hba1c,gender,3
hba1c,gensini score,1
hba1c,gliclazide,1
hba1c,glycemic control,4
hba1c,heart failure,4
hba1c,heart rate,3
hba1c,heart valve calcium,1
hba1c,height,2
hba1c,highdensity lipoprotein,2
hba1c,history of coronary disease,1
hba1c,homair,4
hba1c,homocysteine,2
hba1c,homocysteine at baseline,1
hba1c,hyperlipidemia,4
hba1c,hypertension,15
hba1c,idf metabolic syndrome,1
hba1c,incretins,1
hba1c,insulin (measurment),5
hba1c,insulin treatment,13
hba1c,interleukin 6,1
hba1c,ischemic heart disease,1
hba1c,left atrial diameter,1
hba1c,left ventricular ejection fraction,3
hba1c,lipid profile,1
hba1c,lipidlowering therapy,7
hba1c,lm treatment,1
hba1c,log101  acr,1
hba1c,logaer,1
hba1c,lowdensity lipoprotein,2
hba1c,macroalbuminuria,2
hba1c,macroangiopathy,1
hba1c,macrovascular complications,1
hba1c,medications,1
hba1c,metformin,3
hba1c,microalbuminuria,8
hba1c,microvascular disease,1
hba1c,mild plaque calcifi cation,1
hba1c,multivessel coronary disease,1
hba1c,myocardial infarction,7
hba1c,nephropathy,2
hba1c,neuropathy,1
hba1c,nterminal probrain natriuretic peptide,2
hba1c,parathyroid harmone (PTH),1
hba1c,percent low density plaque,1
hba1c,percutaneous coronary intervention,1
hba1c,peripheral arterial occlusive disease,1
hba1c,peripheral artery disease,6
hba1c,peripheral neuropathy,1
hba1c,phosphate,6
hba1c,physical activity,2
hba1c,pioglitazone treatment,1
hba1c,plaque thickness,1
hba1c,plaque volume,1
hba1c,prior coronary artery bypass,1
hba1c,pro btype natriuretic peptide quartiles,1
hba1c,proteinuria,2
hba1c,provider quality controls,1
hba1c,pulse pressure,1
hba1c,race/ethnicity,4
hba1c,referring physician,1
hba1c,renal impairment,1
hba1c,renin-angiotensin system inhibitors,3
hba1c,retinopathy,6
hba1c,rosiglitazone during followup,1
hba1c,secretagogues,1
hba1c,sensory neuropathy,1
hba1c,sensory neuropathy presentabsent,1
hba1c,significant proximal lad disease,1
hba1c,smoking,30
hba1c,sociodemographics,6
hba1c,socioeconomic variables,3
hba1c,sodium concentration,1
hba1c,statins,15
hba1c,stent,1
hba1c,stroke,5
hba1c,sulfonylurea,3
hba1c,syntax score,1
hba1c,systolic blood pressure,37
hba1c,the presence of total occlusion,1
hba1c,the use of drugs yesno,1
hba1c,therapy for hypercoagulation,1
hba1c,threevessel disease,1
hba1c,tot chol,1
hba1c,treatment,1
hba1c,triacylglycerol,3
hba1c,triglycerides,39
hba1c,troponin,3
hba1c,ultrafiltration volume,2
hba1c,uric acid,4
hba1c,urinary,1
hba1c,urinary acr,5
hba1c,urinary albumin excretion rate,6
hba1c,use of sulfonamides,1
hba1c,waist measurements,2
hba1c,weight,1
hba1c,year fixed effects,1
hba1c,years of enrolment,1
hba1c,young severity index,1
heart failure,ARBs,1
heart failure,RCT,2
heart failure,age,2
heart failure,albumin,2
heart failure,antidepressants,1
heart failure,antihypertensive use,1
heart failure,arteriovenous fistula,1
heart failure,aspirin therapy,1
heart failure,atrial fibrillation,1
heart failure,biomarkers (general),1
heart failure,blockers,1
heart failure,blood glucose,1
heart failure,bmi,3
heart failure,bnp,2
heart failure,c-reactive protein,3
heart failure,cholesterol,6
heart failure,chronic kidney disease,2
heart failure,coronary heart disease,1
heart failure,creatinine,4
heart failure,depression,1
heart failure,diabetes,1
heart failure,diabetes duration,4
heart failure,dialysis,3
heart failure,egfr,5
heart failure,fibrates,1
heart failure,gender,1
heart failure,glycemic control,1
heart failure,hba1c,7
heart failure,heart rate,1
heart failure,hyperlipidemia,4
heart failure,hypertension,4
heart failure,insulin treatment,1
heart failure,left ventricular ejection fraction,1
heart failure,macroalbuminuria,2
heart failure,metformin,1
heart failure,myocardial infarction,4
heart failure,neuropathy,1
heart failure,peripheral artery disease,3
heart failure,peripheral vascular disease,1
heart failure,phosphate,2
heart failure,pro btype natriuretic peptide quartiles,1
heart failure,retinopathy,1
heart failure,smoking,6
heart failure,sodium concentration,1
heart failure,statins,1
heart failure,stroke,1
heart failure,sulfonylurea,1
heart failure,systolic blood pressure,2
heart failure,thiazolidinediones,1
heart failure,triglycerides,2
heart failure,troponin,1
heart failure,ultrafiltration volume,2
heart rate,ApoAI,1
heart rate,RCT,1
heart rate,age,1
heart rate,albumin,1
heart rate,angina,1
heart rate,apoAI/apoB ratio,1
heart rate,apoB,1
heart rate,atrial fibrillation,3
heart rate,beta-blocker,1
heart rate,blood glucose,1
heart rate,bmi,3
heart rate,c-reactive protein,1
heart rate,calcium channel blockers,1
heart rate,cardiovascular disease,1
heart rate,cerebrovascular disease,1
heart rate,cholesterol,13
heart rate,creatinine,4
heart rate,diabetes,1
heart rate,diabetic neuropathy,1
heart rate,diastolic blood pressure,1
heart rate,ecg abnormalities,2
heart rate,egfr,3
heart rate,fibrinogen,1
heart rate,gastrointestinal bleeding in past 5 years,1
heart rate,glycated hemoglobin,1
heart rate,haemoglobin,1
heart rate,hba1c,5
heart rate,heart failure,1
heart rate,homair,1
heart rate,homocysteine,1
heart rate,hyperuricemia-gout,1
heart rate,idf metabolic syndrome,1
heart rate,insulin (measurment),1
heart rate,left bundle branch block,1
heart rate,left ventricular ejection fraction,1
heart rate,lung disease,1
heart rate,macroalbuminuria,2
heart rate,microalbuminuria,1
heart rate,myocardial infarction,1
heart rate,myocardial spect,1
heart rate,pacemaker implantation,1
heart rate,percutaneous coronary intervention,1
heart rate,peripheral artery disease,2
heart rate,prior coronary artery bypass,1
heart rate,retinopathy,1
heart rate,smoking,1
heart rate,sodium concentration,1
heart rate,systolic blood pressure,4
heart rate,triglycerides,4
heart rate,uric acid,1
heart rate,use of blockers,1
heart rate,white blood cell count,1
heart valve calcium,egfr,1
height,antihypertensive use,2
height,coronary artery calcium score,1
height,ecg abnormalities,1
height,hyperlipidemia,1
height,hypertension,1
height,insulin treatment,1
height,lipidlowering therapy,1
height,myocardial infarction,1
height,smoking,2
height,systolic blood pressure,1
hemodynamic measures,diabetes duration,1
hemodynamic measures,hba1c,1
hemoglobin,ACEI/ARB,1
hemoglobin,cholesterol,1
hemoglobin,egfr,1
hemoglobin,insulin treatment,1
hgi,fasting plasma glucose,1
hgi,hba1c,1
hgi,triglycerides,1
high density lipoprotein level,smoking,1
high density lipoprotein level,systolic blood pressure,1
high rlp levels,hba1c,1
high rlp levels,threevessel disease,1
highdensity lipoprotein,aspirin therapy,2
highdensity lipoprotein,cholesterol,2
highdensity lipoprotein,diabetes duration,1
highdensity lipoprotein,glycated hemoglobin,1
highdensity lipoprotein,hypertension,1
highdensity lipoprotein,insulin treatment,2
highdensity lipoprotein,lipidlowering therapy,1
highdensity lipoprotein,metformin,1
highdensity lipoprotein,microvascular disease,1
highdensity lipoprotein,statins,2
history of copd,RCT,1
history of copd,aspirin therapy,1
history of copd,atrial fibrillation,1
history of copd,cholesterol,2
history of copd,creatinine,1
history of copd,egfr,1
history of copd,hba1c,1
history of copd,heart failure,1
history of copd,smoking,1
history of coronary disease,RCT,1
history of coronary disease,antiplatelet therapy,1
history of coronary disease,aspirin therapy,1
history of coronary disease,atrial fibrillation,1
history of coronary disease,cholesterol,2
history of coronary disease,creatinine,1
history of coronary disease,egfr,1
history of coronary disease,hba1c,1
history of coronary disease,heart failure,1
history of coronary disease,history of copd,1
history of coronary disease,peripheral artery disease,1
history of coronary disease,smoking,2
homair,adiponectin,1
homair,blood glucose,1
homair,c-reactive protein,1
homair,cholesterol,3
homair,creatinine,3
homair,ecg abnormalities,1
homair,egfr,2
homair,fibrinogen,2
homair,hemoglobin,1
homair,homocysteine,2
homair,homocysteine at baseline,1
homair,interleukin 6,2
homair,parathyroid harmone (PTH),1
homair,phosphate,1
homair,systolic blood pressure,1
homair,triacylglycerol,1
homair,triglycerides,1
homocysteine,blood glucose,1
hormone therapy,alcohol use,1
hormone therapy,alternative healthy eating index ahei diet quality score quintiles,1
hormone therapy,bmi,1
hormone therapy,cholesterol,1
hormone therapy,hypertension,1
hormone therapy,myocardial infarction,1
hormone therapy,physical activity,1
hormone therapy,smoking,1
hormone therapy,white blood cell count,1
hyperlipidemia,ACEI/ARB,1
hyperlipidemia,age,2
hyperlipidemia,albumin,2
hyperlipidemia,alphaglucosidase inhibitor,1
hyperlipidemia,angina,2
hyperlipidemia,antidiabetic medication,1
hyperlipidemia,antiplatelet therapy,2
hyperlipidemia,aspirin therapy,1
hyperlipidemia,beta-blocker,2
hyperlipidemia,biomarkers (general),1
hyperlipidemia,blood glucose,3
hyperlipidemia,bmi,3
hyperlipidemia,c-reactive protein,2
hyperlipidemia,calcium channel blockers,1
hyperlipidemia,cardiovascular disease,1
hyperlipidemia,cholesterol,11
hyperlipidemia,chronic kidney disease,1
hyperlipidemia,chronic obstructive pulmonary disease,1
hyperlipidemia,cimt,1
hyperlipidemia,clopidigrel,1
hyperlipidemia,complete revascularization,1
hyperlipidemia,coronary artery calcium score,1
hyperlipidemia,coronary artery disease,3
hyperlipidemia,coronary heart disease,1
hyperlipidemia,creatinine,3
hyperlipidemia,dcb use,1
hyperlipidemia,diabetes duration,2
hyperlipidemia,diabetes treatment,4
hyperlipidemia,dipeptidyl peptidase 4 inhibitor at discharge,1
hyperlipidemia,dipyridamole stress test,1
hyperlipidemia,dpucmgp,1
hyperlipidemia,ecg abnormalities,5
hyperlipidemia,egfr,6
hyperlipidemia,fasting plasma glucose,1
hyperlipidemia,gender,1
hyperlipidemia,glycemic control,1
hyperlipidemia,hba1c,9
hyperlipidemia,hypertension,3
hyperlipidemia,insulin (measurment),1
hyperlipidemia,insulin treatment,3
hyperlipidemia,ischemia,1
hyperlipidemia,left ventricular ejection fraction,3
hyperlipidemia,lm treatment,1
hyperlipidemia,metformin,1
hyperlipidemia,myocardial infarction,4
hyperlipidemia,neuropathy,1
hyperlipidemia,percutaneous coronary intervention,2
hyperlipidemia,peripheral artery disease,3
hyperlipidemia,peripheral vascular disease,1
hyperlipidemia,prior coronary artery bypass,1
hyperlipidemia,pro btype natriuretic peptide quartiles,1
hyperlipidemia,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
hyperlipidemia,renin-angiotensin system inhibitors,1
hyperlipidemia,secretagogues,1
hyperlipidemia,smoking,8
hyperlipidemia,statins,5
hyperlipidemia,stent,1
hyperlipidemia,stroke,3
hyperlipidemia,sulfonylurea,1
hyperlipidemia,syntax score,1
hyperlipidemia,systolic blood pressure,1
hyperlipidemia,therapy for hypercoagulation,1
hyperlipidemia,triglycerides,2
hyperlipidemia,troponin,1
hypertension,ACE inhibitors,2
hypertension,ACEI/ARB,2
hypertension,ARBs,2
hypertension,Lp(a),1
hypertension,RCT,2
hypertension,acute coronary syndrome,2
hypertension,age,4
hypertension,albumin,14
hypertension,albumin excretion rate,1
hypertension,alcohol use,3
hypertension,andor nitroglycerin,1
hypertension,angina,2
hypertension,ankle-brachial index (ABI),2
hypertension,antiaggregating agents,1
hypertension,antialdosterone,1
hypertension,anticoagulants,1
hypertension,antidiabetic medication,1
hypertension,antihypertensive use,1
hypertension,antiplatelet therapy,4
hypertension,apo(a) phenotypes,1
hypertension,apoAI/apoB ratio,1
hypertension,aspirin therapy,11
hypertension,atrial fibrillation,1
hypertension,autonomic dysfunction,2
hypertension,autonomic nervous function,1
hypertension,beta-blocker,3
hypertension,biomarkers (general),1
hypertension,blockers,1
hypertension,blood glucose,8
hypertension,bmi,19
hypertension,bnp,3
hypertension,c-reactive protein,9
hypertension,calcium channel blockers,2
hypertension,cardiovascular disease,8
hypertension,cerebrovascular disease,1
hypertension,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
hypertension,choleseterol,1
hypertension,cholesterol,80
hypertension,chronic kidney disease,2
hypertension,chronic obstructive pulmonary disease,1
hypertension,chronic renal failure,1
hypertension,cimt,3
hypertension,clopidigrel,1
hypertension,clopidogrel,1
hypertension,combined alox12 genotypes,1
hypertension,complex lesions,1
hypertension,coronary artery calcium score,3
hypertension,coronary artery disease,9
hypertension,coronary heart disease,2
hypertension,creatinine,11
hypertension,diabetes,2
hypertension,diabetes duration,14
hypertension,diabetes treatment,13
hypertension,diabetic neuropathy,1
hypertension,diastolic blood pressure,5
hypertension,dipyridamole stress test,1
hypertension,distal polyneuropathy,1
hypertension,diuretic therapy,2
hypertension,dpucmgp,1
hypertension,dyslipidaemia,1
hypertension,ecg abnormalities,7
hypertension,echolucent plaque,1
hypertension,egfr,17
hypertension,ejection fraction 40,1
hypertension,endothelial dysfunction,1
hypertension,fasting plasma glucose,3
hypertension,fibrinogen,1
hypertension,final timi flow,1
hypertension,gender,4
hypertension,glycated hemoglobin,1
hypertension,glycemic control,3
hypertension,hab1c,1
hypertension,hba1c,33
hypertension,heart attack,1
hypertension,heart failure,1
hypertension,heart rate,1
hypertension,highdensity lipoprotein,2
hypertension,history of coronary disease,1
hypertension,hyperlipidemia,20
hypertension,incretins,1
hypertension,insulin treatment,16
hypertension,ischemia,1
hypertension,ischemic heart disease,3
hypertension,left ventricular ejection fraction,5
hypertension,left ventricular hypertrophy,1
hypertension,lipidlowering therapy,1
hypertension,logaer,1
hypertension,macroalbuminuria,1
hypertension,macroangiopathy,1
hypertension,macrovascular complications,8
hypertension,metformin,5
hypertension,microalbuminuria,2
hypertension,microvascular disease,7
hypertension,monocyte chemoattractant protin1 m,1
hypertension,multivessel coronary disease,3
hypertension,myocardial infarction,9
hypertension,nephropathy,1
hypertension,neuropathy,1
hypertension,nitrates,1
hypertension,pc screen time,2
hypertension,percutaneous coronary intervention,2
hypertension,peripheral artery disease,4
hypertension,peripheral neuropathy,1
hypertension,peripheral vascular disease,1
hypertension,physical activity,1
hypertension,plaque thickness,1
hypertension,prior coronary artery bypass,2
hypertension,pro btype natriuretic peptide quartiles,1
hypertension,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
hypertension,proteinuria,2
hypertension,race/ethnicity,1
hypertension,renal insufficiency,1
hypertension,renin-angiotensin system inhibitors,2
hypertension,retinopathy,2
hypertension,secretagogues,1
hypertension,sleep duration,2
hypertension,smoking,37
hypertension,sociodemographics,1
hypertension,socioeconomic variables,1
hypertension,statins,20
hypertension,stent,3
hypertension,stroke,3
hypertension,study treatment,1
hypertension,sulfonylurea,1
hypertension,systolic blood pressure,13
hypertension,the ukpds risk score,1
hypertension,therapy for hypercoagulation,1
hypertension,triglycerides,18
hypertension,troponin,1
hypertension,tv viewing,2
hypertension,uric acid,1
hypertension,wasting,1
hyperuricemia-gout,diabetes,1
hyperuricemia-gout,egfr,1
hyperuricemia-gout,gastrointestinal bleeding in past 5 years,1
hyperuricemia-gout,lung disease,1
hyperuricemia-gout,systolic blood pressure,1
hypoglycaemic treatment,antihypertensive use,1
hypoglycaemic treatment,blood pressure,1
hypoglycaemic treatment,bmi,1
hypoglycaemic treatment,hba1c,1
hypoglycaemic treatment,lipidlowering therapy,1
hypoglycaemic treatment,microalbuminuria,1
idf metabolic syndrome,c-reactive protein,1
idf metabolic syndrome,fibrinogen,1
idf metabolic syndrome,homair,1
idf metabolic syndrome,homocysteine,1
idf metabolic syndrome,insulin (measurment),1
incretins,ARBs,1
incretins,age,1
incretins,antiplatelet therapy,1
incretins,beta-blocker,2
incretins,calcium channel blockers,2
incretins,hyperlipidemia,1
incretins,neuropathy,1
incretins,peripheral artery disease,1
incretins,secretagogues,1
indigenous australian,cardiovascular disease,1
indigenous australian,coronary heart disease,1
indigenous australian,neuropathy,1
indigenous australian,retinopathy,1
indigenous australian,urinary acr,1
inflammatory markers,cardiovascular risk factors,1
inflammatory markers,hba1c,1
initial timi,age,1
initial timi,blood glucose,1
initial timi,final timi flow,1
initial timi,gender,1
initial timi,hypertension,1
initial timi,left ventricular ejection fraction,1
initial timi,multivessel coronary disease,1
initial timi,myocardial infarction,2
initial timi,percutaneous coronary intervention,1
initial timi,smoking,1
initial timi,stent,1
insulin (measurment),ACE inhibitors,1
insulin (measurment),beta-blocker,1
insulin (measurment),blood glucose,1
insulin (measurment),c-reactive protein,2
insulin (measurment),diastolic blood pressure,1
insulin (measurment),diuretic therapy,1
insulin (measurment),fibrinogen,1
insulin (measurment),homair,1
insulin (measurment),homocysteine,1
insulin (measurment),metformin,1
insulin (measurment),pioglitazone treatment,1
insulin (measurment),statins,1
insulin (measurment),sulfonylurea,1
insulin (measurment),systolic blood pressure,1
insulin treatment,ACE inhibitors,1
insulin treatment,ARBs,3
insulin treatment,age,2
insulin treatment,albumin to creatinine ratio,2
insulin treatment,alcohol use,2
insulin treatment,angina,1
insulin treatment,antidepressants,1
insulin treatment,antihypertensive use,4
insulin treatment,antiplatelet therapy,3
insulin treatment,aspirin therapy,5
insulin treatment,beta-blocker,2
insulin treatment,blockers,1
insulin treatment,blood glucose,1
insulin treatment,blood pressure,1
insulin treatment,bmi,7
insulin treatment,bnp,2
insulin treatment,calcium channel blockers,2
insulin treatment,cardiovascular disease,2
insulin treatment,cerebrovascular disease,1
insulin treatment,cholesterol,11
insulin treatment,coronary artery calcium score,1
insulin treatment,coronary heart disease,1
insulin treatment,diabetes duration,4
insulin treatment,diastolic blood pressure,4
insulin treatment,diuretic therapy,1
insulin treatment,ecg abnormalities,2
insulin treatment,egfr,3
insulin treatment,family history of diabetes,1
insulin treatment,fasting plasma glucose,1
insulin treatment,fibrates,1
insulin treatment,gender,1
insulin treatment,glycemic control,1
insulin treatment,hba1c,5
insulin treatment,hyperlipidemia,1
insulin treatment,hypertension,4
insulin treatment,incretins,1
insulin treatment,lowdensity lipoprotein,1
insulin treatment,macrovascular complications,1
insulin treatment,metformin,2
insulin treatment,microvascular disease,1
insulin treatment,monocyte chemoattractant protin1 m,1
insulin treatment,myocardial infarction,1
insulin treatment,neuropathy,1
insulin treatment,pc screen time,1
insulin treatment,peripheral artery disease,1
insulin treatment,physical activity,2
insulin treatment,pulse pressure,1
insulin treatment,renin-angiotensin system inhibitors,1
insulin treatment,retinopathy,2
insulin treatment,sds summed difference score,1
insulin treatment,secretagogues,1
insulin treatment,sleep duration,1
insulin treatment,smoking,4
insulin treatment,sodium concentration,1
insulin treatment,statins,7
insulin treatment,sulfonylurea,1
insulin treatment,summed stress score sss,1
insulin treatment,systolic blood pressure,5
insulin treatment,tot chol,1
insulin treatment,triglycerides,3
insulin treatment,tv viewing,1
insulin treatment,uric acid,1
insulin treatment,urinary acr,1
intensive treatment,diabetes duration,2
interleukin 6,cholesterol,1
interleukin 6,creatinine,1
interleukin 6,egfr,1
interleukin 6,hemoglobin,1
interleukin 6,parathyroid harmone (PTH),1
interleukin 6,phosphate,1
intervention arm no interaction model,clinic gamma frailty,1
ischemia,antihypertensive use,1
ischemia,blood glucose,1
ischemia,bmi,1
ischemia,cardiovascular disease,1
ischemia,cholesterol,3
ischemia,diabetes duration,1
ischemia,insulin treatment,1
ischemia,microalbuminuria,1
ischemia,pulse pressure,1
ischemia,retinopathy,1
ischemia,smoking,1
ischemia,stroke,1
ischemia,triglycerides,1
ischemic heart disease,bnp,1
ischemic heart disease,cholesterol,1
ischemic heart disease,chronic renal failure,1
ischemic heart disease,diabetes duration,1
ischemic heart disease,diabetes treatment,1
ischemic heart disease,hba1c,2
ischemic heart disease,retinopathy,1
ischemic heart disease,statins,1
kidney function,cardiovascular disease,2
kidney function,lowdensity lipoprotein,1
kidney function,other conventional risk factors,1
kidney function,smoking,1
kidney function,systolic blood pressure,1
lack of coronary revascularization,age,1
lack of coronary revascularization,glycated hemoglobin,1
lack of coronary revascularization,haemoglobin,1
lack of coronary revascularization,heart rate,1
lack of coronary revascularization,myocardial infarction,1
lack of coronary revascularization,prior coronary artery bypass,1
left atrial diameter,egfr,1
left atrial diameter,heart valve calcium,1
left bundle branch block,atrial fibrillation,1
left bundle branch block,cholesterol,1
left bundle branch block,creatinine,1
left bundle branch block,uric acid,1
left ventricular ejection fraction,ACEI/ARB,1
left ventricular ejection fraction,alphaglucosidase inhibitor,1
left ventricular ejection fraction,antidiabetic medication,1
left ventricular ejection fraction,antiplatelet therapy,2
left ventricular ejection fraction,beta-blocker,1
left ventricular ejection fraction,c-reactive protein,2
left ventricular ejection fraction,cholesterol,3
left ventricular ejection fraction,clopidigrel,1
left ventricular ejection fraction,complete revascularization,1
left ventricular ejection fraction,dcb use,1
left ventricular ejection fraction,diabetes,1
left ventricular ejection fraction,diastolic blood pressure,1
left ventricular ejection fraction,dipeptidyl peptidase 4 inhibitor at discharge,1
left ventricular ejection fraction,diuretic therapy,1
left ventricular ejection fraction,egfr,1
left ventricular ejection fraction,fibrinogen,1
left ventricular ejection fraction,glycemic control,1
left ventricular ejection fraction,hba1c,2
left ventricular ejection fraction,hypertension,1
left ventricular ejection fraction,insulin (measurment),1
left ventricular ejection fraction,insulin treatment,2
left ventricular ejection fraction,ischemia,1
left ventricular ejection fraction,lm treatment,1
left ventricular ejection fraction,previous pcicabg,1
left ventricular ejection fraction,smoking,1
left ventricular ejection fraction,statins,3
left ventricular ejection fraction,sulfonylurea,1
left ventricular ejection fraction,syntax score,1
left ventricular ejection fraction,systolic blood pressure,1
left ventricular ejection fraction,troponin,1
left ventricular hypertrophy,cholesterol,2
left ventricular hypertrophy,coronary artery disease,1
left ventricular hypertrophy,diabetes duration,1
left ventricular hypertrophy,ecg abnormalities,1
left ventricular hypertrophy,hba1c,1
left ventricular hypertrophy,hypertension,1
left ventricular hypertrophy,macroalbuminuria,1
left ventricular hypertrophy,microalbuminuria,1
left ventricular hypertrophy,renal insufficiency,1
left ventricular hypertrophy,statins,1
lipid profile,Serum 25-hydroxyvitamin D,1
lipid profile,antihypertensive use,1
lipid profile,coronary heart disease,1
lipid profile,glycemic control,1
lipid profile,heart failure,1
lipid profile,peripheral artery disease,1
lipid profile,systolic blood pressure,1
lipidlowering therapy,ARBs,1
lipidlowering therapy,ApoAI,1
lipidlowering therapy,RCT,1
lipidlowering therapy,age,2
lipidlowering therapy,albumin,2
lipidlowering therapy,alcohol use,1
lipidlowering therapy,antihypertensive use,5
lipidlowering therapy,antiplatelet therapy,3
lipidlowering therapy,apoAI/apoB ratio,1
lipidlowering therapy,apoB,1
lipidlowering therapy,aspirin therapy,3
lipidlowering therapy,atrial fibrillation,1
lipidlowering therapy,blood glucose,2
lipidlowering therapy,blood pressure,1
lipidlowering therapy,bmi,4
lipidlowering therapy,c-reactive protein,1
lipidlowering therapy,cardiovascular disease,2
lipidlowering therapy,cholesterol,8
lipidlowering therapy,creatinine,3
lipidlowering therapy,diabetes,1
lipidlowering therapy,diastolic blood pressure,2
lipidlowering therapy,fibrinogen,1
lipidlowering therapy,hba1c,2
lipidlowering therapy,heart failure,2
lipidlowering therapy,heart rate,1
lipidlowering therapy,homair,1
lipidlowering therapy,homocysteine,1
lipidlowering therapy,idf metabolic syndrome,1
lipidlowering therapy,insulin (measurment),1
lipidlowering therapy,physical activity,1
lipidlowering therapy,race/ethnicity,1
lipidlowering therapy,renal impairment,1
lipidlowering therapy,socioeconomic variables,1
lipidlowering therapy,systolic blood pressure,3
lipidlowering therapy,triglycerides,4
lipidlowering therapy,waist measurements,3
living alone,albumin,1
living alone,bmi,1
living alone,cholesterol,1
living alone,creatinine,1
living alone,diabetes treatment,1
living alone,hypertension,1
living alone,physical activity,1
living alone,smoking,1
living alone,triglycerides,1
living alone,wasting,1
lm treatment,alphaglucosidase inhibitor,1
lm treatment,antiplatelet therapy,2
lm treatment,complete revascularization,1
lm treatment,dcb use,1
lm treatment,dipeptidyl peptidase 4 inhibitor at discharge,1
lm treatment,glycemic control,1
lm treatment,insulin (measurment),1
lm treatment,statins,2
lm treatment,sulfonylurea,1
log101  acr,ACE inhibitors,1
log101  acr,antihypertensive use,1
log101  acr,egfr,1
log101  acr,insulin (measurment),1
log101  acr,peripheral artery disease,1
log101  acr,retinopathy,1
log101  acr,sensory neuropathy,1
log101  acr,stroke,2
logaer,bnp,1
logaer,cardiovascular disease,1
lowdensity lipoprotein,aspirin therapy,1
lowdensity lipoprotein,bmi,1
lowdensity lipoprotein,cardiovascular disease,1
lowdensity lipoprotein,cholesterol,1
lowdensity lipoprotein,highdensity lipoprotein,1
lowdensity lipoprotein,lipidlowering therapy,1
lowdensity lipoprotein,smoking,1
lowdensity lipoprotein,systolic blood pressure,2
lowdensity lipoprotein,triglycerides,1
lung disease,diabetes,1
macroalbuminuria,age,1
macroalbuminuria,cholesterol,2
macroalbuminuria,fibrinogen,1
macroalbuminuria,hba1c,1
macroalbuminuria,insulin treatment,1
macroalbuminuria,left ventricular ejection fraction,1
macroalbuminuria,microalbuminuria,1
macroalbuminuria,peripheral artery disease,1
macroalbuminuria,renal insufficiency,1
macroalbuminuria,sociodemographics,2
macroangiopathy,ARBs,1
macroangiopathy,age,1
macroangiopathy,antiplatelet therapy,1
macroangiopathy,beta-blocker,2
macroangiopathy,calcium channel blockers,2
macroangiopathy,hyperlipidemia,1
macroangiopathy,incretins,1
macroangiopathy,insulin treatment,1
macroangiopathy,metformin,1
macroangiopathy,neuropathy,1
macroangiopathy,peripheral artery disease,1
macroangiopathy,secretagogues,1
macrovascular complications,albumin,1
macrovascular complications,alcohol use,1
macrovascular complications,antihypertensive use,1
macrovascular complications,antiplatelet therapy,1
macrovascular complications,aspirin therapy,6
macrovascular complications,blood glucose,1
macrovascular complications,bmi,1
macrovascular complications,c-reactive protein,1
macrovascular complications,cholesterol,16
macrovascular complications,coronary artery calcium score,1
macrovascular complications,creatinine,1
macrovascular complications,diabetes duration,1
macrovascular complications,diastolic blood pressure,1
macrovascular complications,ecg abnormalities,1
macrovascular complications,fasting plasma glucose,1
macrovascular complications,glycemic control,1
macrovascular complications,hba1c,7
macrovascular complications,highdensity lipoprotein,1
macrovascular complications,hypertension,1
macrovascular complications,insulin treatment,3
macrovascular complications,left ventricular hypertrophy,1
macrovascular complications,microvascular disease,3
macrovascular complications,nterminal probrain natriuretic peptide,1
macrovascular complications,psychiatric medications,1
macrovascular complications,smoking,1
macrovascular complications,statins,8
macrovascular complications,systolic blood pressure,4
macrovascular complications,troponin,1
marital status,albumin,1
marital status,albumin to creatinine ratio,1
marital status,bmi,1
marital status,chronic kidney disease,1
marital status,diabetes treatment,1
marital status,egfr,1
marital status,hba1c,1
marital status,heart failure,1
marital status,myocardial infarction,1
marital status,smoking,1
marital status,sociodemographics,1
marital status,socioeconomic variables,1
mca stenosis,albumin,1
mca stenosis,cholesterol,3
mca stenosis,hba1c,1
mean blood pressure,bmi,1
mean blood pressure,cholesterol,1
mean blood pressure,gender,1
mean blood pressure,triglycerides,1
medical diabetic treatment,coronary artery disease,1
medical diabetic treatment,diabetes duration,1
medical diabetic treatment,hba1c,1
medical diabetic treatment,hemodynamic measures,1
medical diabetic treatment,minimum lumen diameter,1
medical diabetic treatment,stent,1
medical diabetic treatment,vessel size,1
medication use,hba1c,1
medications,albumin,1
menopausal status pre post uncertain missing,alcohol use,1
menopausal status pre post uncertain missing,alternative healthy eating index ahei diet quality score quintiles,1
menopausal status pre post uncertain missing,bmi,1
menopausal status pre post uncertain missing,cholesterol,1
menopausal status pre post uncertain missing,hormone therapy,1
menopausal status pre post uncertain missing,hypertension,1
menopausal status pre post uncertain missing,myocardial infarction,1
menopausal status pre post uncertain missing,physical activity,1
menopausal status pre post uncertain missing,smoking,1
menopausal status pre post uncertain missing,white blood cell count,1
metabolic syndrome markers,age,1
metabolic syndrome markers,bmi,1
metabolic syndrome markers,hba1c,1
metabolic syndrome markers,hyperlipidemia,1
metabolic syndrome markers,hypertension,1
metformin,ACE inhibitors,1
metformin,ARBs,2
metformin,age,2
metformin,alcohol use,1
metformin,antidepressants,1
metformin,antihypertensive use,2
metformin,antiplatelet therapy,2
metformin,aspirin therapy,1
metformin,beta-blocker,3
metformin,blockers,1
metformin,blood glucose,1
metformin,bmi,1
metformin,calcium channel blockers,2
metformin,cholesterol,3
metformin,diabetes duration,1
metformin,diuretic therapy,1
metformin,fibrates,1
metformin,gender,1
metformin,hyperlipidemia,1
metformin,hypertension,1
metformin,incretins,1
metformin,insulin treatment,2
metformin,macrovascular complications,1
metformin,microvascular disease,2
metformin,neuropathy,1
metformin,peripheral artery disease,1
metformin,pioglitazone treatment,1
metformin,psychiatric medications,1
metformin,secretagogues,1
metformin,smoking,1
metformin,statins,4
metformin,sulfonylurea,2
metformin,systolic blood pressure,1
metformin,thiazolidinediones,1
metformin,year of followup start,1
microalbuminuria,ACE inhibitors,1
microalbuminuria,RCT,1
microalbuminuria,acute coronary syndrome,1
microalbuminuria,ankle-brachial index (ABI),2
microalbuminuria,antihypertensive use,2
microalbuminuria,antiplatelet therapy,1
microalbuminuria,autonomic dysfunction,1
microalbuminuria,autonomic nervous function,1
microalbuminuria,beta-blocker,1
microalbuminuria,blood glucose,1
microalbuminuria,blood pressure,1
microalbuminuria,bmi,3
microalbuminuria,cardiovascular disease,1
microalbuminuria,cholesterol,11
microalbuminuria,coronary artery disease,1
microalbuminuria,creatinine,1
microalbuminuria,diabetes duration,2
microalbuminuria,dialysis,1
microalbuminuria,distal polyneuropathy,1
microalbuminuria,diuretic therapy,1
microalbuminuria,dyslipidaemia,1
microalbuminuria,ecg abnormalities,1
microalbuminuria,hba1c,1
microalbuminuria,heart rate,1
microalbuminuria,hypertension,1
microalbuminuria,insulin (measurment),1
microalbuminuria,insulin treatment,2
microalbuminuria,kidney function,1
microalbuminuria,lipidlowering therapy,2
microalbuminuria,lowdensity lipoprotein,1
microalbuminuria,macroalbuminuria,1
microalbuminuria,metformin,1
microalbuminuria,myocardial infarction,1
microalbuminuria,myocardial spect,1
microalbuminuria,peripheral arterial occlusive disease,1
microalbuminuria,physical activity,1
microalbuminuria,pioglitazone treatment,1
microalbuminuria,prior coronary artery bypass,1
microalbuminuria,provider quality controls,1
microalbuminuria,pulse pressure,1
microalbuminuria,retinopathy,1
microalbuminuria,smoking,5
microalbuminuria,sociodemographics,1
microalbuminuria,statins,2
microalbuminuria,stroke,1
microalbuminuria,sulfonylurea,2
microalbuminuria,systolic blood pressure,1
microalbuminuria,triglycerides,2
microalbuminuria,year fixed effects,1
microvascular disease,ACEI/ARB,1
microvascular disease,alcohol use,2
microvascular disease,antihypertensive use,2
microvascular disease,antiplatelet therapy,1
microvascular disease,aspirin therapy,6
microvascular disease,blood glucose,1
microvascular disease,bmi,2
microvascular disease,cholesterol,15
microvascular disease,diabetes treatment,2
microvascular disease,diastolic blood pressure,1
microvascular disease,fasting plasma glucose,1
microvascular disease,glycemic control,1
microvascular disease,hba1c,6
microvascular disease,highdensity lipoprotein,1
microvascular disease,hyperlipidemia,1
microvascular disease,hypertension,3
microvascular disease,insulin treatment,3
microvascular disease,lipidlowering therapy,1
microvascular disease,macrovascular complications,4
microvascular disease,psychiatric medications,1
microvascular disease,smoking,1
microvascular disease,sociodemographics,1
microvascular disease,statins,7
microvascular disease,systolic blood pressure,4
microvascular disease,therapy for hypercoagulation,1
microvascular disease,triglycerides,1
minimum lumen diameter,diabetes duration,1
minimum lumen diameter,hba1c,1
minimum lumen diameter,hemodynamic measures,1
mpv mean platelet volume,syntax score,1
multivessel coronary disease,apo(a) phenotypes,1
multivessel coronary disease,complex lesions,1
multivessel coronary disease,diuretic therapy,1
multivessel coronary disease,final timi flow,1
multivessel coronary disease,insulin treatment,1
multivessel coronary disease,left ventricular ejection fraction,2
multivessel coronary disease,stent,1
myocardial infarction,ACE inhibitors,1
myocardial infarction,ACEI/ARB,1
myocardial infarction,RCT,2
myocardial infarction,acute coronary syndrome,1
myocardial infarction,age,1
myocardial infarction,alcohol use,2
myocardial infarction,alphaglucosidase inhibitor,1
myocardial infarction,alternative healthy eating index ahei diet quality score quintiles,1
myocardial infarction,angina,1
myocardial infarction,antidiabetic medication,1
myocardial infarction,antiplatelet therapy,2
myocardial infarction,aspirin therapy,1
myocardial infarction,atrial fibrillation,2
myocardial infarction,beta-blocker,2
myocardial infarction,biomarkers (general),1
myocardial infarction,blood glucose,5
myocardial infarction,bmi,8
myocardial infarction,c-reactive protein,3
myocardial infarction,cerebrovascular disease,2
myocardial infarction,cholesterol,10
myocardial infarction,chronic kidney disease,1
myocardial infarction,clopidigrel,1
myocardial infarction,complete revascularization,1
myocardial infarction,complex lesions,1
myocardial infarction,coronary artery calcium score,1
myocardial infarction,coronary artery disease,1
myocardial infarction,creatinine,5
myocardial infarction,dcb use,1
myocardial infarction,diabetes,1
myocardial infarction,diabetes duration,2
myocardial infarction,diabetes treatment,1
myocardial infarction,dipeptidyl peptidase 4 inhibitor at discharge,1
myocardial infarction,dipyridamole stress test,1
myocardial infarction,diuretic therapy,2
myocardial infarction,ecg abnormalities,5
myocardial infarction,egfr,7
myocardial infarction,ejection fraction,1
myocardial infarction,fasting status yes or no,1
myocardial infarction,final timi flow,2
myocardial infarction,gender,4
myocardial infarction,glycemic control,1
myocardial infarction,hba1c,7
myocardial infarction,heart failure,3
myocardial infarction,heart rate,1
myocardial infarction,hyperlipidemia,4
myocardial infarction,hypertension,7
myocardial infarction,insulin (measurment),2
myocardial infarction,insulin treatment,3
myocardial infarction,ischemia,1
myocardial infarction,ischemic heart disease,1
myocardial infarction,left ventricular ejection fraction,6
myocardial infarction,lm treatment,1
myocardial infarction,macroalbuminuria,1
myocardial infarction,metformin,1
myocardial infarction,multivessel coronary disease,3
myocardial infarction,percutaneous coronary intervention,6
myocardial infarction,peripheral arterial occlusive disease,1
myocardial infarction,peripheral artery disease,1
myocardial infarction,peripheral vascular disease,1
myocardial infarction,physical activity,2
myocardial infarction,pioglitazone treatment,1
myocardial infarction,prior coronary artery bypass,2
myocardial infarction,pro btype natriuretic peptide quartiles,1
myocardial infarction,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
myocardial infarction,smoking,9
myocardial infarction,sociodemographics,1
myocardial infarction,sodium concentration,1
myocardial infarction,statins,5
myocardial infarction,stent,3
myocardial infarction,stroke,2
myocardial infarction,sulfonylurea,2
myocardial infarction,syntax score,1
myocardial infarction,systolic blood pressure,1
myocardial infarction,tot chol,1
myocardial infarction,triglycerides,1
myocardial infarction,troponin,1
myocardial infarction,urinary,1
myocardial infarction,urinary albumin excretion rate,1
myocardial infarction,white blood cell count,1
myocardial spect,cholesterol,2
nephropathy,aspirin therapy,1
nephropathy,bmi,1
nephropathy,cholesterol,3
nephropathy,diabetes duration,1
nephropathy,diastolic blood pressure,1
nephropathy,egfr,2
nephropathy,lipidlowering therapy,1
nephropathy,systolic blood pressure,1
nephropathy,triglycerides,1
neuropathy,ARBs,1
neuropathy,antidepressants,1
neuropathy,antihypertensive use,1
neuropathy,beta-blocker,1
neuropathy,blockers,1
neuropathy,calcium channel blockers,1
neuropathy,chronic kidney disease,1
neuropathy,depression,1
neuropathy,fibrates,1
neuropathy,insulin treatment,1
neuropathy,metformin,1
neuropathy,peripheral artery disease,1
neuropathy,secretagogues,1
neuropathy,statins,1
neuropathy,sulfonylurea,1
neuropathy,thiazolidinediones,1
nitrates,acute coronary syndrome,1
nitrates,andor nitroglycerin,1
nitrates,bnp,1
nitrates,diuretic therapy,1
nitrates,insulin treatment,2
nitrates,monocyte chemoattractant protin1 m,1
nitrates,sds summed difference score,1
nitrates,summed stress score sss,1
not specified,age,1
not specified,albumin to creatinine ratio,1
not specified,gender,1
not specified,marital status,1
not specified,race/ethnicity,1
not specified,socioeconomic variables,1
nzdep quintile,antiplatelet therapy,1
nzdep quintile,blood pressure,1
nzdep quintile,bmi,1
nzdep quintile,cardiovascular disease,1
nzdep quintile,cholesterol,1
nzdep quintile,diabetes,1
nzdep quintile,diastolic blood pressure,1
nzdep quintile,heart failure,1
nzdep quintile,lipidlowering therapy,1
nzdep quintile,systolic blood pressure,1
other complications,cardiovascular risk factors,2
other complications,metformin,1
other complications,serum magnesium,1
pIMT,egfr,1
pIMT,hypertension,1
pIMT,smoking,1
parathyroid harmone (PTH),c-reactive protein,1
parathyroid harmone (PTH),cholesterol,1
parathyroid harmone (PTH),creatinine,1
parathyroid harmone (PTH),ecg abnormalities,1
parathyroid harmone (PTH),egfr,1
parathyroid harmone (PTH),hemoglobin,1
parathyroid harmone (PTH),insulin (measurment),1
parathyroid harmone (PTH),systolic blood pressure,1
pc screen time,alcohol use,1
pc screen time,sleep duration,1
percent low density plaque,mild plaque calcifi cation,1
percutaneous coronary intervention,ACEI/ARB,1
percutaneous coronary intervention,age,1
percutaneous coronary intervention,alphaglucosidase inhibitor,1
percutaneous coronary intervention,angina,1
percutaneous coronary intervention,antidiabetic medication,1
percutaneous coronary intervention,antiplatelet therapy,2
percutaneous coronary intervention,atrial fibrillation,1
percutaneous coronary intervention,beta-blocker,1
percutaneous coronary intervention,bmi,1
percutaneous coronary intervention,cerebrovascular disease,2
percutaneous coronary intervention,cholesterol,5
percutaneous coronary intervention,clopidigrel,1
percutaneous coronary intervention,complete revascularization,1
percutaneous coronary intervention,creatinine,1
percutaneous coronary intervention,dcb use,1
percutaneous coronary intervention,dipeptidyl peptidase 4 inhibitor at discharge,1
percutaneous coronary intervention,ecg abnormalities,3
percutaneous coronary intervention,egfr,2
percutaneous coronary intervention,final timi flow,1
percutaneous coronary intervention,gender,1
percutaneous coronary intervention,glycemic control,1
percutaneous coronary intervention,hba1c,2
percutaneous coronary intervention,heart failure,1
percutaneous coronary intervention,insulin (measurment),1
percutaneous coronary intervention,insulin treatment,1
percutaneous coronary intervention,left ventricular ejection fraction,3
percutaneous coronary intervention,lm treatment,1
percutaneous coronary intervention,macroalbuminuria,1
percutaneous coronary intervention,multivessel coronary disease,1
percutaneous coronary intervention,peripheral artery disease,1
percutaneous coronary intervention,peripheral vascular disease,1
percutaneous coronary intervention,sociodemographics,1
percutaneous coronary intervention,sodium concentration,1
percutaneous coronary intervention,statins,3
percutaneous coronary intervention,stent,1
percutaneous coronary intervention,stroke,1
percutaneous coronary intervention,sulfonylurea,1
percutaneous coronary intervention,syntax score,1
percutaneous coronary intervention,systolic blood pressure,1
peripheral arterial occlusive disease,ACE inhibitors,1
peripheral arterial occlusive disease,beta-blocker,1
peripheral arterial occlusive disease,diuretic therapy,1
peripheral arterial occlusive disease,insulin (measurment),1
peripheral arterial occlusive disease,metformin,1
peripheral arterial occlusive disease,pioglitazone treatment,1
peripheral arterial occlusive disease,statins,1
peripheral arterial occlusive disease,stroke,1
peripheral arterial occlusive disease,sulfonylurea,1
peripheral artery disease,ACE inhibitors,1
peripheral artery disease,RCT,1
peripheral artery disease,age,1
peripheral artery disease,albumin,3
peripheral artery disease,antihypertensive use,1
peripheral artery disease,aspirin therapy,2
peripheral artery disease,atrial fibrillation,1
peripheral artery disease,beta-blocker,1
peripheral artery disease,blood glucose,1
peripheral artery disease,bmi,1
peripheral artery disease,bnp,1
peripheral artery disease,c-reactive protein,1
peripheral artery disease,calcium channel blockers,1
peripheral artery disease,cholesterol,11
peripheral artery disease,chronic obstructive pulmonary disease,1
peripheral artery disease,creatinine,2
peripheral artery disease,diabetes,1
peripheral artery disease,diabetes duration,2
peripheral artery disease,diabetes treatment,2
peripheral artery disease,dialysis,1
peripheral artery disease,egfr,2
peripheral artery disease,fasting plasma glucose,1
peripheral artery disease,framingham risk score,1
peripheral artery disease,gastrointestinal bleeding in past 5 years,1
peripheral artery disease,hba1c,7
peripheral artery disease,heart failure,1
peripheral artery disease,history of copd,1
peripheral artery disease,hyperuricemia-gout,1
peripheral artery disease,insulin (measurment),1
peripheral artery disease,ischemic heart disease,1
peripheral artery disease,lung disease,1
peripheral artery disease,mca stenosis,1
peripheral artery disease,myocardial infarction,1
peripheral artery disease,nephropathy,2
peripheral artery disease,neuropathy,1
peripheral artery disease,phosphate,1
peripheral artery disease,retinopathy,2
peripheral artery disease,secretagogues,1
peripheral artery disease,smoking,1
peripheral artery disease,statins,1
peripheral artery disease,stroke,3
peripheral artery disease,systolic blood pressure,1
peripheral artery disease,the use of drugs yesno,1
peripheral artery disease,triglycerides,2
peripheral artery disease,ultrafiltration volume,1
peripheral artery disease,white blood cell count,1
peripheral neuropathy,albumin,1
peripheral neuropathy,metformin,1
peripheral vascular disease,albumin,1
peripheral vascular disease,alphaglucosidase inhibitor,1
peripheral vascular disease,antiplatelet therapy,2
peripheral vascular disease,bnp,1
peripheral vascular disease,c-reactive protein,1
peripheral vascular disease,cardiovascular disease,1
peripheral vascular disease,charlson index,1
peripheral vascular disease,cholesterol,2
peripheral vascular disease,chronic kidney disease,1
peripheral vascular disease,complete revascularization,1
peripheral vascular disease,dcb use,1
peripheral vascular disease,dipeptidyl peptidase 4 inhibitor at discharge,1
peripheral vascular disease,ecg abnormalities,1
peripheral vascular disease,egfr,1
peripheral vascular disease,glycemic control,1
peripheral vascular disease,hba1c,2
peripheral vascular disease,insulin (measurment),1
peripheral vascular disease,left ventricular ejection fraction,1
peripheral vascular disease,lm treatment,1
peripheral vascular disease,metformin,1
peripheral vascular disease,peripheral neuropathy,1
peripheral vascular disease,retinopathy,1
peripheral vascular disease,statins,2
peripheral vascular disease,sulfonylurea,1
peripheral vascular disease,syntax score,1
peripheral vascular disease,total baseline expenditures,1
peripheral vascular disease,triglycerides,1
phosphate,albumin,1
phosphate,arteriovenous fistula,1
phosphate,bnp,1
phosphate,c-reactive protein,2
phosphate,cholesterol,3
phosphate,creatinine,2
phosphate,dialysis,1
phosphate,ecg abnormalities,2
phosphate,egfr,2
phosphate,hemoglobin,1
phosphate,homair,1
phosphate,insulin (measurment),1
phosphate,interleukin 6,1
phosphate,parathyroid harmone (PTH),2
phosphate,systolic blood pressure,1
phosphate,triglycerides,1
phosphate,ultrafiltration volume,1
physical activity,ApoAI,1
physical activity,albumin,2
physical activity,albumin to creatinine ratio,1
physical activity,alcohol use,1
physical activity,ankle-brachial index (ABI),1
physical activity,antihypertensive use,1
physical activity,apoAI/apoB ratio,1
physical activity,apoB,1
physical activity,aspirin therapy,4
physical activity,average of 3 daily 2hour bg levels after meals,1
physical activity,blood glucose,1
physical activity,blood pressure,1
physical activity,bmi,6
physical activity,c-reactive protein,1
physical activity,cardiovascular disease,2
physical activity,cholesterol,13
physical activity,chronic kidney disease,1
physical activity,ci,1
physical activity,coronary heart disease,3
physical activity,creatinine,4
physical activity,diabetes treatment,2
physical activity,diastolic blood pressure,2
physical activity,ecg abnormalities,1
physical activity,egfr,1
physical activity,fasting status yes or no,1
physical activity,fibrinogen,2
physical activity,glycemic control,2
physical activity,hba1c,7
physical activity,heart rate,3
physical activity,homair,1
physical activity,homocysteine,1
physical activity,hyperlipidemia,1
physical activity,hypertension,8
physical activity,idf metabolic syndrome,1
physical activity,indigenous australian,1
physical activity,insulin (measurment),1
physical activity,insulin treatment,1
physical activity,macrovascular complications,2
physical activity,microvascular disease,1
physical activity,neuropathy,1
physical activity,retinopathy,3
physical activity,smoking,3
physical activity,socioeconomic variables,1
physical activity,statins,1
physical activity,systolic blood pressure,4
physical activity,total energy kcalday,1
physical activity,triglycerides,3
physical activity,urinary acr,1
physical activity,waist measurements,2
physical activity,wasting,1
physical inactivity,aspirin therapy,4
physical inactivity,cholesterol,8
physical inactivity,diastolic blood pressure,1
physical inactivity,fasting plasma glucose,1
physical inactivity,glycemic control,1
physical inactivity,hba1c,3
physical inactivity,highdensity lipoprotein,1
physical inactivity,hypertension,3
physical inactivity,insulin treatment,3
physical inactivity,macrovascular complications,4
physical inactivity,microalbuminuria,1
physical inactivity,microvascular disease,4
physical inactivity,statins,4
physical inactivity,systolic blood pressure,4
plaque thickness,antiaggregating agents,1
plaque thickness,echolucent plaque,1
plaque volume,mild plaque calcifi cation,1
plaque volume,percent low density plaque,1
postpci thrombolysis in mitimiflow,atrial fibrillation,1
postpci thrombolysis in mitimiflow,left ventricular ejection fraction,1
previous diseases,blood transfusion,1
previous diseases,bmi,1
previous diseases,diabetes,1
previous diseases,egfr,1
previous diseases,gastrointestinal bleeding in past 5 years,1
previous diseases,heart rate,1
previous diseases,hyperuricemia-gout,1
previous diseases,lung disease,1
previous diseases,peripheral artery disease,1
previous diseases,systolic blood pressure,1
previous diseases,white blood cell count,1
previous pcicabg,c-reactive protein,1
previous pcicabg,cholesterol,1
previous pcicabg,diastolic blood pressure,1
previous pcicabg,fibrinogen,1
previous pcicabg,hba1c,1
previous pcicabg,systolic blood pressure,1
prior coronary artery bypass,ACE inhibitors,1
prior coronary artery bypass,acute coronary syndrome,1
prior coronary artery bypass,beta-blocker,1
prior coronary artery bypass,blood glucose,1
prior coronary artery bypass,c-reactive protein,1
prior coronary artery bypass,complex lesions,1
prior coronary artery bypass,diuretic therapy,2
prior coronary artery bypass,egfr,1
prior coronary artery bypass,insulin (measurment),1
prior coronary artery bypass,insulin treatment,1
prior coronary artery bypass,left ventricular ejection fraction,1
prior coronary artery bypass,metformin,1
prior coronary artery bypass,multivessel coronary disease,1
prior coronary artery bypass,myocardial infarction,2
prior coronary artery bypass,peripheral arterial occlusive disease,1
prior coronary artery bypass,pioglitazone treatment,1
prior coronary artery bypass,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
prior coronary artery bypass,statins,1
prior coronary artery bypass,stroke,1
prior coronary artery bypass,sulfonylurea,1
prior cv event,age,1
prior cv event,diabetes duration,2
prior cv event,intensive treatment,1
prior cv event,triglycerides,1
pro btype natriuretic peptide quartiles,c-reactive protein,1
proteinuria,antidiabetic medication,1
proteinuria,antihypertensive use,1
proteinuria,antiplatelet therapy,2
proteinuria,c-reactive protein,1
proteinuria,cardiovascular disease,1
proteinuria,cholesterol,1
proteinuria,current multifactorial care,1
proteinuria,diabetes duration,1
proteinuria,ecg abnormalities,1
proteinuria,hba1c,1
proteinuria,history of coronary disease,1
proteinuria,insulin treatment,1
proteinuria,myocardial infarction,1
proteinuria,peripheral artery disease,1
proteinuria,retinopathy,1
proteinuria,smoking,1
proteinuria,statins,1
provider quality controls,sociodemographics,1
provider quality controls,year fixed effects,1
psychiatric medications,blood glucose,1
psychiatric medications,cholesterol,1
pulse pressure,ankle-brachial index (ABI),1
pulse pressure,antihypertensive use,1
pulse pressure,cholesterol,1
pulse pressure,diabetes duration,1
pulse pressure,ecg abnormalities,3
pulse pressure,egfr,1
pulse pressure,significant proximal lad disease,1
pulse pressure,smoking,1
pulse pressure,the presence of total occlusion,1
qt interval,bmi,1
qt interval,cholesterol,2
qt interval,heart rate,1
qt interval,microalbuminuria,1
qt interval,myocardial spect,1
race/ethnicity,ACE inhibitors,1
race/ethnicity,ACEI/ARB,1
race/ethnicity,ARBs,1
race/ethnicity,ApoAI,1
race/ethnicity,RCT,6
race/ethnicity,albumin,1
race/ethnicity,albumin to creatinine ratio,2
race/ethnicity,alcohol use,2
race/ethnicity,antidepressants,1
race/ethnicity,antihypertensive use,3
race/ethnicity,antiplatelet therapy,1
race/ethnicity,apoAI/apoB ratio,1
race/ethnicity,apoB,1
race/ethnicity,atrial fibrillation,1
race/ethnicity,blockers,1
race/ethnicity,blood glucose,1
race/ethnicity,blood pressure,2
race/ethnicity,blood transfusion,1
race/ethnicity,bmi,7
race/ethnicity,c-reactive protein,1
race/ethnicity,cardiovascular disease,6
race/ethnicity,cholesterol,22
race/ethnicity,chronic kidney disease,1
race/ethnicity,ci,1
race/ethnicity,creatinine,3
race/ethnicity,depression,1
race/ethnicity,diabetes,2
race/ethnicity,diabetes duration,9
race/ethnicity,diabetes treatment,2
race/ethnicity,diabetic neuropathy,1
race/ethnicity,diastolic blood pressure,3
race/ethnicity,egfr,5
race/ethnicity,fibrates,1
race/ethnicity,fibrinogen,1
race/ethnicity,gastrointestinal bleeding in past 5 years,1
race/ethnicity,gender,3
race/ethnicity,hba1c,6
race/ethnicity,heart failure,4
race/ethnicity,heart rate,4
race/ethnicity,high density lipoprotein level,1
race/ethnicity,homair,1
race/ethnicity,homocysteine,1
race/ethnicity,hypertension,7
race/ethnicity,hyperuricemia-gout,1
race/ethnicity,idf metabolic syndrome,1
race/ethnicity,insulin (measurment),1
race/ethnicity,insulin treatment,1
race/ethnicity,left ventricular ejection fraction,1
race/ethnicity,lipidlowering therapy,2
race/ethnicity,lung disease,1
race/ethnicity,macroalbuminuria,1
race/ethnicity,macrovascular complications,1
race/ethnicity,marital status,1
race/ethnicity,metformin,1
race/ethnicity,microalbuminuria,1
race/ethnicity,microvascular disease,1
race/ethnicity,mild plaque calcifi cation,1
race/ethnicity,neuropathy,1
race/ethnicity,nzdep quintile,1
race/ethnicity,percent low density plaque,1
race/ethnicity,peripheral artery disease,1
race/ethnicity,physical activity,3
race/ethnicity,plaque volume,1
race/ethnicity,previous diseases,1
race/ethnicity,prior event,1
race/ethnicity,retinopathy,2
race/ethnicity,smoking,14
race/ethnicity,sociodemographics,2
race/ethnicity,socioeconomic variables,4
race/ethnicity,statins,5
race/ethnicity,sulfonylurea,1
race/ethnicity,systolic blood pressure,10
race/ethnicity,the ukpds risk score,1
race/ethnicity,thiazolidinediones,1
race/ethnicity,triglycerides,7
race/ethnicity,waist measurements,3
race/ethnicity,white blood cell count,1
ratio between total,albumin excretion rate,1
ratio between total,cholesterol,1
ratio between total,fibrinogen,1
ratio between total,triglycerides,1
ratio between total,white blood cell count,1
reactive hyperemia index,inflammatory markers,1
referring physician,coronary heart disease,1
referring physician,hypertension,1
referring physician,smoking,1
renal impairment,albumin,1
renal impairment,heart failure,1
renal insufficiency,microalbuminuria,1
renin-angiotensin system inhibitors,antiplatelet therapy,1
renin-angiotensin system inhibitors,blood glucose,1
renin-angiotensin system inhibitors,bmi,1
renin-angiotensin system inhibitors,cardiovascular disease,1
renin-angiotensin system inhibitors,cholesterol,2
renin-angiotensin system inhibitors,diastolic blood pressure,2
renin-angiotensin system inhibitors,egfr,2
renin-angiotensin system inhibitors,hba1c,3
renin-angiotensin system inhibitors,nephropathy,1
renin-angiotensin system inhibitors,statins,3
renin-angiotensin system inhibitors,systolic blood pressure,2
renin-angiotensin system inhibitors,triglycerides,1
renin-angiotensin system inhibitors,uric acid,1
renin-angiotensin system inhibitors,urinary acr,1
retinopathy,ACE inhibitors,2
retinopathy,ARBs,1
retinopathy,RCT,1
retinopathy,albumin,1
retinopathy,antidepressants,1
retinopathy,antihypertensive use,3
retinopathy,antiplatelet therapy,1
retinopathy,blockers,1
retinopathy,blood glucose,1
retinopathy,bmi,2
retinopathy,cardiovascular disease,1
retinopathy,charlson index,1
retinopathy,cholesterol,8
retinopathy,chronic kidney disease,1
retinopathy,coronary heart disease,1
retinopathy,depression,1
retinopathy,diabetes duration,1
retinopathy,diabetic neuropathy,1
retinopathy,diastolic blood pressure,1
retinopathy,ecg abnormalities,1
retinopathy,egfr,1
retinopathy,fibrates,1
retinopathy,hba1c,5
retinopathy,insulin (measurment),1
retinopathy,insulin treatment,3
retinopathy,mca stenosis,1
retinopathy,metformin,1
retinopathy,neuropathy,2
retinopathy,peripheral artery disease,2
retinopathy,pulse pressure,1
retinopathy,renin-angiotensin system inhibitors,1
retinopathy,sensory neuropathy,1
retinopathy,sensory neuropathy presentabsent,1
retinopathy,smoking,2
retinopathy,statins,2
retinopathy,stroke,3
retinopathy,sulfonylurea,1
retinopathy,systolic blood pressure,1
retinopathy,the use of drugs yesno,1
retinopathy,thiazolidinediones,1
retinopathy,total baseline expenditures,1
retinopathy,triglycerides,2
retinopathy,uric acid,1
retinopathy,urinary acr,2
rosiglitazone during followup,years of enrolment,1
secretagogues,beta-blocker,1
secretagogues,calcium channel blockers,1
sensory neuropathy,ACE inhibitors,1
sensory neuropathy,antihypertensive use,1
sensory neuropathy,insulin (measurment),1
sensory neuropathy,peripheral artery disease,1
sensory neuropathy,stroke,2
sensory neuropathy presentabsent,peripheral artery disease,1
sensory neuropathy presentabsent,stroke,1
sensory neuropathy presentabsent,the use of drugs yesno,1
serum magnesium,metformin,1
significant proximal lad disease,the presence of total occlusion,1
skinfold thickness,ApoAI,1
skinfold thickness,coronary artery disease,1
skinfold thickness,fibrinogen,1
skinfold thickness,peripheral arterial occlusive disease,1
skinfold thickness,stroke,1
sleep duration,alcohol use,1
smoking,ACE inhibitors,6
smoking,ACEI/ARB,3
smoking,ARBs,4
smoking,ApoAI,1
smoking,Lp(a),1
smoking,RCT,5
smoking,Serum 25-hydroxyvitamin D,1
smoking,acr,2
smoking,acute coronary syndrome,3
smoking,age,4
smoking,albumin,16
smoking,albumin excretion rate,7
smoking,albumin to creatinine ratio,7
smoking,alcohol use,19
smoking,alternative healthy eating index ahei diet quality score quintiles,1
smoking,andor nitroglycerin,1
smoking,angina,4
smoking,ankle-brachial index (ABI),5
smoking,antiaggregating agents,1
smoking,antialdosterone,1
smoking,anticoagulants,1
smoking,antidepressants,1
smoking,antidiabetic medication,1
smoking,antihyperlipidemic drugs,1
smoking,antihypertensive use,18
smoking,antiplatelet therapy,7
smoking,apo(a) phenotypes,1
smoking,apoAI/apoB ratio,2
smoking,apoB,2
smoking,arteriovenous fistula,1
smoking,aspirin therapy,13
smoking,atrial fibrillation,3
smoking,autonomic dysfunction,2
smoking,average of 3 daily 2hour bg levels after meals,1
smoking,bapwv,1
smoking,baseline claudication,1
smoking,beta-blocker,2
smoking,biomarkers (general),1
smoking,blockers,2
smoking,blood glucose,13
smoking,blood pressure,12
smoking,blood transfusion,1
smoking,bmi,49
smoking,bnp,9
smoking,c-reactive protein,13
smoking,calcium channel blockers,1
smoking,cancer,1
smoking,cardiovascular disease,23
smoking,carotid artery imt,1
smoking,cerebrovascular disease,3
smoking,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
smoking,cholesterol,150
smoking,chronic kidney disease,5
smoking,chronic obstructive pulmonary disease,1
smoking,chronic renal failure,1
smoking,cimt,1
smoking,clinic,1
smoking,clopidigrel,1
smoking,clopidogrel,1
smoking,complex lesions,1
smoking,coronary artery calcium score,4
smoking,coronary artery disease,7
smoking,coronary heart disease,7
smoking,creatinine,29
smoking,depression,1
smoking,diabetes,7
smoking,diabetes duration,27
smoking,diabetes treatment,17
smoking,diabetic neuropathy,1
smoking,dialysis,4
smoking,diastolic blood pressure,18
smoking,dipyridamole stress test,1
smoking,distal polyneuropathy,1
smoking,diuretic therapy,3
smoking,dpucmgp,1
smoking,ecg abnormalities,13
smoking,echolucent plaque,1
smoking,egfr,28
smoking,ejection fraction 40,1
smoking,endothelial dysfunction,1
smoking,fasting plasma glucose,4
smoking,fasting status yes or no,1
smoking,fibrates,2
smoking,fibrinogen,7
smoking,final timi flow,1
smoking,fpi,1
smoking,gastrointestinal bleeding in past 5 years,1
smoking,gender,4
smoking,gliclazide,1
smoking,glycated hemoglobin,1
smoking,glycemic control,8
smoking,hba1c,87
smoking,heart attack,1
smoking,heart failure,7
smoking,heart rate,7
smoking,height,1
smoking,hemoglobin,1
smoking,highdensity lipoprotein,2
smoking,history of coronary disease,1
smoking,homair,2
smoking,homocysteine,1
smoking,homocysteine at baseline,1
smoking,hyperlipidemia,12
smoking,hypertension,43
smoking,hyperuricemia-gout,1
smoking,idf metabolic syndrome,1
smoking,indigenous australian,1
smoking,insulin (measurment),3
smoking,insulin treatment,21
smoking,ischemia,1
smoking,ischemic heart disease,4
smoking,left ventricular ejection fraction,5
smoking,left ventricular hypertrophy,1
smoking,"leisure time physical activity",1
smoking,lipid profile,1
smoking,lipidlowering therapy,14
smoking,log101  acr,1
smoking,logaer,1
smoking,lowdensity lipoprotein,1
smoking,lung disease,1
smoking,macrovascular complications,10
smoking,mca stenosis,1
smoking,medication use,1
smoking,metformin,3
smoking,microalbuminuria,5
smoking,microvascular disease,8
smoking,mild plaque calcifi cation,1
smoking,monocyte chemoattractant protin1 m,1
smoking,multivessel coronary disease,3
smoking,myocardial infarction,11
smoking,nephropathy,2
smoking,neuropathy,2
smoking,nitrates,1
smoking,nterminal probrain natriuretic peptide,2
smoking,nzdep quintile,1
smoking,other lifestyle risk factors,1
smoking,pc screen time,1
smoking,percent low density plaque,1
smoking,percutaneous coronary intervention,2
smoking,peripheral arterial occlusive disease,1
smoking,peripheral artery disease,9
smoking,peripheral vascular disease,1
smoking,phosphate,2
smoking,physical activity,14
smoking,physical inactivity,4
smoking,pioglitazone treatment,1
smoking,plaque thickness,1
smoking,plaque volume,1
smoking,previous diseases,1
smoking,previous pcicabg,1
smoking,prior coronary artery bypass,2
smoking,pro btype natriuretic peptide quartiles,1
smoking,proteinuria,1
smoking,pulse pressure,2
smoking,race/ethnicity,3
smoking,ratio between total,1
smoking,renal impairment,1
smoking,renin-angiotensin system inhibitors,3
smoking,retinopathy,11
smoking,rosiglitazone during followup,1
smoking,sensory neuropathy,1
smoking,sensory neuropathy presentabsent,1
smoking,significant proximal lad disease,1
smoking,sleep duration,2
smoking,sociodemographics,3
smoking,socioeconomic variables,6
smoking,statins,23
smoking,stent,2
smoking,stroke,10
smoking,sulfonylurea,3
smoking,systolic blood pressure,58
smoking,the presence of total occlusion,1
smoking,the use of drugs yesno,1
smoking,thiazolidinediones,1
smoking,"to tal",1
smoking,tot chol,1
smoking,total energy kcalday,1
smoking,triacylglycerol,3
smoking,triglycerides,39
smoking,troponin,2
smoking,tv viewing,1
smoking,type of treatment,1
smoking,ultrafiltration volume,2
smoking,uric acid,3
smoking,urinary,1
smoking,urinary acr,5
smoking,urinary albumin excretion rate,6
smoking,urinary protein log,1
smoking,use of blockers,1
smoking,use of sulfonamides,1
smoking,waist measurements,6
smoking,wasting,1
smoking,white blood cell count,2
smoking,years of enrolment,1
sociodemographics,Elixhauser comorbidies,1
sociodemographics,RCT,1
sociodemographics,albumin,1
sociodemographics,albumin to creatinine ratio,1
sociodemographics,alcohol use,3
sociodemographics,antihypertensive use,3
sociodemographics,antiplatelet therapy,1
sociodemographics,aspirin therapy,1
sociodemographics,biomarkers,1
sociodemographics,blood pressure,2
sociodemographics,bmi,8
sociodemographics,calcium channel blockers,1
sociodemographics,cardiovascular disease,1
sociodemographics,cardiovascular risk factors,1
sociodemographics,charlson index,1
sociodemographics,cholesterol,9
sociodemographics,chronic kidney disease,2
sociodemographics,clinical variables,1
sociodemographics,coronary heart disease,1
sociodemographics,creatinine,2
sociodemographics,diabetes,1
sociodemographics,diabetes duration,4
sociodemographics,diabetes treatment,2
sociodemographics,diastolic blood pressure,2
sociodemographics,drug use,1
sociodemographics,egfr,5
sociodemographics,expected costs,1
sociodemographics,fibrinogen,3
sociodemographics,hba1c,8
sociodemographics,heart failure,1
sociodemographics,heart rate,1
sociodemographics,hypertension,1
sociodemographics,insulin treatment,2
sociodemographics,lipidlowering therapy,2
sociodemographics,metformin,1
sociodemographics,microalbuminuria,2
sociodemographics,myocardial infarction,1
sociodemographics,other complications,1
sociodemographics,peripheral vascular disease,1
sociodemographics,physical activity,3
sociodemographics,provider quality controls,1
sociodemographics,retinopathy,2
sociodemographics,serum magnesium,1
sociodemographics,smoking,7
sociodemographics,sulfonylurea,1
sociodemographics,systolic blood pressure,4
sociodemographics,total baseline expenditures,1
sociodemographics,treatment,1
sociodemographics,treatment intensity,1
sociodemographics,triacylglycerol,1
sociodemographics,triglycerides,2
sociodemographics,urinary protein log,1
sociodemographics,use of blockers,1
sociodemographics,waist measurements,1
sociodemographics,year fixed effects,1
sociodemographics,young severity index,1
socioeconomic variables,albumin,1
socioeconomic variables,albumin to creatinine ratio,2
socioeconomic variables,antidiabetic medication,1
socioeconomic variables,antihypertensive use,3
socioeconomic variables,antiplatelet therapy,1
socioeconomic variables,blood pressure,2
socioeconomic variables,bmi,3
socioeconomic variables,cardiovascular disease,1
socioeconomic variables,cholesterol,4
socioeconomic variables,chronic kidney disease,2
socioeconomic variables,coronary heart disease,1
socioeconomic variables,creatinine,1
socioeconomic variables,diabetes duration,1
socioeconomic variables,diabetes treatment,1
socioeconomic variables,diastolic blood pressure,1
socioeconomic variables,egfr,1
socioeconomic variables,hba1c,3
socioeconomic variables,heart failure,2
socioeconomic variables,hyperlipidemia,1
socioeconomic variables,hypertension,1
socioeconomic variables,insulin treatment,1
socioeconomic variables,lipid profile,1
socioeconomic variables,marital status,1
socioeconomic variables,myocardial infarction,1
socioeconomic variables,peripheral artery disease,1
socioeconomic variables,proteinuria,1
socioeconomic variables,sleep duration,1
socioeconomic variables,smoking,3
socioeconomic variables,sociodemographics,1
socioeconomic variables,statins,1
socioeconomic variables,systolic blood pressure,3
socioeconomic variables,waist measurements,1
sodium concentration,age,1
sodium concentration,bnp,1
sodium concentration,cholesterol,1
sodium concentration,macroalbuminuria,1
sodium concentration,peripheral artery disease,1
statins,ACE inhibitors,3
statins,ACEI/ARB,1
statins,ARBs,2
statins,acute coronary syndrome,1
statins,age,1
statins,albumin,2
statins,alphaglucosidase inhibitor,2
statins,andor nitroglycerin,1
statins,antialdosterone,1
statins,antidepressants,1
statins,antidiabetic medication,1
statins,antihypertensive use,2
statins,antiplatelet therapy,2
statins,arteriovenous fistula,1
statins,aspirin therapy,8
statins,beta-blocker,1
statins,blockers,1
statins,blood glucose,3
statins,bmi,3
statins,bnp,2
statins,c-reactive protein,2
statins,cardiovascular disease,1
statins,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
statins,cholesterol,17
statins,coronary artery calcium score,1
statins,coronary artery disease,2
statins,creatinine,2
statins,diabetes duration,3
statins,dialysis,3
statins,diastolic blood pressure,4
statins,dipeptidyl peptidase 4 inhibitor at discharge,2
statins,diuretic therapy,1
statins,ecg abnormalities,1
statins,egfr,4
statins,fasting plasma glucose,1
statins,fibrates,2
statins,framingham risk score,1
statins,gender,1
statins,gliclazide,1
statins,glycemic control,3
statins,hba1c,10
statins,heart failure,2
statins,hypertension,2
statins,insulin (measurment),2
statins,insulin treatment,5
statins,macrovascular complications,1
statins,metformin,1
statins,microvascular disease,1
statins,monocyte chemoattractant protin1 m,1
statins,nitrates,1
statins,peripheral artery disease,1
statins,phosphate,2
statins,pioglitazone treatment,1
statins,psychiatric medications,1
statins,rosiglitazone during followup,1
statins,smoking,5
statins,stroke,2
statins,sulfonylurea,2
statins,systolic blood pressure,6
statins,the ukpds risk score,1
statins,tot chol,1
statins,triglycerides,3
statins,ultrafiltration volume,2
statins,uric acid,1
statins,urinary acr,1
statins,years of enrolment,1
stent,apo(a) phenotypes,1
stent,diabetes duration,1
stent,hba1c,1
stent,hemodynamic measures,1
stent,left ventricular ejection fraction,1
stent,minimum lumen diameter,1
stent,multivessel coronary disease,1
stent,prior coronary artery bypass,1
stent,progressive arterial stiffness defined as a bapwv of 1730 or greater,1
stroke,ACE inhibitors,3
stroke,ACEI/ARB,1
stroke,albumin,2
stroke,alphaglucosidase inhibitor,1
stroke,angina,1
stroke,antidiabetic medication,1
stroke,antihypertensive use,3
stroke,antiplatelet therapy,2
stroke,arteriovenous fistula,1
stroke,beta-blocker,2
stroke,blood glucose,2
stroke,bmi,1
stroke,bnp,2
stroke,c-reactive protein,2
stroke,cardiovascular disease,1
stroke,cholesterol,12
stroke,clopidigrel,1
stroke,complete revascularization,1
stroke,coronary artery disease,1
stroke,creatinine,2
stroke,dcb use,1
stroke,diabetes duration,1
stroke,diabetes treatment,1
stroke,dialysis,3
stroke,dipeptidyl peptidase 4 inhibitor at discharge,1
stroke,diuretic therapy,1
stroke,ecg abnormalities,3
stroke,egfr,1
stroke,glycemic control,1
stroke,hba1c,6
stroke,heart failure,2
stroke,insulin (measurment),4
stroke,insulin treatment,2
stroke,ischemic heart disease,1
stroke,left ventricular ejection fraction,2
stroke,lm treatment,1
stroke,metformin,1
stroke,microalbuminuria,1
stroke,myocardial infarction,2
stroke,percutaneous coronary intervention,1
stroke,peripheral arterial occlusive disease,1
stroke,peripheral artery disease,2
stroke,peripheral vascular disease,2
stroke,phosphate,2
stroke,pioglitazone treatment,1
stroke,pulse pressure,1
stroke,retinopathy,1
stroke,smoking,1
stroke,statins,4
stroke,sulfonylurea,2
stroke,syntax score,1
stroke,the use of drugs yesno,1
stroke,triglycerides,4
stroke,ultrafiltration volume,2
sulfonylurea,ACE inhibitors,1
sulfonylurea,ARBs,1
sulfonylurea,antidepressants,1
sulfonylurea,antihypertensive use,1
sulfonylurea,aspirin therapy,1
sulfonylurea,beta-blocker,1
sulfonylurea,blockers,1
sulfonylurea,dipeptidyl peptidase 4 inhibitor at discharge,1
sulfonylurea,diuretic therapy,1
sulfonylurea,fibrates,1
sulfonylurea,insulin (measurment),1
sulfonylurea,insulin treatment,1
sulfonylurea,pioglitazone treatment,1
sulfonylurea,provider quality controls,1
sulfonylurea,sociodemographics,1
sulfonylurea,statins,2
sulfonylurea,thiazolidinediones,1
sulfonylurea,year fixed effects,1
summed stress score sss,sds summed difference score,1
syntax score,alphaglucosidase inhibitor,1
syntax score,antiplatelet therapy,2
syntax score,complete revascularization,1
syntax score,dcb use,1
syntax score,dipeptidyl peptidase 4 inhibitor at discharge,1
syntax score,glycemic control,1
syntax score,insulin (measurment),1
syntax score,lm treatment,1
syntax score,statins,2
syntax score,sulfonylurea,1
systolic blood pressure,ACE inhibitors,2
systolic blood pressure,ACEI/ARB,2
systolic blood pressure,ARBs,1
systolic blood pressure,ApoAI,1
systolic blood pressure,RCT,3
systolic blood pressure,Serum 25-hydroxyvitamin D,1
systolic blood pressure,acr,2
systolic blood pressure,age,2
systolic blood pressure,albumin,8
systolic blood pressure,albumin excretion rate,5
systolic blood pressure,albumin to creatinine ratio,5
systolic blood pressure,alcohol use,8
systolic blood pressure,alphaglucosidase inhibitor,1
systolic blood pressure,angina,2
systolic blood pressure,ankle-brachial index (ABI),1
systolic blood pressure,antiaggregating agents,1
systolic blood pressure,antidiabetic medication,1
systolic blood pressure,antihyperlipidemic drugs,2
systolic blood pressure,antihypertensive use,16
systolic blood pressure,antiplatelet therapy,6
systolic blood pressure,apoAI/apoB ratio,1
systolic blood pressure,apoB,1
systolic blood pressure,arteriovenous fistula,1
systolic blood pressure,aspirin therapy,5
systolic blood pressure,atrial fibrillation,3
systolic blood pressure,bapwv,1
systolic blood pressure,beta-blocker,1
systolic blood pressure,biomarkers (general),1
systolic blood pressure,blood glucose,7
systolic blood pressure,blood pressure,4
systolic blood pressure,bmi,18
systolic blood pressure,bnp,4
systolic blood pressure,c-reactive protein,5
systolic blood pressure,cancer,1
systolic blood pressure,cardiovascular disease,14
systolic blood pressure,carotid artery imt,1
systolic blood pressure,cerebrovascular disease,2
systolic blood pressure,cholesterol,120
systolic blood pressure,chronic kidney disease,1
systolic blood pressure,clopidigrel,1
systolic blood pressure,complete revascularization,1
systolic blood pressure,coronary artery calcium score,2
systolic blood pressure,coronary artery disease,2
systolic blood pressure,coronary heart disease,4
systolic blood pressure,creatinine,17
systolic blood pressure,dcb use,1
systolic blood pressure,diabetes,4
systolic blood pressure,diabetes duration,14
systolic blood pressure,diabetes treatment,8
systolic blood pressure,dialysis,2
systolic blood pressure,diastolic blood pressure,39
systolic blood pressure,dipeptidyl peptidase 4 inhibitor at discharge,1
systolic blood pressure,ecg abnormalities,9
systolic blood pressure,echolucent plaque,1
systolic blood pressure,egfr,30
systolic blood pressure,fasting cpeptide,1
systolic blood pressure,fasting plasma glucose,1
systolic blood pressure,fibrinogen,5
systolic blood pressure,gender,3
systolic blood pressure,glycated hemoglobin,1
systolic blood pressure,glycemic control,5
systolic blood pressure,hba1c,52
systolic blood pressure,heart failure,5
systolic blood pressure,heart rate,2
systolic blood pressure,highdensity lipoprotein,1
systolic blood pressure,history of coronary disease,1
systolic blood pressure,homair,1
systolic blood pressure,homocysteine,1
systolic blood pressure,homocysteine at baseline,1
systolic blood pressure,hyperlipidemia,8
systolic blood pressure,hypertension,15
systolic blood pressure,idf metabolic syndrome,1
systolic blood pressure,insulin (measurment),3
systolic blood pressure,insulin treatment,7
systolic blood pressure,ischemic heart disease,1
systolic blood pressure,left ventricular ejection fraction,2
systolic blood pressure,lipid profile,1
systolic blood pressure,lipidlowering therapy,11
systolic blood pressure,lm treatment,1
systolic blood pressure,log101  acr,1
systolic blood pressure,lung disease,1
systolic blood pressure,macrovascular complications,4
systolic blood pressure,mca stenosis,1
systolic blood pressure,medication use,1
systolic blood pressure,microalbuminuria,3
systolic blood pressure,microvascular disease,3
systolic blood pressure,mild plaque calcifi cation,1
systolic blood pressure,myocardial infarction,8
systolic blood pressure,nephropathy,1
systolic blood pressure,nterminal probrain natriuretic peptide,2
systolic blood pressure,pacemaker implantation,1
systolic blood pressure,pc screen time,1
systolic blood pressure,percent low density plaque,1
systolic blood pressure,percutaneous coronary intervention,2
systolic blood pressure,peripheral artery disease,5
systolic blood pressure,peripheral vascular disease,1
systolic blood pressure,peripherovascular morbidity,1
systolic blood pressure,phosphate,1
systolic blood pressure,physical activity,1
systolic blood pressure,plaque thickness,1
systolic blood pressure,plaque volume,1
systolic blood pressure,pro btype natriuretic peptide quartiles,1
systolic blood pressure,proteinuria,3
systolic blood pressure,pulse pressure,1
systolic blood pressure,race/ethnicity,3
systolic blood pressure,ratio between total,1
systolic blood pressure,renal impairment,1
systolic blood pressure,renin-angiotensin system inhibitors,1
systolic blood pressure,retinopathy,6
systolic blood pressure,sensory neuropathy,1
systolic blood pressure,sensory neuropathy presentabsent,1
systolic blood pressure,significant proximal lad disease,1
systolic blood pressure,sleep duration,2
systolic blood pressure,smoking,41
systolic blood pressure,sociodemographics,1
systolic blood pressure,socioeconomic variables,3
systolic blood pressure,statins,10
systolic blood pressure,stroke,7
systolic blood pressure,sulfonylurea,1
systolic blood pressure,syntax score,1
systolic blood pressure,the presence of total occlusion,1
systolic blood pressure,the use of drugs yesno,1
systolic blood pressure,triacylglycerol,2
systolic blood pressure,triglycerides,29
systolic blood pressure,troponin,2
systolic blood pressure,tryglycerides,1
systolic blood pressure,tv viewing,1
systolic blood pressure,ultrafiltration volume,1
systolic blood pressure,uric acid,1
systolic blood pressure,urinary,1
systolic blood pressure,urinary acr,3
systolic blood pressure,urinary albumin excretion rate,8
systolic blood pressure,urinary protein log,1
systolic blood pressure,waist measurements,6
systolic blood pressure,white blood cell count,1
thiazolidinediones,ARBs,1
thiazolidinediones,antidepressants,1
thiazolidinediones,antihypertensive use,1
thiazolidinediones,blockers,1
thiazolidinediones,fibrates,1
thiazolidinediones,insulin treatment,1
thiazolidinediones,statins,1
tnfalpha,carotid intima media thickness,1
"to tal",bmi,1
"to tal",cholesterol,2
"to tal",hba1c,1
"to tal",height,1
"to tal",triglycerides,1
top three multidimensional scaling axes,clinic gamma frailty,1
top three multidimensional scaling axes,intervention arm no interaction model,1
total baseline expenditures,cardiovascular disease,1
treatment,hba1c,2
treatment,lipid profile,1
treatment intensity,bmi,1
treatment intensity,expected costs,1
treatment intensity,hba1c,1
treatment intensity,physical activity,1
treatment intensity,smoking,1
triacylglycerol,ACE inhibitors,1
triacylglycerol,RCT,1
triacylglycerol,aspirin therapy,1
triacylglycerol,blood pressure,1
triacylglycerol,bmi,1
triacylglycerol,cholesterol,1
triacylglycerol,coronary heart disease,1
triacylglycerol,creatinine,1
triacylglycerol,diastolic blood pressure,1
triacylglycerol,egfr,1
triacylglycerol,fasting plasma glucose,1
triacylglycerol,fibrinogen,1
triacylglycerol,hba1c,2
triacylglycerol,hgi,1
triacylglycerol,highdensity lipoprotein,1
triacylglycerol,homocysteine at baseline,1
triacylglycerol,insulin treatment,1
triacylglycerol,lipidlowering therapy,1
triacylglycerol,lowdensity lipoprotein,1
triacylglycerol,physical activity,1
triacylglycerol,retinopathy,2
triacylglycerol,triglycerides,1
triacylglycerol,urinary acr,1
triglycerides,ACE inhibitors,4
triglycerides,ACEI/ARB,2
triglycerides,ARBs,2
triglycerides,ApoAI,2
triglycerides,RCT,3
triglycerides,acr,1
triglycerides,acute coronary syndrome,2
triglycerides,age,2
triglycerides,albumin,9
triglycerides,albumin excretion rate,3
triglycerides,albumin to creatinine ratio,1
triglycerides,alcohol use,1
triglycerides,andor nitroglycerin,1
triglycerides,ankle-brachial index (ABI),1
triglycerides,antialdosterone,1
triglycerides,anticoagulants,1
triglycerides,antidepressants,1
triglycerides,antihyperlipidemic drugs,1
triglycerides,antihypertensive use,10
triglycerides,antiplatelet therapy,2
triglycerides,apo(a) phenotypes,1
triglycerides,apoAI/apoB ratio,2
triglycerides,apoB,2
triglycerides,aspirin therapy,3
triglycerides,atrial fibrillation,2
triglycerides,autonomic dysfunction,2
triglycerides,bapwv,1
triglycerides,beta-blocker,1
triglycerides,blockers,2
triglycerides,blood glucose,6
triglycerides,blood pressure,1
triglycerides,bmi,10
triglycerides,bnp,3
triglycerides,c-reactive protein,9
triglycerides,calcium channel blockers,1
triglycerides,cardiovascular disease,7
triglycerides,carotid artery imt,1
triglycerides,cerebrovascular disease,2
triglycerides,change of esrage endogenous secretory receptor of advanced glycated endproducts,1
triglycerides,cholesterol,40
triglycerides,chronic kidney disease,3
triglycerides,cimt,3
triglycerides,clopidogrel,1
triglycerides,combined alox12 genotypes,1
triglycerides,coronary artery disease,2
triglycerides,creatinine,10
triglycerides,depression,1
triglycerides,diabetes,1
triglycerides,diabetes duration,6
triglycerides,diabetes treatment,9
triglycerides,diabetic neuropathy,1
triglycerides,diastolic blood pressure,4
triglycerides,distal polyneuropathy,1
triglycerides,diuretic therapy,2
triglycerides,dpucmgp,1
triglycerides,ecg abnormalities,1
triglycerides,egfr,11
triglycerides,ejection fraction 40,1
triglycerides,endothelial dysfunction,1
triglycerides,fasting plasma glucose,2
triglycerides,fibrates,1
triglycerides,fibrinogen,3
triglycerides,gender,4
triglycerides,glycemic control,1
triglycerides,hba1c,12
triglycerides,heart failure,2
triglycerides,height,2
triglycerides,history of coronary disease,1
triglycerides,homair,2
triglycerides,homocysteine,3
triglycerides,hyperlipidemia,1
triglycerides,hypertension,8
triglycerides,idf metabolic syndrome,2
triglycerides,inflammatory markers,1
triglycerides,insulin (measurment),4
triglycerides,insulin treatment,4
triglycerides,intensive treatment,1
triglycerides,left ventricular ejection fraction,1
triglycerides,left ventricular hypertrophy,1
triglycerides,"leisure time physical activity",1
triglycerides,lipidlowering therapy,6
triglycerides,log101  acr,1
triglycerides,macroalbuminuria,1
triglycerides,macrovascular complications,1
triglycerides,metformin,3
triglycerides,microalbuminuria,2
triglycerides,microvascular disease,1
triglycerides,monocyte chemoattractant protin1 m,1
triglycerides,multivessel coronary disease,1
triglycerides,myocardial infarction,3
triglycerides,nephropathy,1
triglycerides,neuropathy,2
triglycerides,nitrates,1
triglycerides,nterminal probrain natriuretic peptide,1
triglycerides,peripheral arterial occlusive disease,1
triglycerides,peripheral artery disease,3
triglycerides,peripheral neuropathy,1
triglycerides,peripheral vascular disease,1
triglycerides,physical activity,1
triglycerides,pioglitazone treatment,1
triglycerides,prior coronary artery bypass,1
triglycerides,proteinuria,1
triglycerides,pulse pressure,1
triglycerides,reactive hyperemia index,1
triglycerides,renal impairment,1
triglycerides,renal insufficiency,1
triglycerides,renin-angiotensin system inhibitors,3
triglycerides,retinopathy,4
triglycerides,sensory neuropathy,1
triglycerides,sensory neuropathy presentabsent,1
triglycerides,smoking,14
triglycerides,sociodemographics,1
triglycerides,statins,6
triglycerides,stent,1
triglycerides,stroke,4
triglycerides,sulfonylurea,2
triglycerides,systolic blood pressure,7
triglycerides,the use of drugs yesno,1
triglycerides,therapy for hypercoagulation,1
triglycerides,thiazolidinediones,1
triglycerides,troponin,1
triglycerides,uric acid,3
triglycerides,urinary acr,1
triglycerides,urinary albumin excretion rate,1
triglycerides,use of blockers,1
triglycerides,waist measurements,3
triglycerides,wasting,1
triglycerides,white blood cell count,1
troponin,c-reactive protein,2
troponin,nterminal probrain natriuretic peptide,1
troponin,pro btype natriuretic peptide quartiles,1
tryglycerides,blood glucose,1
tv viewing,alcohol use,1
tv viewing,pc screen time,1
tv viewing,sleep duration,1
type of treatment,albumin excretion rate,1
type of treatment,bmi,1
type of treatment,cholesterol,1
type of treatment,diastolic blood pressure,1
type of treatment,fibrinogen,1
type of treatment,ratio between total,1
type of treatment,systolic blood pressure,1
type of treatment,triglycerides,1
type of treatment,white blood cell count,1
ultrafiltration volume,albumin,2
ultrafiltration volume,arteriovenous fistula,1
ultrafiltration volume,bnp,1
ultrafiltration volume,c-reactive protein,1
ultrafiltration volume,cholesterol,2
ultrafiltration volume,dialysis,1
ultrafiltration volume,hba1c,2
ultrafiltration volume,phosphate,1
ultrafiltration volume,triglycerides,1
uric acid,ACEI/ARB,1
uric acid,age,1
uric acid,bmi,2
uric acid,cardiovascular disease,1
uric acid,carotid intima media thickness,1
uric acid,cholesterol,2
uric acid,creatinine,2
uric acid,diastolic blood pressure,1
uric acid,egfr,1
uric acid,hba1c,2
uric acid,left ventricular ejection fraction,1
uric acid,lipidlowering therapy,1
uric acid,mpv mean platelet volume,1
uric acid,syntax score,1
uric acid,systolic blood pressure,1
uric acid,tnfalpha,1
uric acid,triglycerides,1
uric acid,urinary acr,1
urinary acr,blood glucose,1
urinary acr,bmi,1
urinary acr,cholesterol,2
urinary acr,diastolic blood pressure,1
urinary acr,fibrates,1
urinary acr,gliclazide,1
urinary acr,hba1c,2
urinary acr,neuropathy,1
urinary acr,renin-angiotensin system inhibitors,1
urinary acr,retinopathy,2
urinary acr,rosiglitazone during followup,1
urinary acr,smoking,1
urinary acr,statins,2
urinary acr,systolic blood pressure,1
urinary acr,triglycerides,1
urinary acr,years of enrolment,1
urinary albumin excretion rate,ACEI/ARB,1
urinary albumin excretion rate,RCT,1
urinary albumin excretion rate,antiplatelet therapy,1
urinary albumin excretion rate,bmi,1
urinary albumin excretion rate,bnp,3
urinary albumin excretion rate,c-reactive protein,1
urinary albumin excretion rate,cholesterol,2
urinary albumin excretion rate,coronary artery calcium score,2
urinary albumin excretion rate,creatinine,1
urinary albumin excretion rate,diabetes duration,1
urinary albumin excretion rate,egfr,3
urinary albumin excretion rate,fasting cpeptide,1
urinary albumin excretion rate,hba1c,2
urinary albumin excretion rate,hypertension,1
urinary albumin excretion rate,ischemic heart disease,1
urinary albumin excretion rate,lipidlowering therapy,1
urinary albumin excretion rate,smoking,1
urinary albumin excretion rate,study treatment,1
urinary albumin excretion rate,triglycerides,1
urinary albumin excretion rate,uric acid,1
urinary protein log,diabetes duration,1
urinary protein log,hba1c,1
use of blockers,calcium channel blockers,1
use of blockers,systolic blood pressure,1
use of sulfonamides,ACE inhibitors,1
use of sulfonamides,ARBs,1
use of sulfonamides,antiplatelet therapy,1
use of sulfonamides,hypertension,1
use of sulfonamides,insulin treatment,1
use of sulfonamides,statins,1
vessel size,diabetes duration,1
vessel size,hba1c,1
vessel size,hemodynamic measures,1
vessel size,minimum lumen diameter,1
vessel size,stent,1
vitamin b12,cholesterol,1
vitamin b12,diabetes duration,1
vitamin b12,folate,1
vitamin b12,hba1c,1
vitamin b12,hypertension,1
vitamin b12,smoking,1
waist measurements,ACE inhibitors,1
waist measurements,ApoAI,2
waist measurements,RCT,1
waist measurements,Serum 25-hydroxyvitamin D,1
waist measurements,albumin to creatinine ratio,1
waist measurements,antihypertensive use,4
waist measurements,antiplatelet therapy,1
waist measurements,apoAI/apoB ratio,2
waist measurements,apoB,2
waist measurements,blood glucose,3
waist measurements,c-reactive protein,2
waist measurements,cardiovascular disease,2
waist measurements,carotid plaque,1
waist measurements,cholesterol,21
waist measurements,chronic kidney disease,1
waist measurements,coronary artery calcium score,1
waist measurements,coronary heart disease,1
waist measurements,creatinine,4
waist measurements,diabetes,1
waist measurements,diabetes treatment,4
waist measurements,diastolic blood pressure,2
waist measurements,egfr,4
waist measurements,fibrinogen,2
waist measurements,fpi,1
waist measurements,glycemic control,1
waist measurements,hba1c,7
waist measurements,heart rate,2
waist measurements,high density lipoprotein level,1
waist measurements,homair,2
waist measurements,homocysteine,2
waist measurements,hypertension,2
waist measurements,idf metabolic syndrome,2
waist measurements,inflammatory markers,1
waist measurements,insulin (measurment),3
waist measurements,insulin treatment,1
waist measurements,lipid profile,1
waist measurements,lipidlowering therapy,3
waist measurements,log101  acr,1
waist measurements,microalbuminuria,1
waist measurements,peripheral artery disease,1
waist measurements,physical activity,1
waist measurements,proteinuria,1
waist measurements,reactive hyperemia index,1
waist measurements,renin-angiotensin system inhibitors,1
waist measurements,retinopathy,1
waist measurements,sensory neuropathy,1
waist measurements,smoking,6
waist measurements,statins,1
waist measurements,stroke,2
waist measurements,systolic blood pressure,8
waist measurements,triglycerides,7
waist measurements,urinary acr,1
wasting,albumin,1
wasting,creatinine,1
wasting,diabetes treatment,1
weight,albumin to creatinine ratio,1
weight,antihypertensive use,1
weight,average of 3 daily 2hour bg levels after meals,1
weight,bmi,1
weight,diastolic blood pressure,1
weight,egfr,1
weight,glycemic control,2
weight,hba1c,1
weight,heart rate,1
weight,height,1
weight,lipidlowering therapy,1
weight,physical activity,1
weight,smoking,2
weight,systolic blood pressure,3
white blood cell count,alcohol use,1
white blood cell count,alternative healthy eating index ahei diet quality score quintiles,1
white blood cell count,ankle-brachial index (ABI),1
white blood cell count,bmi,2
white blood cell count,c-reactive protein,1
white blood cell count,cholesterol,2
white blood cell count,creatinine,1
white blood cell count,diabetes,1
white blood cell count,diabetes duration,2
white blood cell count,diastolic blood pressure,1
white blood cell count,ecg abnormalities,3
white blood cell count,egfr,2
white blood cell count,gastrointestinal bleeding in past 5 years,1
white blood cell count,hba1c,2
white blood cell count,heart failure,1
white blood cell count,hyperlipidemia,1
white blood cell count,hypertension,2
white blood cell count,hyperuricemia-gout,1
white blood cell count,lung disease,1
white blood cell count,myocardial infarction,1
white blood cell count,physical activity,1
white blood cell count,pro btype natriuretic peptide quartiles,1
white blood cell count,pulse pressure,1
white blood cell count,significant proximal lad disease,1
white blood cell count,smoking,3
white blood cell count,systolic blood pressure,3
white blood cell count,the presence of total occlusion,1
white blood cell count,troponin,1
year fixed effects,sociodemographics,1
year of followup start,alcohol use,1
year of followup start,antihypertensive use,1
year of followup start,antiplatelet therapy,1
year of followup start,blood glucose,1
year of followup start,bmi,1
year of followup start,cholesterol,1
year of followup start,macrovascular complications,1
year of followup start,microvascular disease,1
year of followup start,psychiatric medications,1
year of followup start,statins,1
young severity index,blood pressure,1
young severity index,bmi,1
young severity index,cholesterol,1
young severity index,creatinine,1
young severity index,microalbuminuria,1
young severity index,provider quality controls,1
young severity index,sociodemographics,1
young severity index,sulfonylurea,1
young severity index,year fixed effects,1
